Kinetic Characterisation of Disease Causing Mutations in the Embryonic and ß-Cardiac Myosin Motor Domain by Walklate, Jonathan
Kent Academic Repository
Full text document (pdf)
Copyright & reuse
Content in the Kent Academic Repository is made available for research purposes. Unless otherwise stated all
content is protected by copyright and in the absence of an open licence (eg Creative Commons), permissions 
for further reuse of content should be sought from the publisher, author or other copyright holder. 
Versions of research
The version in the Kent Academic Repository may differ from the final published version. 
Users are advised to check http://kar.kent.ac.uk for the status of the paper. Users should always cite the 
published version of record.
Enquiries
For any further enquiries regarding the licence status of this document, please contact: 
researchsupport@kent.ac.uk
If you believe this document infringes copyright then please contact the KAR admin team with the take-down 
information provided at http://kar.kent.ac.uk/contact.html
Citation for published version
Walklate, Jonathan  (2016) Kinetic Characterisation of Disease Causing Mutations in the Embryonic
and ß-Cardiac Myosin Motor Domain.   Doctor of Philosophy (PhD) thesis, University of Kent,.
DOI








Kinetic Characterisation of Disease Causing Mutations in 




A Thesis submitted to the University of Kent for the degree of  
Doctor of Philosophy in Biochemistry  








Department of Biosciences 
i 
 
I would like to dedicate this thesis to my loving wife Joss who has kept me going through 





The two manifolds for the stopped-flow spectrometer were designed by my supervisor 
Professor Michael A. Geeves and Ted King. This was a collaborative project between TgK 
scientific and our laboratory. Myosin and actin purification used for these investigations 
were carried out by Sam Lynn or Dr Nancy Adamek.  
 
The investigation into the wild type embryonic myosin (Chapter 4), the three Freeman-
Sheldon Syndrome mutations in embryonic myosin (Chapter 5) and the juvenile 
hypertrophic cardiomyopathy mutation (Chapter 6) was part of a collaboration between 
Professor Leslie A. Leinwand from the University of Colorado, USA and our laboratory. Her 
PhD student Carlos Vera, Dr. Stephen Langers, and technician Ariana Combs cloned the 
sequences, grew the viruses, transfected and grew the C2C12 cells and shipped cell 
pellets for purification. Carlos Vera also conducted all the ATPase assays presented here. 
 
No part of this thesis has been submitted in support of an application for any degree or 













I wish to thank Professor Michael A. Geeves for giving me the opportunity to study for this PhD 
and for his continued guidance and support throughout. I would also like to thank the NIH for 
providing me with funding for this PhD. 
A special thank you to my collaborators in the Leinwand laboratory. Professor Leslie Leinwand for 
allowing me to visit her laboratory and her support. Stephen Langers and Ariana Combs for 
producing the recombinant protein. Special thanks to Carlos Vera who has shared the joys and 
tribulations of this project. 
I would also like to thank from the bottom of my heart my colleagues in the Geeves lab (past and 
present) who helped, encouraged and supported me through this PhD: Dr Nancy Adamek, Dr 
Marieke Bloemink, Dr Dave Pearson, Dr Anja Schmidtmann, Dr Miro Janco, Dr Zoltan Ujfalusi, Dr 
Alice Racca, Sam Lynn, Cassidy Mackenzie, Rory Parsons, Sarah Jeanfavre, and Michael Coghlan. I 
would also like to thank the other members of the MADCAP groups from the Mulvihill, Kad, 
Toseland, and Goult laboratories. I would also like to thank the members of my postgraduate 
committee Professor David Brown and Dr Tobias von der Haar. 
Finally I would like to thank my family and my fiancée Jocelyn Rebera for all of their love and 
support.   
iv 
 
Table of Contents 
Declaration ....................................................................................................................................ii 
Acknowledgements ....................................................................................................................... iii 
Table of Contents .......................................................................................................................... iv 
Abstract ........................................................................................................................................ 1 
Abbreviations ................................................................................................................................ 2 
1. Introduction .......................................................................................................................... 6 
1.1. General biochemistry and biophysical characteristics of myosin ........................................ 6 
1.1.1. Myosin........................................................................................................................... 6 
1.1.2. Myosin class II ................................................................................................................ 8 
1.1.3. Protein structure ........................................................................................................... 8 
1.1.4. Structure and proteins of the sarcomere...................................................................... 12 
1.1.5. Cross-bridge cycle ........................................................................................................ 18 
1.2. Myosin isoforms .............................................................................................................. 21 
1.2.1. Isoform genes .............................................................................................................. 21 
1.2.1.1. Adult skeletal isoforms ............................................................................................. 21 
1.2.1.2. Cardiac isoforms ...................................................................................................... 23 
1.2.1.3. Extraocular isoform .................................................................................................. 24 
1.2.1.4. Developmental isoforms .......................................................................................... 24 
1.2.2. Sequence identity ........................................................................................................ 24 
1.2.3. Sequence differences relate to functional divergence .................................................. 26 
1.2.4. Expression of isoforms ................................................................................................. 26 
1.3. Myopathies ..................................................................................................................... 29 
1.3.1. Hypertrophic cardiomyopathy ..................................................................................... 29 
1.3.2. Freeman-Sheldon Syndrome ........................................................................................ 33 
1.3.3. Other myopathies ........................................................................................................ 36 
1.4. Stopped-flow Spectroscopy ............................................................................................. 39 
1.4.1. How it works ................................................................................................................ 39 
v 
 
1.4.2. Uses ............................................................................................................................. 40 
1.4.3. Limitations ................................................................................................................... 41 
1.5. Aim of the project............................................................................................................ 43 
2 Materials and methods ....................................................................................................... 46 
2.1 Materials ......................................................................................................................... 46 
2.1.1 Chemicals .................................................................................................................... 46 
2.1.2 Buffers ......................................................................................................................... 46 
2.1.3 Hardware and apparatus ............................................................................................. 48 
2.2 Protein preparation and purification ................................................................................ 50 
2.2.1 Rabbit myosin and S1 preparation and purification ...................................................... 50 
2.2.1.1 Rabbit myosin extraction ............................................................................................. 50 
2.2.1.2 Rabbit myosin subfragment 1 (S1) preparation and purification ................................... 50 
2.2.1.3 Recombinant His-tagged human S1 expression ............................................................ 51 
2.2.1.4 Recombinant His-tagged human S1 purification ........................................................... 52 
2.2.2 Actin purification and preparation ............................................................................... 53 
2.2.2.1 Acetone powder .......................................................................................................... 53 
2.2.2.2 F-actin preparation ...................................................................................................... 53 
2.2.2.3 Pyrene labelling of F-actin ............................................................................................ 54 
2.2.2.4 Stabilisation of actin with phalloidin ............................................................................ 55 
2.2.3 SDS-Page gel ................................................................................................................ 55 
2.3 Kinetic measurements ..................................................................................................... 56 
2.3.1 Fluorescent signals....................................................................................................... 56 
2.3.2 Stopped-flow ............................................................................................................... 56 
2.3.2.1 Transient Kinetics ........................................................................................................ 57 
2.3.2.2 Temperature effect ...................................................................................................... 64 
2.3.3 NADH-coupled ATPase assay ........................................................................................ 65 
3 New methods for measuring kinetic parameters and equilibrium constants...................... 67 
3.1 Temperature manifold ..................................................................................................... 67 
vi 
 
3.1.1 Temperature manifold development ........................................................................... 69 
3.1.2 Calibration of the manifold .......................................................................................... 70 
3.1.3 ATP induced dissociation data at different temperatures ............................................. 73 
3.2 Discussion ....................................................................................................................... 81 
3.3 Micro-volume manifold ................................................................................................... 82 
3.3.1 Micro-volume manifold (MVM) development .............................................................. 82 
3.3.2 Load volume calibration ............................................................................................... 85 
3.3.3 Determining the actin affinity using the micro-volume manifold .................................. 90 
3.4 Discussion ....................................................................................................................... 94 
3.4.1 Micro-volume Manifold ............................................................................................... 94 
3.4.2 Conclusions.................................................................................................................. 95 
4 Characterisation of wild type embryonic skeletal muscle myosin S1 .................................. 96 
4.1 Introduction .................................................................................................................... 96 
4.2 WT Embryonic myosin stopped-flow kinetics ................................................................. 101 
4.2.1 Purification of recombinant S1 ................................................................................... 101 
4.2.2 Differences ŝŶŶƵĐůĞŽƚŝĚĞďŝŶĚŝŶŐƚŽtdĞŵďƌǇŽŶŝĐ^ ?ĐŽŵƉĂƌĞĚƚŽtdɴ^ ? ............ 104 
4.2.3 Differences ŝŶŶƵĐůĞŽƚŝĚĞďŝŶĚŝŶŐƚŽtdĞŵďƌǇŽŶŝĐĂĐƚŝŽ ?^ ?ƚŽtdɴĂĐƚŽ ?^ ?............ 106 
4.2.4 Differences ŝŶĂĐƚŝŶĂĨĨŝŶŝƚǇƚŽtdĞŵďƌǇŽŶŝĐ^ ?ĐŽŵƉĂƌĞĚƚŽtdɴ^  ? ...................... 108 
4.2.5 Steady state ATPase data ........................................................................................... 110 
4.3 Discussion ..................................................................................................................... 113 
4.3.1 Comparison of wild type MyHC-emb to wild type MyHC-ɴ ......................................... 113 
4.3.2 Limitations of assays .................................................................................................. 115 
5 Characterisation of Freeman-Sheldon Syndrome causing mutations R672H, R672C, and 
T178I ........................................................................................................................................ 116 
5.1 Introduction .................................................................................................................. 116 
5.2 FSS mutation stopped-flow kinetics ............................................................................... 119 
5.2.1 Differences in nucleotide binding to R672H, R672C, and T178I embryonic S1 compared 
to WT embryonic S1 .................................................................................................................. 119 
vii 
 
5.2.2 Differences in nucleotide binding to R672H, R672C, and T178I embryonic acto.S1 
compared to WT embryonic acto.S1.......................................................................................... 121 
5.2.3 Differences in actin affinity to R672H, R672C, and T178I embryonic S1 compared to WT 
embryonic S1 ............................................................................................................................ 125 
5.2.4 Steady state ATPase data ........................................................................................... 127 
5.2.5 Modelling the ATPase cycle........................................................................................ 130 
5.2.6 Interaction changes between surrounding residues in mutants and WT MyHC-emb .. 139 
5.3 Discussion ..................................................................................................................... 144 
5.3.1 Kinetic differences between FSS mutants and wild type MyHC-emb .......................... 144 
5.3.2 Berkley Madonna modelling ...................................................................................... 145 
5.3.3 Significance of interaction losses in the mutated myosin motor ................................. 145 
6 Characterisation of Juvenile Hypertrophic Cardiomyopathy mutation H251N ................. 148 
6.1 Introduction .................................................................................................................. 148 
6.1.1 Background................................................................................................................ 148 
6.1.2 Aim ............................................................................................................................ 149 
6.2 MyHC-ɴ, ? ? ?EŬŝŶĞƚŝĐƐ ................................................................................................. 150 
6.2.1 Differences in nucleotide ďŝŶĚŝŶŐƚŽ, ? ? ?Eɴ^ ?ĐŽŵƉĂƌĞĚƚŽtdDǇ,-ɴ^ ? ........... 150 
6.2.2 Differences ŝŶŶƵĐůĞŽƚŝĚĞďŝŶŐŝŶŐƚŽ, ? ? ?EɴĂĐƚŽ ?^ ?ĐŽŵƉĂƌĞĚƚŽtdDǇ,-ɴĂĐƚŽ ?^ ?
 152 
6.2.3 Differences in actin affinity to H251N MyHC-ɴ^ ?ĐŽŵƉĂƌĞĚƚŽtdDǇ,-ɴ^ ? .......... 157 
6.2.4 Structure analysis ...................................................................................................... 160 
6.3 Discussion ..................................................................................................................... 164 
6.3.1 Kinetics ...................................................................................................................... 164 
6.3.2 Structure ................................................................................................................... 165 
7 General Discussion and Conclusions ................................................................................. 167 
7.1 General discussion ......................................................................................................... 167 
7.1.1 Stopped-flow modifications ....................................................................................... 167 
7.1.1.1 Temperature manifold ............................................................................................... 167 
viii 
 
7.1.1.2 Micro-volume manifold ............................................................................................. 170 
7.1.1.3 Wild type MyHC-emb ................................................................................................. 172 
7.1.2 FSS mutations ............................................................................................................ 175 
7.1.3 MyHC-ɴ, ? ? ?EŵƵƚĂƚŝŽŶƐ ......................................................................................... 177 
7.2 Limitations..................................................................................................................... 179 
7.3 Future work ................................................................................................................... 180 
8 References ........................................................................................................................ 182 
Publication list .......................................................................................................................... 201 
 
  





Myosin myopathies are a growing area of research not only to understand the nature of 
the disease and how it can occur, but also to gain insight into how the myosin molecule 
works. Point mutations are a great way of examining how regions of myosin interact, 
however, given that there are over 800 amino acids in the motor domain alone, 
pinpointing key residues can be challenging. The missense mutations in the myosin 
molecule that lead to disease are ideal then to investigate residue changes that will have 
an effect on the function of the motor. The expression of recombinant skeletal myosin 
class II molecules has only recently become possible. 
Previous studies into the function of the embryonic myosin isoform have shown it to be a 
ƐůŽǁƚǇƉĞŵǇŽƐŝŶƐŝŵŝůĂƌƚŽƚŚĞɴ-cardiac isoform. Here stopped-flow kinetic analysis of 
recombinant embryonic myosin S1 showed it has a tight ADP affinity and slow ADP 
ƌĞůĞĂƐĞ ? ĐŚĂƌĂĐƚĞƌŝƐƚŝĐ ŽĨ ƚŚĞ ɴ-cardiac myosin. Analysis of the three most common 
mutations in the embryonic myosin that cause Freeman-Sheldon syndrome (R672H, 
R672C, and T178I) showed a significantly reduced ATP hydrolysis, and ATPase Vmax and 
KM. Modelling of the cycle found that the mutations will be detached from actin for longer 
due to reduced ATP hydrolysis rate and a slower estimated phosphate release step. 
Another more common myopathy is hypertrophic cardiomyopathy (HCM) which can be 
cause by mutĂƚŝŽŶƐ ŝŶ Ă ŵƵůƚŝƚƵĚĞ ŽĨ ƐĂƌĐŽŵĞƌŝĐ ƉƌŽƚĞŝŶƐ ? ŵŽƐƚ ŶŽƚĂďůǇ ƚŚĞ ɴ-cardiac 
myosin. HCM is usually found in adolescents and young adults; however cases are 
beginning to emerge involving young children. Stopped-flow kinetic analysis of one of 
these mutations, H251N, shows more significant effects on the myosin function than 
 ‘ĂĚƵůƚ ?,DŵƵƚĂƚŝŽŶƐ ? ŝŶĐůƵĚŝŶŐ ?ĂǁĞĂŬĞƌWĂĨĨŝŶŝƚǇ ? ŝŐŚƚĞƌdWĂĨĨŝŶŝƚǇ ?ĂŶĚƐůŽǁĞƌ
detachment from actin rate constant. However the difference in severity is not 
apparently clear from the stopped-flow data alone. 
These results highlight new key areas on the myosin molecule that are essential for its 
correct function. The myosin motor is an intricate machine with multiple parts that need 
further investigation to truly understand its function and the impact of disease causing 
mutations 




[ ]   indicates a concentration 
Å   angstrom 
°C   degree Celsius 
A   actin 
Acto.myosin  actin-myosin complex 
ADP, D   ĂĚĞŶŽƐŝŶĞ ? ?ĚŝƉŚŽƐƉŚĂƚĞ 
A.M   actin-myosin complex 
A.M.D   actin-myosin-ADP complex 
A.M.D.P  actin-myosin-ADP-phosphate complex 
A.M.T   actin-myosin-ATP complex 
ATP, T   ĂĚĞŶŽƐŝŶĞ ? ?ƚƌŝƉŚŽƐƉŚĂƚĞ 
Ca2+   calcium ion 
cm, mm, µm, nm centimetre, millimetre, micrometre, nanometre 
C-terminal  carboxy terminal 
DA   distal arthrogryposis 
DA2A   distal arthrogryposis 2A 
DCM   dilated cardiomyopathy 
dH2O   distilled water 
DTT   dithiothreitol 
EDTA   ethlenediaminetetraacetic acid 
ELC   essential light chain 
F-actin   filamentous actin 
FPLC   fast protein liquid chromatography 
FSS   Freeman-Sheldon syndrome 
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g, mg   gram, milligram 
G-actin   globular actin 
h   hour 
HCM   hypertrophic cardiomyopathy 
HEPES   N-(2-ŚǇĚƌŽǆǇĞƚŚǇů )ƉŝƉĞƌĂǌŝŶĞE ?-(2-ethanesulfonic) acid 
HMM   heavy meromyosin  
k   rate constant 
kobs   observed rate constant 
kDa   kilo Dalton 
L50   lower 50 kDa domain of myosin 
L, mL, µL  litre, millilitre, microlitre  
LDH   lactate dehydrogenase 
LVH   left ventricle hypertrophy 
M, mM, µM, nM molar, millimolar, micromolar, nanomolar 
MDa   mega Dalton 
M.D.P   myosin-ADP-phosphate complex 
Min   minute 
Mg2+   magnesium ion  
M.T   myosin-ATP complex 
MOPS   N-(2-morpholino) propanesulfonic acid 
mRNA   messenger ribonucleic acid 
MVM   micro-volume manifold 
MyBP-C  myosin binding protein C 
MYH   myosin heavy chain gene 
MyHC   myosin heavy chain 
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MyHC-ɲ  ŵǇŽƐŝŶŚĞĂǀǇĐŚĂŝŶɲ 
MyHC-ɴ  ŵǇŽƐŝŶŚĞĂǀǇĐŚĂŝŶɴ 
MyHC-emb  myosin heavy chain embryonic 
MyHC-eo  myosin heavy chain extraocular 
MyHC-IIa  myosin heavy chain IIa 
MyHC-IIb  myosin heavy chain IIb 
MyHC-IIx  myosin heavy chain IIx 
MyHC-peri  myosin heavy chain perinatal 
N-terminal  amino terminal 
NAD   nicotinamide adenine dinucleotide 
NADH   nicotinamide adenine dinucleotide plus a proton 
PEEK    polyether ether ketone 
PEP   phosphoenolpyruvate 
Pi   inorganic phosphate 
PK   pyruvate kinase 
PMSF   phenylmethylsulfonyl fluoride 
Pyrene actin  actin labelled with pyrene at residue Cysteine-374 
RLC   regulatory light chain 
rpm   rotations per minute 
RT   room temperature 
S1   subfragment 1 of myosin 
S2   subfragment 2 of myosin 
SCD   sudden cardiac death 
SDS-PAGE  sodium docecylsulfate polyacrylamide gel electrophoresis  
SHS   Sheldon-Hall syndrome 
   
5 
 
Tm   tropomyosin 
Tn   troponin 
TnC   troponin C 
TnI   troponin I 
TnT   troponin T 
Tris   2-amino-2-(hydroxylmethyl)-1,3-propanediol 
U50   upper 50 kDa domain of myosin 
v/v   volume per volume 
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Myosin is a motor protein found in almost all cells of the human body. The myosin family 
is large with 35 subgroups which play different roles including muscle contraction, cargo 
movement and strain sensors. As a major component of muscle tissue their correct 
function is essential for working muscle. Muscle myopathies are a group of diseases that 
lead to muscle weakness. A leading cause of muscle myopathies are mutations in myosin 
and other sarcomeric proteins. Using kinetic measurements such as stopped-flow 
spectroscopy and ATPase assays it is possible to determine how the myosin cross-bridge 
cycle is affected by myosin mutations. By understanding the effects of the mutations on 
myosin function our understanding of how the residues within the myosin molecule 
interact and work together will increase. 
1.1. General biochemistry and biophysical characteristics of myosin 
1.1.1. Myosin  
 
Myosin is a ubiquitous actin associated motor protein found in cells from the nucleus (de 
Lanerolle, Serebryannyy 2011) to the cytoskeleton (Coluccio 2008). The myosin family is 
large with approximately 35 subgroups (Odronitz, Kollmar 2007). The myosin class II 
group includes; non-muscle, smooth muscle and striated muscle myosins (Figure 1.1). 
Myosin is a molecular motor that uses chemical energy from hydrolysis of ATP to ADP + 
inorganic phosphate (Pi) to move along actin filaments. In most cells the job of myosin is 
to move cargo around the cell or act as strain sensors, while in smooth and striated 
muscle the myosin is used for muscle contraction. 
All myosins are composed of three function groups: head, neck, and tail domains. The 
head domain is also referred to as the motor domain due to its catalytic activity. The 
motor domain contains the nucleotide binding pocket, actin binding interface, as well as a 
converter region linking to the lever arm which moves the myosin along the actin. The 
neck region (lever arm) is a long variable helix which contains a number of IQ motifs. IQ 
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motifs get their name from the sequence (IQXXXRGXXXR, (Cheney, Mooseker 1992)) and 
bind either light chains or calmodulin. The tail domain of myosins is very variable in both 
length and sequence. The major roles of the tail are cellular localisation and function of 
the myosin, i.e. carrying cargo or filament assembly. 
 
 
Figure 1.1  W Phylogenetic tree of 1,984 myosin motor domains divided into 35 subgroups. The 
expanded view shows the sequences of myosin class-VI and distribution within taxa. The scale 
bar represents estimated amino acid substitutions per site. Figure from (Odronitz, Kollmar 
2007). 
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Myosins can be subdivided into two groups: conventional and unconventional. 
Conventional myosins encompass the myosin-II myosins while unconventional myosins 
contain the rest of the myosins. 
1.1.2. Myosin class II 
 
Conventional myosin class II (myosin-II) is probably the most recognisable as it is the 
protein responsible for muscle contraction. Myosin-II is a hexameric protein composed of: 
2 heavy chains, 2 essential light chains (ELC), and 2 regulatory light chains (RLC). The C-
terminus of the heavy chain is termed the tail domain which forms a coiled-coil with the 
other myosin heavy chain (Figure 1.2). The N-terminus of myosin contains a globular head 
domain which contains the nucleotide binding pocket and actin binding region. The head 
of myosin is referred to as the motor domain and binds to actin.  
 
 
1.1.3. Protein structure 
 
tŚĞŶ ƐƵďũĞĐƚĞĚ ƚŽ ƉƌŽƚĞŽůǇƚŝĐ ĚŝŐĞƐƚ ďǇ ɲ-chymotrypsin the myosin molecule can be 
divided into two sections: the light meromyosin (LMM) and heavy meromyosin (HMM, 
Figure 1.2  W Cartoon representation of the myosin-II hexamer. The tail domain of myosin forms 
a coiled-coil around a second myosin tail. The myosin heads are located at the N-terminus of 
the molecule containing the motor domain. Between the tail and head domains is the neck 
region where the light chains bind. The tails in this figure look as though they are one on top  
of the other when in reality they are wrapped around each other. Figure from (Mulvihill, 
Hyams 2001). 
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Figure 1.3). LMM is composed of just the coiled-coil tail domains, while the HMM 
contains the globular head domain, lever arm (neck) and some of the coiled-coil tails. 
&ƵƌƚŚĞƌĚŝŐĞƐƚŝŽŶŽĨƚŚĞ,DDǁŝƚŚɲ-chymotrypsin or papain cleaves the protein at the 
end of the lever arm. This results in two domains termed subfragment 1 (S1) and 
subfragment 2 (S2). S2 contains the tail domains of the HMM and the RLC while S1 
contains the motor domain as well as the lever arm with the ELC on its IQ motif (Figure 
1.3). A benefit of using the S1 and HMM is that the entire motor domain is intact and is 
more soluble in lower ionic strength buffers. Since S1 is just a single motor domain the 
kinetics can be easier to interpret.  
 
A benefit of the S1 domain is that it can be crystallised unlike full length myosin. The first 
crystal structure of S1 solved (Figure 1.4) was of chicken skeletal myosin in high salt with a 
bound sulphate rather than a nucleotide (Rayment, Rypniewski et al. 1993).  
Figure 1.3  W Diagram of myosin which can be digested into light meromyosin (LMM) and heavy 
meromyosin (HMM). The HMM can be further digested to an S1 and S2 domain. The S1 domain 
contains the motor domain and the essential and regulatory light chains. Figure from (Hooper, 
Thuma 2005). 
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With further proteolytic digestion the S1 domain can be broken down into 3 fragments 
named after their apparent molecular weights: the N-terminal 25 kDa, central 50 kDa, 
and C-terminal 20 kDa. It was thought that these fragments were representative of 
subdomains, however it appears the cleavage sites are related to two flexible loop 
regions (loop 1 and loop 2, Figure 1.4). The central 50 kDa fragment spans two structural 
domains: the upper 50 kDa (U50) and lower 50 kDa (L50) which are separated by the actin 
binding cleft and actin binding region. The L50 is sometimes called the actin binding 
domain since it is formed of a major part of the actin binding sites (Geeves, Fedorov et al. 
2005). The N-terminus of the 25 kDa fragment is close to the lever arm and contains the 
SH3-ůŝŬĞ ɴ-barrel (Figure 1.5) which has an unknown function. The 25 kDa and U50 
domains form one large structural domain which includes 6 of the 7 strands of the central 
ɴ-ƐŚĞĞƚƚŚĂƚƌƵŶƐƚŚƌŽƵŐŚƚŚĞŵŝĚĚůĞŽĨƚŚĞƉƌŽƚĞŝŶ ?dŚŝƐɴ-sheet separates the actin and 
Figure 1.4  W Post-rigor crystal structure of the myosin motor domain (Rayment, Rypniewski et 
al. 1993). The N-terminus is shown in green, upper 50 kDa domain in red and lower 50 kDa 
domain in grey. The nucleotide binding P-loop and neighbouring helix are shown in yellow. A 
and B mark the start and end point of loop 1, C and D show where loop 2 would be. The light 
blue shows switch 2 of the nucleotide pocket and the relay helix. The dark blue shows the 
converter and the lever arm. The essential and regulatory light chains are shown in magenta 
and yellow respectively.  
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nucleotide binding sites by 40-50 Å (Geeves, Fedorov et al. 2005). The U50 domain 
contains the nucleotide binding pocket made up by the P-loop, switch 1 and switch 2 with 
the latter ĂĐƚŝŶŐ ĂƐ ɶ-phosphate sensors. These switches move together when ATP is 
present and move away when ADP is bound. 
 
 
The 20 kDa fragment begins with a long helix that runs from loop 2 to the 3rd strand in the 
ɴƐŚĞĞƚǁŚŝĐŚ ŝƐ ĨŽůůŽǁĞĚďǇĂďƌŽŬĞŶŚĞůŝǆ ?ŽƚŚƐĞŐŵĞŶƚƐŽĨƚŚŝƐďƌŽŬĞŶŚĞůŝǆĐŽŶƚĂŝŶ
reactive thiol groups and therefore this region is referred to as the SH1-SH2 helix. 
Following this is a compact area known as the converter domain (Dominquez, Freyzon et 
al. 1998). This is located close to the essential light chain binding site and is critical for 
communication between the active sites and the lever arm. 
The relay helix is another area of interest found in the L50 subdomain (Figure 1.5). 
Throughout the cross bridge cycle the relay helix bends and straightens. This bending 
leads to a 60° rotation of the converter domain relative to the rest of the motor domain 
Figure 1.5  W dŽƉŽůŽŐŝĐĂůŵĂƉŽĨƚŚĞŵǇŽƐŝŶŵŽƚŽƌĚŽŵĂŝŶ ?,ĞůŝĐĞƐĂƌĞƐŚŽǁŶĂƐĐŝƌĐůĞƐǁŚŝůĞɴ
strands are shown as triangles. The N-terminal SH-3  W ůŝŬĞ ɴ  W barrel is coloured yellow, U50 
subdomain  W pink, L50 subdomain  W light green, converter domain  W blue. The ceŶƚƌĂůɴ-sheet is 
shown by red triangles, Relay helix by a green circle, and SH1-SH2 by yellow circles. Figure from 
(Geeves, Fedorov et al. 2005).  
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which in turn rotates the lever arm 60°. A loop at the end of the relay helix (relay loop) 
contains a tryptophan (W508). Upon ATP binding the C-terminus of the relay helix moves 
relative to the rest of the molecule. When excited at the correct wavelength the 
fluorescence of this tryptophan can be measured to observe ATP binding and sometimes 
hydrolysis. 
The binding of myosin to actin is coordinated by several regions including: loop 3 and the 
helix-loop-helix of the L50, the cardiomyopathy loop and loop 4 of the U50 and loops 1 
and 2 which link the U50 and L50. The helix-loop-helix motif has a number of hydrophobic 
residues flanked by ionic and polar groups. Loop 2 has been found to have different 
amino acid sequences in different myosins and has been shown to be involved in weak 
and strong actin binding interactions (Furch, Geeves et al. 1998, Van Dijk, Furch et al. 
1999b). Loop 3 contains positively charged residues involved in electrostatic interactions 
with F-actin (Van Dijk, Furch et al. 1999a). Although in atomic models of the F-
actin.myosin complex loop 4 does not appear to interact, some unconventional myosins 
have an extended loop 4 with a high density of charged amino acids, which may stabilise 
the complex (Kliche, Fujita-Becker et al. 2001). The cardiomyopathy loop is important for 
normal myosin function. This was the location of the first missense point mutation, 
R403Q, ŝŶɴ-myosin that was linked familial hypertrophic cardiomyopathy (HCM, Chapter 
1.3.4, (Geisterfer-Lowrance, Kass et al. 1990)). 
1.1.4. Structure and proteins of the sarcomere 
 
The sarcomere is the basic contractile unit of skeletal and cardiac muscle. This highly 
ordered structure contains myosin, actin, tropomyosin, troponin, and other actin or 
myosin associated proteins (Clark, McElhinny et al. 2002). Electron microscopy of the 
muscle fibre reveals some of the ultrastructure of the sarcomere showing alternating light 
and dark bands (Figure 1.6). 
The light bands are also referred to as I-bands (isotropic bands) which are composed of 
just the thin filaments (actin, tropomyosin, and troponin complex). These filaments are 
anchored into the Z-ĚŝƐĐ  ?ĨƌŽŵ ƚŚĞ 'ĞƌŵĂŶ  ‘ǁĞŝƐĐŚĞŶƐĐŚĞŝďĞ ? ŵĞĂŶŝŶŐ ƚŚĞ ĚŝƐĐ ŝŶ
                                                                                                                                Chapter 1  W Introduction 
   
13 
 
between). The Z-disc can be seen as a thick band running vertically in the middle of the I-
band (Figure 1.6).  
The dark bands, also referred to as the A-bands (anisotropic bands), are composed of the 
thin filaments and thick filaments (myosin, light chains, and myosin binding protein-C). 
The thick filaments are aligned by the M-ůŝŶĞ ?ĨƌŽŵƚŚĞ'ĞƌŵĂŶ ‘DŝƚƚĞůƐĐŚĞŝďĞ ?ŵĞĂŶŝŶŐ
disc in the middle) which links the thick filament in the centre of the sarcomere. This can 
be seen as a slightly darker band running vertically through the middle of the A-band 
(Figure 1.6). 
 
Precise alignment of the actin and myosin is required for the function of skeletal and 
cardiac muscle. To achieve this, a wide variety of accessory proteins are needed. The Z-
ĚŝƐĐǁŚŝĐŚĂŶĐŚŽƌƐƚŚĞĂĐƚŝŶŝƐĐŽŵƉŽƐĞĚŵĂŝŶůǇŽĨɲ-actinin by cross-linking into a lattice 
to hold the actin filaments in place (Maruyama, Ebashi 1965, Blanchard, Ohanian et al. 
Figure 1.6  W Electron micrograph of the sarcomere in the skeletal muscle showing the 
ultrastructure from an unidentified species. The A-band (A) in this image corresponds to the 
overlap of the thick filament and thin filament. The I-band (I) contains just the thin filaments, 
there is no overlap with the thick filament. The Z-disc (Z) is the thick band in the middle of the I-
band where actin filaments attach. The M-line (M) is the band in the middle of the A-band. 
Unfortunately in this figure the ends of the thin filaments cannot be seen very clearly. The red 
line indicates where the actin filaments would be. Figure from (Tajsharghi 2008). 
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1989). Titin is a huge protein sometimes referred to as the third filament of the 
sarcomere (Figure 1.7). Spanning from the Z disc to the M-line titin is longer than 1 µm; 
the molecular weight is predicted to be 3 MDa and composed of 244 immunoglobulin and 
fibronectin type 3 domains. The roles of titin in the sarcomere are filament assembly, 
maintaining resting tension and elasticity (Labeit, Kolmerer 1995). Myosin binding 
protein-C (MyBP-C) forms 7 strips that run parallel to the M-line (Tajsharghi 2008) (Figure 
1.7) interacting with both the thick and thin filament (Figure 1.8). These stripes appear at 
regular intervals of 43 nm in the C-zone of the A-band (Morimoto 2007). The exact 
function of MyBP-C is unknown however due to the interaction with both thick and thin 
filaments it is thought to align the filaments in the A-band (Clark, McElhinny et al. 2002). 
 
 
The presence of MyBP-C reduces the concentration of myosin needed for polymerisation. 
Figure 1.7  W Schematic drawing of the sarcomere structure. Actin filaments (thin filaments) 
protrude from the Z-disc towards the middle of the sarcomere. Tropomyosin coils around the 
actin filaments blocking the myosin binding sites of actin. Troponin T, I, and C form a troponin 
complex (shown as troponin) and binds two thirds of the way along tropomyosin. Myosin 
(MyHC) tails form filaments (thick filaments) that run parallel to the actin from the M-line 
towards the Z-discs, however they do not reach the Z-disc. Titin is a huge protein that spans 
from the Z-disc to the M-line making it half the length of the sarcomere. Myosin binding 
protein-C (MyBP-C) binds to myosin forming 7-9 transverse stripes across the myosin 
filaments. In reality the MyBP-C does not cover the entirety of the thick filament and is 
especially not present in the bare zone. However this cartoon demonstrates the general 
location of the sarcomeric proteins. The locations of the H and C zone are also a general 
location and not an accurate representation.  Figure from (Morimoto 2007). 
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Polymerisation in the presence of MyBP-C leads to longer filaments of a more uniform 
length compared to those formed in the absence of MyBP-C (Koretz 1979, Davis 1988). 
The major component of the thick filament is myosin which has been described already. 
The major components of the thin filaments are actin, nebulin (not discussed here), 
tropomyosin, and the troponin complex (Figure 1.8).  
 
Globular actin (G-actin) is a protein composed of 4 subdomains (Figure 1.9) which 
surround the binding pocket for a nucleotide (ATP or ADP) and a divalent cation (Mg2+ or 
Ca+2, (Gordon, Homsher et al. 2000)). The sequence of actin is highly conserved, for 
example the amino-acid sequence in human skeletal muscle is 87% identical to yeast 
actin. This high level of conservation is possibly due to over 50 specific actin binding 
proteins being identified in lower and higher eukaryotes (Geeves, Fedorov et al. 2005).  
G-actin can spontaneously polymerise into filaments (F-actin) which forms the backbone 
to the thin filament. F-actin appears to form a helix as the filamentous actin twists (Figure 
1.8). The helix repeats every 13 actin molecules or every 360 Å. The larger subdomains 3 
and 4 are located internally in the double helix and interact with subdomain 3 and 4 of 
the actin in the opposite filament. Subdomains 1 and 2 however are on the outer side of 
Figure 1.8  W Close up schematic diagram of part of the sarcomere. Actin (red) forms the thin 
filament with tropomyosin (dark) coiled around it. The troponin complex is shown as the three 
component parts: troponin T , troponin I, and troponin C. Thick filament proteins myosin 
(green) and myosin binding protein-C (blue) and titin (yellow) are also shown. Figure from 
(Lynch and Sadayappan 2014). 
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the filament and so are exposed to the solvent. These also interact with myosin, in 
particular the N- and C-terminal ends of actin which are found in subdomain 1. Each actin 
interacts with 4 other molecules; one before, one after, and two on the other long-pitch 
helical strand ?dŚĞƐĞŝŶƚĞƌĂĐƚŝŽŶƐĂƌĞƉƌĞĚŝĐƚĞĚƚŽďŝŶĚƚŚƌŽƵŐŚ ? ?ƐƵƌĨĂĐĞůŽŽƉƐĂŶĚ ?ɲ-
helices (Milligan 1996). The total area on the actin surface where myosin binds is 
approximately 2000 Å2 (Geeves, Fedorov et al. 2005).  
 
Tropomyosin (Tm) is an extended molecule (׽42 nm long) that binds to actin (Figure 1.8). 
/ƚŝƐĨŽƌŵĞĚŽĨĂŶɲ-helical coiled-ĐŽŝůŽĨĞŝƚŚĞƌ Pɲ ?ɲŚŽŵŽĚŝŵĞƌƐŝŶĐĂƌĚŝĂĐŵƵƐĐůĞŝŶůĂƌŐĞ
maŵŵĂůƐŽƌɲ ?ɴŚĞƚĞƌŽĚŝŵĞƌƐ (ɲĂŶĚɴĂƌĞĚŝĨĨĞƌĞŶƚŝƐŽĨŽƌŵƐŽĨƚƌŽƉŽŵǇƐŽŝŶ ) in skeletal 
muscle and cardiac muscle of small mammals (Tobacman 1996). Tm is stabilised by 
hydrophobic interactions of non-polar residues in each of the two chains making it more 
energetically favourable for the two chains to form a coil around each other. Tm is 284 
residues long and spans 7 actin monomers on each strand of the F-actin (Gordon, 
Homsher et al. 2000, Schmidt, Lehman et al. 2015). There is a 14 residue quasi-equivalent 
repeat in the structure of Tm and it is thought that the overlap between each successive 
Tm increases the binding affinity of Tm to actin. This was determined by deleting some of 
these repeats which had little effect (Landis, Bobkova et al. 1997, Hitchcock-DeGregori, 
Figure 1.9  W Crystal structure of actin monomer (G-actin). G-actin contains 4 sub-domains 
(numbered 1-4), a nucleotide, and domains that can bind divalent cations. Figure adapted from  
(Clinicgate, 2015). 
                                                                                                                                Chapter 1  W Introduction 
   
17 
 
An 1996) whereas deletion of the overlap region showed a reduction of Tm affinity (Mak, 
Smillie 1981). Tm regulates the binding of myosin to actin through the troponin complex. 
hƉŽŶ^ ?ďŝŶĚŝŶŐƚŽĂĐƚŝŶdŵ ?ƐĂĨĨŝŶŝƚǇĨŽƌĂĐƚŝŶŝŶĐƌĞĂƐĞƐ(Cassell, Tobacman 1996, Eaton 
1976) and flexibility decreases (Szczesna, Fajer 1995) which helps to push myosin off of 
actin when the myosin is in the weakly attached state after the power stroke. These 
effects are greater in cardiac Tm compared to skeletal (Chandy, Lo et al. 1999). 
Troponin (Tn) is a complex of three subunits: troponin I (TnI), troponin C (TnC) and 
troponin T (TnT). TnI binds to actin, inhibiting the actomyosin ATPase in a Ca2+-insensitive 
manner, TnC binds Ca2+, and TnT links the Tm and Tn complex together (Greaser, Gergely 
1973, Mak, Smillie 1981).  
TnI is a subunit of the Tn that holds the complex together and onto actin by binding actin, 
TnC, and TnT. Many of these interactions are regulated by Ca2+. TnI binds to the N-
terminal region of actin (Syska, Wilkinson et al. 1976) and can inhibit myosin binding, 
hence the name TnI (inhibitory troponin). However this inhibitory effect is not responsible 
for the regulation of actin since it is only present in a 1:7 ratio to actin. Binding occurs 
between TnI and TnC dependent upon the presence of Mg2+ or Ca2+ (Ingraham, Swenson 
1984). Upon Ca2+ binding to TnC this interaction between TnI-TnC weakens the binding of 
TnI to actin, to the point where in isolated TnI-TnC bound to actin, the binding of Ca2+ 
abolishes this interaction (Potter, Gergely 1974). 
TnC is the calcium binding subunit of the troponin and senses Ca2+ in muscle regulation. 
When TnC is removed from the muscle it becomes insensitive to Ca2+ activation (Moss, 
Giulian et al. 1985) while added to reconstituted fibres restores Ca2+ sensitivity. TnC 
contains two globular domains at the N- and C-terminal domains connected by a long 
helix. Each globular domain contains two possible Ca2+ binding sites in the form of E-F 
hands (helix-loop-helix motif). The C-terminal end has high affinity for both Ca2+ and Mg2+ 
and while under relaxed conditions Mg2+ is usually bound. This E-F hand also enhances 
the binding of TnI to TnC and TnC to the thin filament (Zot, Potter 1982). The N-terminus 
on the other hand is much more selective for Ca2+ binding over Mg2+ (Potter, Gergely 
1974). Removal of this domain renders muscle fibres insensitive to Ca2+ activation (Sheng, 
Strauss et al. 1990, Sorenson, da Silva et al. 1995). 
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The TnT subunit is involved in holding the Tn complex together and onto Tm by binding to 
TnI, TnC, Tm, and actin. However the role of TnT is not only to bind the complex and Tm 
to actin, it also aids in cooperative activation of the thin filament (Gordon, Homsher et al. 
2000). The C-terminal end of TnT binds to TnC, TnI, and Tm while the N-terminal end 
binds to Tm at the region of overlap which is responsible for Tm affinity to actin (Mak, 
Smillie 1981, White, Cohen et al. 1987). This region of overlap is the most flexible part of 
Tm and so the TnT is in a position to influence this flexibility. TnT isoforms contain hyper 
variable region and some are formed from alternate splice variants (Breitbart, Nguyen et 
al. 1985, Smillie, Golosinska et al. 1988) which gives different TnT isoforms a diverse 
function.  
1.1.5. Cross-bridge cycle 
 
The idea of a cross-bridge cycle by which myosin binds to actin, hydrolyses ATP and walks 
its way along actin had been around since the 1950's. However it was Lymm and Taylor 
who first proposed a correlation between enzymatic and structural changes within the 
myosin (Lymm, Taylor 1971). Myosin on its own will bind and hydrolyse ATP to ADP, 
however this basal activity is very slow. Actin activates the myosin cross-bridge cycle 
acting a competitor to the nucleotide. Compared to the cycle shown below (Figure 1.10) 
the Lymm and Taylor model is a very simple only containing 4 steps. The model used for 
assays in this thesis (Figure 1.10) has a total of 7 steps. In the first step ATP binds to 
myosin in a rigor complex with actin (A.M.T). A rigor complex is unlikely to exist in a living 
muscle due to the abundance of nucleotide (Geeves, Holmes 2005). Geeves and Holmes 
stated that, in the second step the myosin.ATP complex (M.T) dissociates from the actin. 
This is caused by switch 1 (Figure 1.5) closing around ATP which pulls the upper 50 kDa 
domain away from the lower 50 kDa domain opening the actin binding cleft which 
releases actin from myosin (Geeves, Holmes 2005). In the third step two separate but 
important events happen. Firstly the switch 2 is brought into proximity of the bound ATP 
which results in the rotation of the converter/light-chain binding domain which completes 
the recovery stroke.  
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This is necessary for priming the myosin to execute its power stroke and move actin. The 
second event is the hydrolysis of ATP to ADP. This only occurs after switch 1 and switch 2 
ĂƌĞ  ‘ĐůŽƐĞĚ ? ĂŶĚ ĨŽƌŵƐ Ă ƐƚĂďůĞ ŵǇŽƐŝŶ ?W ?Wi complex (M.D.P). The forth step is actin 
rebinding which involves the lower 50 kDa domain binding to actin and the upper 50 kDa 
domain binds and closes the cleft. The closing of the cleft leads into step 5 where Pi is 
released and the relay helix rotates releasing the kink and generates the force needed to 
produce the power stroke which moves the load 5-10 nm. The strain in the converter 
Figure 1.10  W ATP induced actomyosin cross-bridge cycle. Step 1  W myosin is bound to actin in a 
rigor bond (A.M) and ATP can bind to form an actomyosin.ATP complex (A.M.T). Step 2  W the 
binding of ATP causing a dissociation of myosin from actin resulting in a myosin.ATP complex 
(M.T). Step 3  W Unbound from actin myosin hydrolyses the ATP to ADP and inorganic phosphate 
(Pi) to form a myosin.ADP.Pi complex (M.D.P). The myosin also primes itself for a new power 
stroke, this is called the recovery stroke. Step 4  W the M.D.P complex rebinds to actin to form an 
actomyosin.ADP.Pi complex (A.M.D.P). Step 5  W Pi is released and the myosin goes through the 
power stroke pulling actin along relative to the myosin. It is not clear which occurs first so they 
have been shown to occur at the same time. Step 6  W the ADP goes from a strong binding to a 
weaker binding affinity (A.M  W D). Step 7  W ADP is released and the myosin returns to the rigor 
state. 
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domain dissipates by the sliding movement. It is at this point that the nucleotide pocket 
opens in step 6. In the seventh and final step ADP is released due to a weak affinity and is 
replaced by a new ATP if there is one available.  
It is worth noting that the order of phosphate release and power stroke is not defined 
and remains under debate. Also if the force produced in step 5 is not significant enough 
to move the load no sliding will take place and will be inhibited until the load is less or 
more myosins bind to actin to move the load. The movement of the relay helix against 
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1.2. Myosin isoforms 
 
1.2.1. Myosin heavy chain isoform genes 
 
The myosin class II family contains numerous proteins that share a common shape and 
function, located on different genes with small sequence changes. There are at least 13 
different myosin class II heavy chain isoforms in humans. These can be divided into 3 
classes: smooth muscle, striated muscle, and non-muscle myosins (Table 1.1). Of these 13 
isoforms, 9 are striated muscle myosin which will be the focus of this section. These 8 
isoforms are: MyHC-IIa, MyHC-IIb, MyHC-IIx, MyHC-ɲ ?DǇ,-ɴ ? MyHC-extraocular, MyHC-
embryonic, and MyHC-perinatal.  
1.2.1.1. Adult skeletal isoforms 
 
dŚĞƌĞ ĂƌĞ ƚŚƌĞĞ ƐŬĞůĞƚĂů  ‘ĂĚƵůƚ ? ŵǇŽƐŝŶ ŝƐŽĨŽƌŵƐ ? DǇ,-IIx, MyHC-IIa, and MyHC-IIb. 
These are encoded by the genes MYH1, MYH2, and MYH4 respectively found on 
chromosome 17 at position 13.1. MyHC-IIb can be detected at the mRNA and protein 
level in small mammals, such as mice. Only the mRNA is detectable in a small subset of 
adult human muscles, with no expression of the protein (Smerdu, Karsch-Mizrachi et al. 
1994, Ennion, Sant'ana Pereira et al. 1995, Sant'ana Pereira, Ennion et al. 1997, Wu, 
Crumley et al. 2000, Horton, Brandon et al. 2001, Allen, Harrison et al. 2001). However 
the gene is intact and using a recombinant system a functioning protein can be expressed 
(Bloemink, Deacon et al. 2013). These isoforms are expressed after birth in the fast 2A 
and 2B fibres (Smerdu, Karsch-Mizrachi et al. 1994) and kinetic characterisation has 
shown the ADP release rate (thought to be the rate limiting step for velocity) to be very 
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Gene Protein Class Expression Function
MYH1 MyHC-IIx Striated muscle skeletal muscle post birth contraction of skeletal muscle
MYH2 MyHC-IIa Striated muscle skeletal muscle post birth contraction of skeletal muscle
MYH3 MyHC-emb Striated muscle embryo skeletal muscle and regenerating muscle contraction of skeletal muscle
MYH4 MyHC-IIb Striated muscle skeletal muscle post birth contraction of skeletal muscle
MYH6 MyHC-ɲ Striated muscle cardiac muscle contraction of cardic muscle
MYH7 MyHC-ɴ Striated muscle cardiac muscle and slow skeletal contraction of cardic muscle
MYH7b MyHC-7B Striated muscle Unknown Slow twich muslce
MYH8 MyHC-peri Striated muscle embryo skeletal muscle and regenerating muscle contraction of skeletal muscle
MYH9 NMMHC-IIa Non-muscle cell cytoplasm cytokinesis, cell motility, maintaining cell shape
MYH10 NMMHC-IIb Non-muscle cell cytoplasm cytokinesis, cell motility, maintaining cell shape
MYH11 SMMHC Smooth muscle smooth muscles contraction of smooth muscle
MYH13 MyHC-eo Striated muscle specialised muscles including extraocular contraction of extraocular and laryngeal muscle
MYH14 NMMHC-IIc Non-muscle cell cytoplasm cytokinesis, cell motility, maintaining cell shape
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1.2.1.2. Cardiac isoforms 
 
There are two cardiac myosin isoforms expressed in the myocardium; MyHC-ɲĂŶĚDǇ,-
ɴ ? dŚĞƐĞ ŝƐŽĨŽƌŵƐ ĂƌĞ ĞŶĐŽĚĞĚ ďǇ ƚŚĞ ŐĞŶĞƐMYH6 and MYH7 respectively found on 
chromosome 14 at position 12. These genes are; regulated during development, 
distributed in the heart, and react to hormones, stress, and exercise differently (Table 
1.2).  
MyHC-ɲŝƐƚŚĞŵĂũŽƌŝƐŽĨŽƌŵĞǆƉƌĞƐƐĞĚŝŶƚŚĞĂƚƌŝĂŽĨĂůůŵĂŵŵĂůƐĂŶĚǀĞŶƚƌŝĐůĞƐŽĨƐŵĂůů
mammals (Lompré, Nadal-Ginard et al. 1984) however is expressed at low levels in the 
ventricles of larger mammals including humans.  
MyHC-ɴ ŝƐ ŝŶ ĂďƵŶĚĂŶĐĞ ŝŶ ƚŚĞ ǀĞŶƚƌŝĐůĞƐ ŽĨ ŵĂŵŵĂůƐ ĚƵƌŝŶŐ ĚĞǀĞůŽƉŵĞŶƚ ĂŶĚ ŝƐ ƚŚĞ
major isoform present in the ventricles of large mammals including humans. MyHC-ɴ ŝƐ




Investigations using recombinant MyHC-ɲĂŶĚDǇ,-ɴĨŽƵŶĚƚŚĞDǇ,-ɲƚŽŚĂǀĞĂ  ? ?-
fold faster ADP release rate than MyHC-ɴ ?ĨĂƐƚWƌĞůĞĂƐĞƌĂƚĞ ŝƐ ŝndicative of a fast 
type myosin and therefore the MyHC-ɲǁĂƐĨŽƵŶĚƚŽďĞĂĨĂƐƚƚǇƉĞŵǇŽƐŝŶǁŚŝůĞDǇ,-ɴ








Table 1.1  W Directional regulation response of cardiac MYH genes. T3 = triiodothyronine 
thyroid hormone. Adapted from (Weiss, Leinwand 1996) 
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1.2.1.3. Extraocular isoform 
 
The MyHC-eo is a specialised isoform that is thought to be very fast due to its expression 
in the fast twitch fibres in the extraocular and laryngeal muscles (Sartore, Mascarello et 
al. 1987, Lucas, Rughani et al. 1995, Brueckner, Itkis et al. 1996). ATPase kinetics using a 
recombinant-GFP construct found the MyHC-eo to have a Vmax similar to the adult skeletal 
isoforms (Resnicow, Deacon et al. 2010) and stopped-flow spectroscopy found the ADP 
affinity to be weak and ADP release rate to be fast (>1100 s-1) which is characteristic of a 
fast type myosin (Bloemink, Deacon et al. 2013). 
1.2.1.4. Developmental isoforms 
 
There are two developmental isoforms, MyHC-emb and MyHC-peri, which are encoded 
for by the genes MYH3 and MYH8 respectively. MyHC-emb is thought to be a slow type 
myosin similar to the MyHC-ɴ ? ǁŚŝůĞ ƚŚĞ DǇ,-peri is likely to be a fast type isoform. 
Both isoforms are expressed in the developing embryo along with MyHC-ɴ ? dŚĞǇ ĂƌĞ
down-regulated after birth and replaced with the adult isoforms, however they are 
upregulated during muscle damage and repair. Some work has been conducted on the 
kinetics of the two isoforms which found the Vmax of the MyHC-peri to be close to the 
adult isoforms while the MyHC-emb was at the slower end (Resnicow, Deacon et al. 
2010). The MyHC-emb will be described in more detail in Chapter 4. 
1.2.2. Sequence identity 
 
Mammalian MYH genes share a similar intron/exon organisation and are highly conserved 
in terms of their primary structure. It has been suggested from evolutionary comparisons 
of the mammalian MYH genes that this gene family arose from multiple duplications of an 
ancestral MYH gene (Stedman, Eller et al. 1990, Moore, Tidyman et al. 1993). Most of 
these genes are large at approximately 30 kb, encoded on 40-41 exons with the coding 
region beginning at exon 3 (Strehler, Strehler-Page et al. 1986). The striated muscle MYH 
genes are highly conserved (Table 1.3) with a 77-95 % sequence identity.  
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This conservation is even greater when comparing the sequence identities of the same 
myosin isoform between species (Table 1.4). A comparison of the sequence of MYH3 and 
MYH7 in mice, rat, human, cow, and elephant show very high similarity (>95%). 
 
dŚĞ ? ?ĂŶĚ ? ?ƵŶƚƌĂŶƐůĂƚĞĚƌĞŐŝŽŶƐ ?hdZƐ )ŽĨƚŚĞMYH sequences are less conserved than 
the rest of the sequence and as such can be targets for gene specific probes (Lyons, 
Schiaffino et al. 1990, Lyons, Ontell et al. 1990). However when the UTRs of the same 
isoform are compared across species there is greater conservation (Periasamy, Wieczorek 




Table 1.3  W Sequence identities of whole myosin (MYH7 or MYH3) from different species. 
Table 1.2  W Sequence identities of whole human myosin isoforms 
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1.2.3. Sequence differences relate to functional divergence 
 
While the sequence identities of the 8 skeletal myosin isoforms are very similar there are 
still areas of divergence. Two of these regions within the myosin head where there is 
divergence are loop-1 and loop-2 (Figure 1.11).  
There has been much interest in the variable loop-2 region with mutagenic studies 
altering the sequence of the loop. Lengthing the loop with no change in charge has no 
measurable effect on actomyosin ATPase, rate of ATP binding or the binding affinities of 
myosin for actin. Insertion of upto 11 uncharged amino acids only decreases the thermal 
stability of the myosin slightly (Ponomarev, Furch et al. 2000). Replacing the loop of 
smooth-muscle HMM with the loop of either skeletal or cardiac myosin prevented HMM 
regulation similar to the donor myosins. There was however no change in the actin 
affinity or the maximum rate of turn over in the presence of actin (Rovner, Freyzon et al. 
1995). Similarly insertion of loop-2 regions from various species inserted into the 
Dictyostelium myosin-II backbone had similar ATPase activity as the donor myosin (Uyeda, 
Ruppel et al. 1994). 
1.2.4. Expression of isoforms 
 
The expression pattern of the two developmental myosin isoforms has been well 
characterised in the mouse and rat models with MyHC-emb appearing 9.5 days post 
coitum (dpc) and MyHC-peri 10.5 dpc in the mouse (Lyons, Ontell et al. 1990). The 
proximal ends of the developmental myosin genes contain E-boxes stimulating muscle 
commitment and differentiation in response to MyoD and Myf5 binding (Beylkin, Allen et 
al. 2006, Konig, Burkman et al. 2002). Along with these two developmental isoforms, a 
myosin indistinguishable from MyHC-ɴ ŝƐ ĞǆƉƌĞƐƐĞĚ ? /ƚ ǁĂƐ ƐƵŐŐĞƐƚĞĚ ƚŚĂƚ ƚŚĞ ŵǇŽƐŝŶ
expressed differs from the adult form (Hughes, Cho et al. 1993); however this has yet to 
be proven. It has also been suggested that this isoform is the slow tonic myosin coded for 
by MYH7b (Rossi, Mammucari et al. 2010), however this is only detected at low levels or 
in rare fibres. For the time being then it appears the three isoforms expressed during 
development are: MyHC-emb, MyHC-peri, and MyHC-ɴ ? 
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In rats, MyHC-emb and MyHC-ɴĂƌĞĞǆƉƌĞƐƐĞĚŝŶƚŚĞĨŝƌƐƚŵƵƐĐůĞĨŝďƌĞƐƚŽĨŽƌŵ ?ƉƌŝŵĂƌǇ
generation fibres (Narusawa, Fitzsimons et al. 1987, Rubinstein, Kelly 1981)). The second 
fibres to be expressed (secondary generation fibres) express MyHC-emb and MyHC-peri 
(Condon, Silberstein et al. 1990). The developmental isoforms disappear at the same time 
as the adult skeletal myosin isoforms (MyHC-IIa, MyHC-IIx, and MyHC-IIb) are expressed. 
In rats the adult skeletal myosins are detected a few days after birth (DeNardi, Ausoni et 
al. 1993) while in mice the transcripts can be detected before birth (Lu, Allen et al. 1999). 
The timing of the downregulation of the developmental isoforms appears to be 
dependent on the body muscle at both the mRNA (Lu, Allen et al. 1999) and protein 
(Agbulut, Noirez et al. 2003) level. 
The switch from developmental to adult isoforms can be modulated by neural influences 
and extrinsic hormones. Thyroid hormone is required for the switch from MyHC-
emb/MyHC-peri to adult fast myosin. Hyperthyroidism can lead to precocious expression 
of the fast myosins, while hypothyroidism can delay the switch (Butler-Browne, 
Herlicoviez et al. 1984, Gambke, Lyons et al. 1983, Russell, Cambon et al. 1988). Neural 
activity does not seem to be necessary for transition from developmental to fast isoforms 
(Gambke, Lyons et al. 1983, Butler-Browne, Bugaisky et al. 1982), however it does appear 
to be required to promote MyHC-ɴĞǆƉƌĞƐƐŝŽŶŝŶƚŚĞƐŽůĞƵƐŵƵƐĐůĞŝŶƉůĂĐĞŽĨDǇ,-emb 
(Narusawa, Fitzsimons et al. 1987).   
The details of the switch from developmental to adult isoforms remain to be established, 
however probably involves specific sequence regulation of the MYH gene cluster where 
they are in the order: MYH3-MYH2-MYH1-MYH4-MYH8-MYH13. It has been reported that 
there is a long non-coding antisense RNA controlled by thyroid hormone that regulates 
the transition during postnatal development and hypothyroidism. This RNA is transcribed 
from a site between the MYH4 and MYH8 genes and appears to repress the MYH8 gene 
(Pandorf, Jiang et al. 2012).  
There appears to also be an enhancer between the MYH3 and MYH2 genes (Sakakibara, 
Santolini et al. 2014) which upregulates the expression of the fast myosin genes and 
suppress MYH7. Whether there are other locations that control the developmental switch 
is not clear. 
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Myopathies are muscular and neuromuscular disorders which present with muscle 
weakness due to dysfunction of the muscle fibre. Other symptoms can include muscle 
cramps, stiffness, and spasm. Myopathies are grouped as: congenital myopathies; 
muscular dystrophies; mitochondrial myopathies; glycogen storage disease of muscle; 
myoglobinurias (myoglobin in the urine); dermatomyositis (inflammation of the skin and 
muscle tissue); myositis ossificans (bone growth in the muscle); familial periodic paralysis; 
polymyositis (inflammation and degradation of the muscle); inclusion body myositis 
(inflammatory disease of the muscle); and related myopathies; neuromyotonia 
(inflammatory disease of the peripheral nerves); stiff-man syndrome; and common 
cramps and stiffness (National Institutes of Health 2015). This thesis will focus on the 
congenital myopathies.  
The first myopathy described to be cause by a mutation in a MYH gene was in 1990 in a 
case of familial hypertrophic cardiomyopathy (Geisterfer-Lowrance, Kass et al. 1990). The 
first skeletal myopathy causing MYH mutation was identified in 2000 (Martinsson, Oldfors 
et al. 2000). 
There are at least 5 MYH genes that have been found to cause myopathies including: 
MYH2, MYH3, MYH6, MYH7, and MYH8. 
1.3.1. Hypertrophic cardiomyopathy 
 
Cardiomyopathy is a collection of diseases of the heart muscle including: hypertrophic 
cardiomyopathy (HCM), dilated cardiomyopathy (DCM), and arrhythmogenic right 
ventricular cardiomyopathy (ARVC). These are the three most common types of 
cardiomyopathy. Mutations in 10 cardiac sarcomeric proteins have been linked to this 
disease (Table 1.5) with mutations in ɴ-cardiac myosin (MyHC-ɴ ) ĂŶĚ ŵǇŽƐŝŶ ďŝŶĚŝŶŐ
protein-C (MyBP-C) being the two major causes (Figure 1.12). 
More than 300 mutations have been identified in MyHC-ɴ (Seidman, Seidman 2001, 
Buvoli, Hamady et al. 2008, Walsh, Rutland et al. 2010, Colegrave, Peckham 2014), the 
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majority of which are found within the motor domain. Hypertrophic cardiomyopathy is a 
disease of the heart leading to left ventricle hypertrophy (LVH, Figure 1.13). This is a 
thickening on the heart muscle and a reduction of the volume within the ventricle. This 
results in less oxygenated blood being pumped at a much higher force which becomes 
dangerous during intense exercise. 
Table 1.5  W Sarcomeric proteins with mutations associated with cardiomyopathies. The 
chromosomal locus and gene are also given. 
This makes HCM a leading cause of sudden cardiac death (SCD) in young adults and 
athletes effecting <1% of the general population (Fatkin, Graham 2002). While the major 
causes of HCM in adults are mutations in sarcomeric proteins it is less clear what the 
causes are in infants and children. 
Generally speaking the presence of a sarcomeric gene mutation leads patients to present 
with symptoms earlier, have a higher prevalence of family history of HCM and sudden 
cardiac death (SCD) than those who have no mutation (Lopes, Zekavati et al. 2013, 
Olivotto, Girolami et al. 2008). The trend also appears that those with a sarcomeric 
protein mutation have more severe hypertrophy, microvascular dysfunction and 
myocardial fibrosis (Olivotto, Girolami et al. 2011). There is also the suggestion that the 
patients with sarcomeric mutations have a poorer prognosis, however due to small 




1q32 TNNT2 Cardiac troponin T (Thierfelder, Watkins et al. 1994) 
2q31 TTN Titin (Satoh, Takahashi et al. 1999) 
3p21 MYL3 Essential myosin light chain (Poetter, Jiang et al. 1996) 
3p21-p14 TNNC1 Cardiac troponin C (Hoffman, Schmidt-Traub et al. 
2001) 
11p11 MYBPC3 Cardiac myosin binding protein-C (Bonne, Carrier et al. 
1995, Watkins, Conner et al. 1995) 
12q23-q24 MYL2 Regulatory myosin light chain (Poetter, Jiang et al. 
1996) 
14q12 MYH7 ɴ-Myosin heavy chain (Geisterfer-Lowrance, Kass et al. 
1990) 
15q14 ACTC Cardiac actin (Olson, Doan et al. 2000) 
15q22 TPM1 ɲ-Tropomyosin (Thierfelder, Watkins et al. 1994) 
19q13 TNNI3 Cardiac troponin I (Kimura, Harada et al. 1997) 
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Syrris et al. 2012, Moolman, Corfield et al. 1997, Anan, Shono et al. 1998, Torricelli, 
Girolami et al. 2003, Nakajima-Taniguchi, Matsui et al. 1997, Lopes, Rahman et al. 2013). 
Mutations in multiple sarcomeric proteins are present in up to 5% of individuals, with a 
more severe phenotype that presents earlier (Ingles, Doolan et al. 2005, Richard, Charron 
et al. 2003, Girolami, Ho et al. 2010).  
In adults, ,DŝƐĚĞĨŝŶĞĚďǇĂǁĂůůƚŚŝĐŬŶĞƐƐŽĨA? ? ?ŵŵŝŶŽŶĞŽƌŵŽƌĞƐĞŐŵĞŶƚƐŽŶƚŚĞ
left ventricle. In children the diagnosis requires a left ventricle wall thickness greater than 
2 standard deviations from the predicated mean (Elliott, Anastasakis et al. 2014). The wall 
thickness can be measured by a variety of imaging techniques including: 
echocardiography, cardiac magnetic resonance imaging, or computed tomography. Other 




Figure 1.11  W The major causes of cardiomyopathy in adolescents and adults are mutations in 
the sarcomeric proteins. Of the 40-60 % of sarcomeric protein gene mutations the majority are 
caused by mutations in either MYH7 or MYBPC3. Figure adapted from (Elliott, Anastasakis et al. 
2014). 
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Histological studies on the myocardium from hypertrophic cardiomyopathy patients 
(Figure 1.14) show the large structure changes in the diseased heart. The histological 
sample in figure 1.14 shows the hallmarks of HCM: regions of myocyte disarray (Davies 
1984), fibrosis (Anderson, Sutton et al. 1979), and small vessel disease (Maron, Wolfson 
et al. 1986). Myocyte disarray can be characterised by the disorganisation of the 
myocytes, however this is not specific just to HCM (Almaas, Amlie 2010). The amount of 
fibrosis is linked with small-vessel disease, increased septal thickness, cardiac mass, 
increasing age, end-stage heart failure progression and sudden cardiac death (SCD 
(Varnava, Elliott et al. 2001, Basso, Thiene et al. 2000)). 
Due to MyHC-ɴďĞŝŶŐĞǆƉƌĞƐƐĞĚŝŶƚŚĞƐŬĞůĞƚĂůŵƵƐĐůĞĂƐǁĞůůĂƐƚŚĞĐĂƌĚŝĂĐ ?ƐƚƵĚŝĞƐŚĂǀĞ
investigated the skeletal muscle of HCM patients. In vitro motility assays have 
demonstrated impaired function due to the mutated protein presence (Cuda, Fananapazir 
et al. 1993). However histological staining has shown HCM mutations in MyHC-ɴŚĂƐǀĞƌǇ
little effect on the skeletal muscle (Oldfors 2007). 
Figure 1.12  W Diagram of the normal (left) and hypertrophic (right) heart. The muscle of the 
left ventricle becomes much thicker reducing the ventricular volume. Figure from (Bajona, 
Turer 2015). 
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1.3.2. Freeman-Sheldon Syndrome 
 
There are two groups of congenital contractures (over contracted joints from birth) 
observed in children; isolated congenital contracture (eg clubfoot) and multiple 
congenital contractures (arthrogryposis). 1 in 3,000 children are born with arthrogryposis, 
often the cases are sporadic. However children with arthrogryposis are usually found to 
have an underlying inherited syndrome (Bamshad, Jorde et al. 1996, Bamshad, Bohnsack 
et al. 1996, Hall, Reed et al. 1982, Krakowiak, O'Quinn et al. 1997). The most common of 
the inherited arthrogryposis syndromes affect the distal limbs (hands and feet) leading to 
camptodactyly and club foot. There are 10 of these distal arthrogryposis (DA) syndromes 
(Bamshad, Jorde et al. 1996). 
Freeman-Sheldon Syndrome (FSS) or DA2A is the most severe but very rare distal 
arthrogryposis syndrome which causes contractures of the orofacial muscles (Freeman, 
Sheldon 1938). This causes a pinching of the lips and reduces the mouth opening, hence 
ƚŚĞŽƚŚĞƌŶĂŵĞŽĨ&^^ ‘ǁŚŝƐƚůŝŶŐĨĂĐĞƐǇŶĚƌŽŵĞ ? ?&ŝŐƵƌĞ  ? ? ? ? ) ?dŚĞƌĞĂƉƉĞĂƌƐƚŽďĞŶŽ
gender preference (Gross-Kieselstein, Abrahamov et al. 1971). The only treatment for 
individuals with FSS is surgery to try and correct the over contracted joints, however this 
leads to a high risk of mortality due to difficulty supplying air to the patient (intubating) 
Figure 1.13  W Example histological images of the myocardium in either a normal (A) and 
hypertrophic cardiomyopathy (B) sample. The hypertrophic cardiomyocytes show myofibre 
disarray and fibrosis. Figure adapted from (Yilmaz, Kindermann et al. 2010) 
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while under anaesthetic (Yamamoto, Osuga et al. 1994) as well as the general risks of 
anaesthetics.  
A reason why the entire musculature system of the mouth is involved in this myopathy is 
unclear. Biopsies of the orbicularis oris (muscle around the mouth), masseter (lower jaw 
muscle), buccinators (muscle within the cheek) and risorius (the muscle of facial 
expression) muscles show atrophy of the fibres and adipose infiltration, as well as fibrosis, 
variation in fibre diameter and central migration of the nucleus (Ferrari, Bettuzzi et al. 
2008, Burian 1962, Malkawi, Tarawneh 1983). 
DA syndromes are characterised as a group of similar disorders characterised by multiple 
congenital contractures of the upper and lower limbs (Hall, Reed et al. 1982, Bamshad, 
Jorde et al. 1996, Beals 2005, Hall 2014). This results in contractures of the hands (Figure 
1.15B) and feet (Figure 1.15C). Unlike other DA syndromes the facial muscles of FSS 
patients are severely contracted resulting in a small oral opening resembling a whistling 
face (Freeman, Sheldon 1938, Stevenson, Carey et al. 2006). 
Unlike the most common DA syndrome Sheldon-Hall syndrome (SHS) the only known 
cause for FSS is a mutation in the embryonic myosin gene, MYH3 (Figure 1.16(Beck, 
McMillin et al. 2014)). Analysis by Beck et al. revealed that the 3 most common mutations 
that cause FSS were: Threonine-178-Isoleucine (T178I), Arginine-672-Cysteine (R672C), 
and Arginine-672-Histidine (R672H). These were ranked in order of severity with T178I 
being the most, R672C the least and R672H intermediately severe. This was determined 
Figure 1.14  W Clinical characteristics of Freeman-Sheldon syndrome. (A) Child with a severe 
contracture of the facial muscles giving the phenotypic whistling face. (B) and (C) A common 
phenotype among DA syndrome patients is contracted hands (Camptodactyly) and feet (club 
foot). Figure from (Toydemir, Rutherford et al. 2006) 
A B C 
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by ranking the affected areas using a severity score with T178I ranking highest in all areas. 
Curvature of the spine (scoliosis), while found in all three mutants with no varying 




It is worth noting that this myopathy while caused by a mutation in the embryonic myosin 
persists beyond the developmental stage where embryonic myosin is expressed.  
Figure 1.16  W Radiograph of an individual with a T178I mutation in the embryonic myosin 
showing the severe curvature of the spine. Figure from (Beck, McMillin et al. 2014). 
Figure 1.15  W Location of mutations on the myosin molecule in MYH3 that cause FSS. They are 
all located in the head and IQ domains. Figure adapted from (Toydemir, Rutherford et al. 2006). 
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Histological samples from a FSS patient at 15 months showed an abnormally large 
number of fibres (>20% of all fibres) expressing the perinatal myosin isoform (Figure 
1.18). This was compared to samples from 8 controls aged 10-15 months where there 
were only the occasional fibres (0-2% of all fibres) expressing the perinatal isoform 
(Tajsharghi, Kimber et al. 2008). 
 
A study into force production and relaxation of myofibrils from a R672C patient showed 
that the specific force was greatly reduced. While the absolute force was increased on the 
wild type the cell diameters were much greater and appeared hypertrophic. The 
relaxation time was also found to be prolonged and the relaxation of the myofibrils never 
reached completion (Racca, Beck et al. 2015).  
1.3.3. Other myopathies 
 
Mutations in the MYH2 gene that encodes the MyHC-IIa myosin isoform lead to 
autosomal dominant myopathy with congenital joint contractures, ophthalmoplegia 
(paralysis ŽĨĞǇĞŵƵƐĐůĞƐ )ĂŶĚƌŝŵŵĞĚǀĂĐƵŽůĞƐ ?/ƚŝƐĂůƐŽŬŶŽǁŶĂƐ ‘ĂƵƚŽƐŽŵĂůĚŽŵŝŶĂŶƚ
ŵǇŽƐŝŶŚĞĂǀǇĐŚĂŝŶ//ĂŵǇŽƉĂƚŚǇ ? ? ? ?< ) ?ĂŶĚ ‘,ĞƌĞĚŝƚĂƌǇŝŶĐůƵƐŝŽŶďŽĚǇŵǇŽƉĂƚŚǇƚǇƉĞ
 ? ?(Oldfors 2007). Clinical characteristics of this myopathy include: congenital joint 
contractures, ophthalmoplegia, mild proximal muscle weakness during childhood, and 
impaired movement in middle age. Children with this disease have either no or very few 
A B
Figure 1.17  W Histological samples stained for the perinatal myosin isoform while the unstained 
ĨŝďƌĞƐ ĂƌĞ ĞǆƉƌĞƐƐŝŶŐ ƚŚĞ ĂĚƵůƚ ĨŝďƌĞƐ ?  ? ? DƵƐĐůĞ ďŝŽƉƐǇ ĨƌŽŵ Ă &^^ ƉĂƚŝĞŶƚ ?Ɛ ƚŝďŝĂůŝƐ ĂŶƚĞƌŝŽƌ
muscle at 15 months. (B) A specimen from a healthy control subject at 11 months showing only 
a few scattered fibres expressing perinatal myosin. Figure from (Tajsharghi, Kimber et al. 2008). 
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and small type 2A muscle fibres (Martinsson, Oldfors et al. 2000, Darin, Kyllerman et al. 
1998, Tajsharghi, Thornell et al. 2002). Adults on the other hand, show dystrophic 
changes with fibre thickness variation and increased interstitial fat and connective tissue. 
Hypertrophic cardiomyopathy is not the only disease caused by a mutation in the MYH7 
gene. Dilated cardiomyopathy (DCM) can also be caused by mutations in the MYH7 
however unlike the LVH seen for HCM the left ventricle wall becomes thinner and the 
volume within the ventricle increases. With this the ventricle becomes stretched or 
 ‘ďĂŐŐǇ ?ĂŶĚ ƚŚĞ ŵƵƐĐůĞ ŝƚƐĞůĨďĞĐŽŵĞƐǁĞĂŬĞƌĂŶĚŶŽƚĂďůĞ ƚŽ ƉƵŵƉďůŽŽĚĂƌŽƵŶĚ ƚŚĞ
body efficiently (British Heart Foundation 2016). 
A second disease associated with a mutation in the MYH7 gene is Laing early onset distal 
myopathy (Laing, Laing et al. 1995). The clinical findings are initially muscle weakness of 
the ankle dorsiflexors and big toe extension. Onset is usually during the first or second 
year of life with slow progression leading to weakness of the wrists and fingers. Weakness 
spreads to the majority of the body however most patients remain mobile throughout 
their lives. One oddity of this disease is that it is a mutation in the MYH7 gene however 
only one case has shown heart failure (Hedera, Petty et al. 2003). 
Another disease associated with a mutation in the developmental myosins is Trismus-
pseudocamptodacyly syndrome (DA7) caused by a mutation of R674Q in the perinatal 
myosin gene MYH8 (Oldfors 2007, Veugelers, Bressan et al. 2004, Toydemir, Chen et al. 
2006). This arginine is paralogous to the R672 that can be mutated in embryonic myosin 
to cause FSS (Toydemir, Rutherford et al. 2006). Symptoms of this myopathy include 
problems opening the mouth (trismus), short finger flexor tendons leading to involuntary 
movement of the fingers when the wrist is bent (pseudocamptodactyly) and short leg 
muscles resulting in foot deformity (Hall, Reed et al. 1982). 
Myopathies are complex diseases where little is known how the mutations can cause the 
severe phenotypes that present. Animal models can only work so far, especially with the 
cardiomyopathies since mice and rats have a different ratio of MyHC-ɲĂŶĚDǇ,-ɴŝŶƚŚĞ
atria and ventricles. In fact mice have almost entirely MyHC-ɲ ŝŶ ƚŚĞ ǀĞŶƚƌŝĐůĞ ǁŚŝĐŚ
becomes problematic when investigating human diseases. For example the mutation of 
R403Q in MyHC-ɲďĞŚĂǀĞƐƚŚĞŽƉƉŽƐŝƚĞƚŽƚŚĞŵƵƚĂƚŝŽŶŝŶDǇ,-ɴ(Lowey, Lesko et al. 
2008).  
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Recombinant myosin II is hard to obtain since chaperones are needed for the protein to 
fold correctly. Using a cell line derived from mouse myoblasts, studies were conducted to 
investigate the roles of these chaperones (Srikakulam, Winkelmann 1999). A by-product 
of this was an expression system that could be used to produce recombinant myosin or 
^ ? ?hƐŝŶŐĂĚĞŶŽǀŝƌƵƐ ?ƚŽ ŝŶĨĞĐƚƚŚĞƐĞĐĞůůƐ ŝƚǁĂƐƉŽƐƐŝďůĞƚŽƉƌŽĚƵĐĞƚŚĞŚƵŵĂŶŵǇŽƐŝŶ
isoforms and mutations for kinetic study (Resnicow, Deacon et al. 2010, Deacon, 
Bloemink et al. 2012, Bloemink, Deacon et al. 2013, Bloemink, Deacon et al. 2014, Nag, 
Sommese et al. 2015). It is with this method that was used here to characterise the 
embryonic myosin isoform as well as disease causing mutations in the MyHC-emb and 
MyHC-ɴ ? 
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1.4. Stopped-flow Spectroscopy 
 
Stopped-flow spectroscopy is a method of measuring kinetic parameters over very small 
time scales allowing fast reactions to be monitored. There are advantages to this method 
over conventional steady state assay in that intermediate products can be observed and 
their lifetimes measured. 
1.4.1. How it works 
 
The stopped-flow spectrometer used in this thesis was produced by TgK Scientific. With 
this set up there are two drive syringes that are filled with the separate reactants (Figure 
1.19). With use of a pneumatic ram the plungers of the syringes are pushed rapidly and 
simultaneously to expel the reactants by a drive plate. The reactants flow rapidly into the 
mixing chamber prior to the observation cell where the reaction is measured. The mixing 
time depends upon the rate at which the samples were pushed and the internal volume 
of the observation cell.  
 
The stopped-flow can either be used to measure fluorescence or absorbance. For 
absorbance the optical light path should be used opposite the detector, while for 
fluorescence the detector needs to be 90° from the light source or the emitted light will 
be lost in the excitation light.  
Figure 1.18  W Schematic of the single mixing stopped-flow. Figure from (TgK Scientific 2016) 
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When the reactants reach the observation cell its volume displaces the previous reactants 
which travel down a separate waste tube to a third syringe, the stopping syringe. As this 
fills the plunger strikes a backstop which is linked to a trigger. When this is activated the 
drive plate stops pushing the two drive syringes ensuring an exact volume of both 
reactants is mixed. It is always important to remember that the concentration of the 
reactants inside the observation cell is half of that in the drive syringes. 
1.4.2. Uses 
 
As mentioned above, stopped-flow can be used to great effect at measuring very rapid 
kinetics on millisecond time scales. It also lends itself to be used with either fluorescence 
or absorbance. While the use of steady state kinetics is invaluable to determine the 
overall behaviour or a reaction, in this case myosin  W the ATPase cycle, transient kinetics 
determined from the stopped-flow can give insights into the intermediates formed 
throughout the cycle (De La Cruz, E. M., Ostap 2009).  
Transient kinetics rather simply only needs 3 things: (1) a signal/chemical/optical change 
that can be measured, (2) rapid physical or chemical change that disrupts equilibrium e.g. 
a concentration or temperature change, (3) the ability to measure the formation of a new 
equilibrium with appropriate time resolution (De La Cruz, E. M., Ostap 2009). 
Stopped-flow therefore lends itself perfectly to measure the rapid kinetics of myosin 
which can bind ATP, detach from actin, hydrolyse ATP, rebind to actin, and release the 
products of hydrolysis in milliseconds. Pyrene is fluorescent tag can be chemically 
attached to actin to allow measurement of the ATPase cycle. When bound to actin the 
myosin molecule can quench the fluorescence of the pyrene. The increase in fluorescence 
associated with the myosin dissociation lends itself to measuring the ATPase cycle. By 
using this increase in fluorescence steps proceeding the dissociation (such as ADP release 
and ATP binding) and the dissociation step can be measured. Scheme 1.1 show the 
constants throughout the ATPase cycle that will be discussed in this thesis. 
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The values of K'1 and K'2 have significance in highlighting myosins that bind ATP weakly or 
tightly and quickly or slowly. For example myosins that bind ATP weakly and slowly do so 
because they have a large and weak K'1. As such the physiological ATP concentrations can 
be nonsaturating. Some myosins can which between an open and closed nucleotide 
pocket (Scheme 1.1). The K'1 can be shifted due to allosteric communication in actin-
attached myosin VI dimmers. Intramolecular load can affect the k'+2 of some myosins (De 
La Cruz, E. M., Ostap 2009).  
ATP binding to myosin can be followed by intrinsic tryptophan fluorescence. For most 
myosins ATP binds rapidly and irreversibly and release phosphate very slowly. 
Interpretation of this data is straight forward and can be due to one of two things. 
1. In a system where there is only a single fluorescence change. ATP induces a 
change originating from the population of Myosin.ADP.Pi state. The transients are 
well described by a single exponential and  plot of the observed rate constant 
versus the ATp concentration is hyperbolic with the maximum rate being the sum 
of the forward and reverse rates of ATP hydrolysis (k+3 + k-3) (De La Cruz, E. M., 
Ostap 2009). 
2. In a system where there are multiple fluorescence changes. Where the transients 
are well described by a double exponential the faster state can be described as the 
Scheme 1.1  W Myosin ATPase cycle used for the data in table 4.1 and figure 4.9. A = actin, M = 
myosin, T = ATP, D = ADP,  P = phosphate, '.' = tightly bound, '-' = weakly bound. Ki = k+i/k-I for 
example K1 = k+1/k-1. 
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fluorescence change upon ATP binding or population of M*.ATP (where * denotes 
a fluorescence change) and the slower component is caused by the population of 
M**.ADP.Pi. In some cases the faster phase can be too fast to be measured by 
stopped-flow spectroscopy and appears as a single exponetial (De La Cruz, E. M., 
Ostap 2009). 
ADP binding to actomyosin can also be measured using stopped-flow spectroscopy to 
determine the ADP affinity. Acto.S1 is rapidly mixed with a constant ATP and varied 
concentrations of ADP. The transients can be described one of two ways: 
1. If mixing of the solutions follows a single exponential at all ADP concentrations it is 
indicative of ADP binding in a rapid equilibrium. As the ADP concentration 
increases the observed rate constant should become slower.  
2. When ADP release is slower than ATP binding and not in rapid equilibrium the 
transients can be well described by double exponentials with fast and slow phases 
depending on the ADP concentration when the ATP concentration is held 
constant. The ADP dependence of the fast phase may depend hyperbolically on 
the ADP concentration which indicates that ADP binding, much like ATP binding 
occurs via a teo-step binding process (De La Cruz, E. M., Ostap 2009).  
1.4.3. Limitations 
 
While stopped-flow seems ideal for measuring the rapid kinetics of chemical and 
biochemical reactions there are some drawbacks that need to be considered. The ability 
to measure a reaction is limited by the dead time which is determined by the end of the 
mixing and the start of the measurement. In order to reduce the dead time a smaller 
observation cell can be used to reduce the dead time to below 1 millisecond. Two other 
limitations are the volume and concentration protein needed to make these 
measurements.  
The concentration of reactants is very dependent on the signal to noise seen in the 
transients. Some fluorophores behave very well and will provide large amplitudes while 
others may only give a flat transient. A second consideration is the concentration of the 
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substrate compared to protein. A substrate concentration is usually 3-fold greater than 
the enzyme to satisfy a pseudo-first order reaction making analysis simpler than a second-
order reaction. 
The volume of reactants needed for the stopped-flow assays is a rather fixed volume. 
EŶŽƵŐŚ ǀŽůƵŵĞ ŚĂƐ ƚŽ ďĞ ƉƵƐŚĞĚ ƚŚƌŽƵŐŚ ƚŚĞ ƐǇƐƚĞŵ ŝŶ ĞĂĐŚ  ‘ƐŚŽƚ ? ƚŽ ĚŝƐƉůĂĐĞ ƚŚĞ
ƉƌĞǀŝŽƵƐ ‘ƐŚŽƚ ?ƚŽĂǀŽŝĚĂŶǇĞƌƌŽƌŝŶŵŝǆŝŶŐ ?ƌƵůĞŽĨƚŚƵŵďƵƐĞĚŝƐĂƐŚŽƚǀŽůƵŵĞ ?ƚŝŵĞƐ
the observation cell volume; therefore for a 5 µL cell as little as 15 µL shot volumes are 
needed. However using a smaller observation cell can compromise the amplitude and 
reduce the signal to noise in transients. These are issues that should be addressed to help 
those wanting to use stopped-flow for the powerful technique it is at determining kinetic 
parameters but are held back by having low yields or expensive protein. 
Another limitation of this method is that the system needs to be kept at a reasonable 
temperature to prevent leaks from occurring. For example if the temperature were to be 
changed from 2 °C to 45 °C, the contraction and expansion of the valves would lead to a 
leak in the system. While specialised equipment exists to measure kinetics at the 
extremes of temperature, there is no simple solution that allows a broad range of 
temperatures to be used without having to change cooling or heating equipment. This is 
therefore something that should be addressed. 
1.5. Aim of the project 
 
1. The first aim of this thesis is to develop a modification to the stopped-flow instrument 
that would allow the assays to be conducted at a constant temperature that is 
different to the main water bath. This would need to be a simple design that could be 
adapted to instruments by different manufacturers and could heat or cool the 
samples before mixing. Most stopped-flow assays are conducted at 20 °C or below to 
reduce expansion or contraction of valves and therefore cause leaks in the system. 
Using an external thermal control before mixing will allow biological assays to be 
conducted at physiological temperatures (e.g. 37 °C) when possible. Investigating this 
prototype in its efficacy at heating and cooling samples before mixing to a desired 
temperature will be essential to determine if it is working as designed. Studies have 
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already shown how temperature affects the ATP induced dissociation of myosin S1 
from pyrene-labelled actin (Millar, Geeves 1983, Iorga, Adamek et al. 2007). 
Comparing the new method to the published data will show how effective this 
manifold is at adjusting the temperature before mixing rather than having no 
manifold present. 
2. The second aim is to address the largest limiting factor of using stopped-flow, which is 
the volume of sample needed. By developing an adaptation to the stopped-flow 
between the drive syringes and observation cell it could be possible to reduce the 
volume of sample needed. Some protein samples can be very precious, whether due 
to a low expression, or an expensive process to produce them. Wasting large 
quantities of these proteins on preparing the system before data collection begins is 
not desirable. This may even be such a limiting factor that stopped-flow cannot be 
used and answers to very important kinetic questions not found. This manifold 
therefore would open the option to used stopped-flow to researchers not previously 
able to use it. 
3. To investigate the effects of the three most common causes of Freeman-Sheldon 
syndrome on the embryonic myosin, the wild type MyHC-emb will firstly need to be 
kinetically characterised. Using the recombinant expression system wild type MyHC-
emb S1 will be expressed and used in stopped-flow and ATPase assays. This will be 
compared to the MyHC-ɴ ? because both are thought to be slow type myosins, and 
therefore have similar kinetic features. Using the same recombinant expression 
system the three mutations; T178I, R672C, and R672H will be individually 
investigated. The aim is to find a common change in the kinetic parameters compared 
to the wild type MyHC-emb. The X-ray crystallography structures of the scallop 
myosin will be used to build homology models of the MyHC-emb as the S1 goes 
through the cross-bridge cycle. The scallop structures will also be investigated to 
validate the interactions observed. The mutations will then be inserted into the 
structures to investigate whether any interactions seen in the wild type myosin are 
lost. This could give a molecular explanation to how the mutations can affect the 
cross-bridge kinetics or cause the myopathy. 
4. Finally I will investigate the kinetic parameters of the hypertrophic cardiomyopathy 
mutation that has been identified as a cause of juvenile HCM. A couple of adult HCM 
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mutations have been characterised previously and showed very small changes in the 
kinetics (Nag, Sommese et al. 2015, Bloemink, Deacon et al. 2014). Since juvenile HCM 
presents itself earlier there is the possibility that the mutations are more severe. The 
aim of this investigation is to observe whether the juvenile HCM mutation H251N is 
more severe than the adult HCM mutations. 
The overall aims of this thesis are to provide better understanding of myosin myopathies. 
Also to provide new modifications to stopped-flow spectrometers, this will allow future 
investigations to be conducted in a simple and cost effective manner. 
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ATP     Boehringer 
ADP     Boehringer 
Pyrene     Molecular Probes 
EDTA free protease inhibitor  Roche 
All other chemicals and reagents used, including distilled water, were supplied from 
Melford laboratories, Sigma-Aldrich, or Fisher chemicals. Stock solutions were made using 
the chemicals for use in buffers. 
2.1.2 Buffers 
 
5X SDS-PAGE sample buffer: 
0.625 M Tris base, 40 % Glycerol, 10 % SDS, 10% 2 mercaptoethanol, 0.005% 
Bromophenol Blue 
 
Rabbit S1 digestion buffe: 
125 mM KCl, 10 mM KPi (pH 6.2 at RT), 2 mM EDTA, 2 mM DTT 
 
Guba-Straub: 
100 mM KH2PO4, 50 mM K2HPO4, 300 mM KCl, pH 6.6 (at RT)   
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Myosin storage buffer: 
500 mM KCl, 10 mM KPi pH 6.5, and 1 mM DTT + equal volume of glycerol 
 
Lysis buffer: 
20 mM Imidazole, 100 mM NaCl, 50 mM Tris pH 7.4, 1 x EDTA free protease inhibitor, 3 
mM ATP, 0.5% Tween-20, 1 mM DTT 
 
His-Trap buffer A: 
50 mM Tri , 500 mM NaCl, 0.05 % Tween-20, 1 mM DTT, pH 7.0   
 
His-Trap buffer B: 
50 mM Tris pH 7.0, 500 mM NaCl, 0.05% Tween-20, 1 mM DTT, 1 M Imidazole, pH 7.0  
 
Acetone powder resuspension buffer:  
10 mM NaHCO3, 10 mM Na2CO3, and 0.1 mM CaCl2 
 
Actin buffer: 
10 mM Tris, 0.5 mM ATP, 0.2 mM CaCl, 1 mM DTT, pH 8.0 (at RT)  
 
Imidazole temperature manifold stopped-flow buffer: 
100 mM KCl, 20 mM Imidazole, 1 mM NaN3, 40 % ethylene glycol, pH 6.5 (at RT)    
 
Cacodylate temperature manifold buffer: 
30  W 100 mM KCl, 20 mM cacodylic acid, 5 mM MgCl2, 1 mM NaN3, (40 % ethylene glycol), 
pH 7.0 (at RT)  
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Micro-volume manifold stopped-flow buffer: 
100 mM KCl, 25 mM HEPES, 5 mM MgCl2, pH 7.0 (at RT)  
 
Recombinant S1 stopped-flow buffer: 
25 mM KCl, 20 mM MOPS, 5 mM MgCl2, 1 mM DTT, pH 7.0 (at RT)  
 
NADH-coupled ATPase assay buffer: 
12 mM PIPES, 2 mM MgCl2 and 1 mM DTT, pH 6.8 (at RT) 
2.1.3 Hardware and apparatus 
 
Stopped-flow SF-61 DX2 
 
TgK (Hi-Tech) Scientific SF-61 DX2:   TgK Scientific, Bradford-on-Avon, UK 
Optical filters:      Schott, Germany 
Temperature controlled water baths:  K20, Haake, Germany 
       RM6, Lauda-Brinkmann, USA 




Cary 50 UV      Varian, Germany 
Quartz cuvettes     Hellma, Germany 
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Eppendorf 5415R     Eppendorf, Germany 
Beckman J-26 XP     Beckman, USA 




Akta FPLC UPC-900, P-920, and FRAC-950  GE Healthcare, UK 




Weighing scales     Sigma-Aldrich 
pH-meter      Sigma-Aldrich 
Pipettes      Gilson, USA 
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2.2 Protein preparation and purification 
 
2.2.1 Rabbit myosin and S1 preparation and purification 
 
The preparation of rabbit muscle proteins, rabbit myosin and rabbit myosin subfragment 
1 (S1) was kindly performed by Dr. Nancy Adamek and Sam Lynn. 
2.2.1.1 Rabbit myosin extraction 
 
The back and leg muscles from two rabbits were dissected immediately post mortem and 
stored on ice. After removing all fat and ligaments the muscle was minced using a meat 
mincer and left to stir in 3 L of Guba-Straub for 30 mins at 4 °C. This was then centrifuged 
at 5 ,000 rpm using a Beckman JA-10 rotor for 30 mins. The supernatant was used for the 
myosin preparation while the pellet was used to purify actin and thin filament proteins. 
Rabbit myosin was prepared by the same method as Margossian and Lowey (Margossian, 
Lowey 1982). Supernatant was filtered through a cheese cloth to remove large parts of 
unhomogenised muscle then through homogenised filter paper to remove fat. The filtrate 
was added rapidly to 30 L of cold water and left overnight at 4 °C to allow the myosin to 
precipitate. The water was then siphoned off and the precipitated myosin centrifuged for 
45 mins at 5 ,000 rpm. The pellet was re-suspended in 1 L 0.5 M KCl and purified further 
by adding the myosin solution to 10 L of cold water and left overnight at 4 °C to 
precipitate the myosin. The supernatant was removed and the precipitated myosin 
centrifuged for 20 mins at 12 ,000 rpm. At this stage the myosin could be stored at -20 °C 
by dissolving the pellet in myosin storage buffer. 
2.2.1.2 Rabbit myosin subfragment 1 (S1) preparation and purification 
 
Fresh myosin or myosin from a glycerol stock was allowed to precipitate in a large volume 
of distilled water (dH2O) overnight. The next day the supernatant was siphoned off and 
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the remainder centrifuged for 45 mins at 5 ,000 rpm. The pellets were dissolved in the 
rabbit S1 digestion buffer. Assaying the myosin at this point should give a concentration 
between 10-20 mg/mL for optimal digestion. The mixture was then warmed to 23 °C and 
0.1 mg Chymotrypsin per mL of solution was added and left to stir at 23 °C for 10 mins 
exactly. To stop the digestion 0.5 mM phenylmethylsulfonyl fluoride (PMSF) was added 
and the solution left to stir for 10 mins. The digested myosin solution was dialysed against 
5 mM KPi pH 6.5 for 12 hours. After dialysis the solution was centrifuged for 1 h at 12 
,000 rpm and the S1 was then purified by use of anion-exchange chromatography on a 
DEAE-sephacel column (500 mL gel bed volume), which had been equilibrated with 50 
mM Imidazole pH 7.0. A KCl gradient of 0-250 mM KCl was used to elute the S1. UV 
spectroscopy was used to determine the final concentration of the S1 using the extinction 
coefficient at 280 nm ɸ1% = 7.9 cm-1 for S1 and a molecular weight of 115 kDa (Boussouf et 
al, 2007).  
An equal amount of sucrose (w/w) of sucrose could be added to S1 and then freeze dried 
to allow for long term storage. The S1 powder could then be dissolved in one of the 
stopped-flow buffers and dialysed into the same buffer to remove sucrose. This solution 
is stable for 2-3 weeks at 4 °C. 
2.2.1.3 Recombinant His-tagged human S1 expression 
 
The expression of the recombinant human myosin S1 proteins were kindly performed by 
Carlos Vera, Stephen Langers, and Ariana Combs as previously described by Resnicow et 
al. 2010 (Resnicow, Deacon et al. 2010). 
Shuttle plasmids containing the coding regions of the MYH3 or MYH7 genes (Methionine-
1  W Serine-843) were constructed upstream of a 6x-Histidine tag. Using the pAdEasy kit 
(MP Biomedicals), these plasmids were used to construct recombinant replication-
deficient adenovirus that expressed either MYH3 or MYH7. The mutations were created 
using site directed mutagenesis to produce the MYH3 R672H, R672C, and T178I mutants 
and the MYH7 H251N mutant. HEK293 cells were used to amplify the viral particles, and 
the cell lysates were clarified using caesium chloride gradients with the concentrated 
virus being stored in a glycol buffer at -20 °C. 
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For the culturing of C2C12 cells 4-ůĂǇĞƌEƵŶĐ ?ĐĞůůĨĂĐƚŽƌǇƐǇƐƚĞŵƐ (Thermo Fisher) were 
used to increase culturing capacity. The C2C12 cells needed to be allowed to differentiate 
from myoblasts to myotubes. To measure the concentration of virus an OD260 = 1.1 x 10
12 
particles per mL was used (Mittereder, March et al. 1996). Infected C2C12 cells were 
incubated for 5 days then frozen into a cell pellet. 
2.2.1.4 Recombinant His-tagged human S1 purification 
 
One cell pellet was incubated at 37 °C for 1 min before addition of 3 mL of lysis buffer. 
When the pellet was fully defrosted the volume was made up to 18 mL with lysis buffer. 
The sample was then homogenised using a glass homogeniser (Fisher Scientific) to form a 
homogeneous solution. The cell lysate was centrifuged at 100 ,000 rpm in the Beckman 
ultracentrifuge for 20 mins to remove the majority of the cell contents. The supernatant 
was then filtered through a 5 µm Minisart single use syringe filter (Sartorius Stedim 
Biotech, Germany) then the volume was made up to 18 mL using lysis buffer. 5 M NaCl 
was added to the solution to bring the final NaCl concentration to 0.5 M. A His-Trap HP 1 
mL nickel column was equilibrated with His-Trap buffer A. The recombinant S1 was added 
to the column, washed with 20 mL of His-Trap buffer A. The recombinant S1 was then 
eluted using a 0-1 M stepped Imidazole gradient, eluting from the column at around 350 
mM Imidazole using His-Trap buffer B. The fractions were run on an SDS-PAGE gel to find 
the best fractions to pool. Samples were dialysed overnight into the recombinant S1 
stopped-flow buffer. The concentration of the S1 was determined using UV spectroscopy 
(extinction coefficient at 280 nm ɸ1% = 7.9 cm-1 and a molecular weight of 115 kDa 
(Boussouf et al, 2007)). Cell pellets weighing approximately 0.6 g derived from 1,500-
3,000 mL would yield between 1-2 mL 10-20 µM active S1. Wild type S1 was stable at 4 °C 
for up to 2 weeks, addition of equal amount of sucrose (w/w) and stored at -20 °C was 
kinetically active for up to 4 months.  
In order to determine the active concentration of S1 an activity test was performed. In 
order to do this the S1 concentration is then doubled to observe the relative amplitude 
also doubles or increases. This is repeated until the relative amplitude remains the same. 
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Dividing the initial concentration by the overall increase in S1 concentration compared to 
the start gives the concentration of active S1. 
2.2.2 Actin purification and preparation 
 
Acetone powder, F-actin, and pyrene-labelled F-actin were kindly prepared by Dr. Nancy 
Adamek and Sam Lynn. 
2.2.2.1 Acetone powder 
 
The pellet obtained from the first centrifugation from the myosin extraction which 
contained the actin and thin filament proteins was dissolved in 5 L of buffer containing 4 
% NaHCO3 and 0.1 mM CaCl2. This was left to stir at 4 °C for 30 mins. The solution was 
then filtered through a cheese cloth, and the filtrate discarded. The residue from the 
filtration step was re-suspended in 1 L of acetone powder resuspension buffer. At room 
temperature, 10 L of water was added, stirred for 1 min and then filtered a second time, 
again discarding the filtrate. The residue was dissolved in 2.5 L cold acetone and left to 
stir for 20 mins. This was filtered through cheese cloth and the filtrate discarded. The 
process of re-suspending in acetone and filtering was repeated 3 further times until the 
residue becomes fibrous. The residue was then dried between two pieces of blotting 
paper for 1-2 days. When the powder was dry it was sieved to form a fine powder and 
could be stored at -20 °C. 
2.2.2.2 F-actin preparation 
 
The method of F-actin preparation is based on the method of Lehrer and Kerwar (Lehrer, 
Kerwar 1972). 1-2 g of acetone powder was dissolved in 200 mL of cold actin buffer and 
left to stir for 30 mins.  Using a double layer of cotton cloth the mixture was filtered 
under vacuum and the filtrate, which extracts the actin from the acetone powder leaving 
behind the tropomyosin and troponin, then centrifuged for 1 h at 30,000 rpm. In order to 
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polymerise the actin 3 M KCl and 1 M MgCl2 was added to give a final concentration of 
100 mM KCl and 2 mM MgCl2. This was left to stir for 1 h after which the solution was 
centrifuged for 3 hours at 30,000 rpm. The pellet was dissolved into a depolymerising 
buffer containing 5 mM Tris, 0.2 mM CaCl, 1 mM NaN3, ph 7.5, homogenised, and 
dialysed for 12 hours against the depolymerisation buffer. Centrifuging the actin the next 
day at 30,000 rpm for 1 h removed any remaining filamentous actin. Using UV 
spectroscopy the actin concentration was determined using the extinction coefficient at 
280 nm ɸ1% = 11.04 cm-1 and molecular weight of 42 kDa (Toseland and Fili, 2014) with 
the final concentration being adjusted to 1 mg/mL. 3 M KCl and 1 M MgCl2 was added to 
the actin to give a concentration of 100 mM KCl and 2 mM MgCl2 and left at room 
temperature to polymerise. The polymerised actin was centrifuged for 3 hours at 30,000 
rpm. The actin pellet was dissolved, homogenised and dialysed for 12 hours in the 
appropriate experimental buffer (2-500 mM KCl, 20 mM MOPS, 5 mM MgCl2, pH 7.0). 
Addition of 1 mM NaN3 prevented the growth of bacteria. The concentration of F-actin 
was usually between 100-200 µM and could be stored for at least 2 weeks at 4 °C.  
2.2.2.3 Pyrene labelling of F-actin 
 
Preparation of pyrene-labelled actin is based on a method by Criddle et al (Criddle, 
Geeves et al. 1985). Pyrene (5 mg/mL dissolved in DMF) was added stepwise to 1 mg/mL 
F-actin solution while stirring to a final concentration of 0.8-1 % pyrene. The solution was 
stirred for 12 hours in the dark and then centrifuged at 8,000 rpm for 1 h to remove 
residual pyrene which precipitates if unbound to actin. The actin was precipitated by 
centrifugation at 30,000 rpm for 3 hours. The actin pellet was dissolved, homogenised 
and dialysed overnight against an appropriate experimental buffer (2-500 mM KCl, 20 
mM MOPS, 5 mM MgCl2, pH 7.0). Addition of 1 mM NaN3 prevented the growth of 
bacteria ? dŚĞ ůĂďĞůůĞĚ ĂĐƚŝŶ ǁĂƐ ĂƐƐĂǇĞĚ ďǇ ĂĐƚŝŶ ĐŽŶƚĞŶƚ  ?ĞǆƚŝŶĐƚŝŽŶ ĐŽĞĨĨŝĐŝĞŶƚ ɸ1% = 
11.04 cm-1 and molecular weight of 42 kDa) and pyrene (extinction coefficient at 280 nm 
ɸ1% = 0.22 ?Ăƚ ? ? ?Ŷŵɸ1% = 0.233) (Toseland and Fili, 2014). Given that pyrene absorbs at 
280 nm this peak will contain both actin and pyrene. To separate these out and 
determine the percentage of labelling. By subtracting the value for the 344 nm peak from 
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the 280 nm peak the concentration of actin can be determined. Then by dividing the 
pyrene concentration by the actin concentration the percentage of labelling can be 
determined. The final concentration of labelled actin was usually 100-200 µM and the 
efficiency of labelling was around 90-100 %.  
2.2.2.4 Stabilisation of actin with phalloidin 
 
When the concentration of actin is below 1 µM F-actin begins to depolymerise since the 
equilibrium between F and G actin is pushed towards G-actin. In order to prevent this in 
stopped-flow assays the actin can be stabilised by the addition of phalloidin (Kurzawa, 
Geeves 1996). An equimolar stock of 10 µM actin and phalloidin (from Amanita 
phalloides) was prepared as a concentrated stock from phalloidin powder dissolved in 
dH2O. The mixture was incubated over night at 4 °C and used within 2-3 days. This has no 
effect on the properties of actin other than keeping it in the filamentous form (Kurzawa, 
Geeves 1996). 
2.2.3 SDS-Page gel 
 
Pre-cast polyacrylamide gels NuPAGE® Novex® 4-12 % Bis-Tris Gels (1.0 mm thick, 12 or 
15  W well) were used to check protein purity after purification.  
Sample buffer (5x) containing 2-mercaptoethanol was added to samples and heated at 95 
°C for 10 mins before loading. The gels were run in MOPS buffer (50 mL of NuPAGE® 
MOPS running buffer (20x) (Life Technologies) mixed with 950 mL dH2O) at 200 V for 45 
mins. The gels were then incubated in Coomassie blue staining solution (1 g Coomassie 
brilliant blue dissolved in 1 L of: 50 % (v/v) methanol, 10 % (v/v) glacial acetic acid, 40 % 
(v/v) dH2O). The gels were then transferred to a destaining solution (7% (v/v) glacial acetic 
acid, 25 % (v/v) methanol, 68 % (v/v) dH2O) 2-3 times to reveal the protein bands. 
WƌŽƚĞŝŶƐ ŽĨ ŝŶƚĞƌĞƐƚ ǁĞƌĞ ŝĚĞŶƚŝĨŝĞĚ ďǇ ĐŽŵƉĂƌŝƐŽŶ ǁŝƚŚ WĂŐĞZƵůĞƌ ? ƵŶƐƚĂŝŶĞĚ ƉƌŽƚĞŝŶ
ladder ranging from 200 to 10 kDa (Fermentas Life Sciences). 
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2.3 Kinetic measurements 
 
Stopped-flow is a method employed to allow the measurement of fast reaction kinetics 
on very short time scales. Due to the reactants being mixed rapidly the reaction can be 
observed and measured from several milliseconds after mixing until equilibrium is 
reached. 
2.3.1 Fluorescent signals 
 
Intrinsic and extrinsic fluorescence were used to measure the kinetics of the stopped-flow 
reactions. 
Intrinsic fluorescence originates from naturally fluorescent groups like certain amino acids 
within a protein such as tryptophan. Tryptophan fluorescence is very commonly used as it 
can respond to changes in the local environment. In the case of the myosin subfragment 1 
(S1) there is a tryptophan residue located on the end of the relay helix which moves 
relative to the rest of the molecule through the ATPase cycle. This can be observed by an 
increase in fluorescence when ATP binds, however the intensity of this fluorescence can 
vary between myosin classes and even myosin isoforms. The tryptophan was excited at a 
wavelength of 295 nm with the emission signal detected above 320 nm via a WG320 cut-
off filter. 
Extrinsic fluorescence derives from an external fluorophore being attached to a protein of 
interest. For the assays in this thesis pyrene was chemically linked to actin filaments via a 
Thio-ether bond to the cysteine-374. The binding of myosin S1 to pyrene-labelled actin 
quenches the fluorescence . The pyrene-actin was excited at a wavelength of 365 nm and 
the emission detected above 399 nm through a KV399 cut-off filter.  
2.3.2 Stopped-flow 
 
The stopped-flow spectrometer used throughout this thesis was a SF-61 DX2 
manufactured by HiTech Scientific which was capable of double mixing but only used for 
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single mixing. The stopped-flow contains two 700 µL sample syringes driven by air-
pressure from an external air pressure pump. Both syringes are triggered simultaneously 
pushing the reactants into an observation cell which is in the optical light path of a high 
intensity light source. The light source used for these experiments was a Xenon-Mercury 
lamp. The wavelength used for excitation could be chosen using a monochromator. The 
fluorescence of the sample was detected via a photomultiplier placed at a right-angle to 
the incoming light. When the samples reached the observation cell they were mixed in a 
1:1 ratio resulting in the concentration of both reactants being halved. As the solution 
leaves the observation cell it fills the empty stop syringe which forces the syringe to hit a 
back-stop which immediately ceases the flow. The samples syringes are temperature 
controlled by an external water bath. 
For assays where millimolar concentrations of ADP were used the ADP was pre-treated 
with hexokinase and glucose to ensure any ATP contamination in the ADP was converted 
to ADP and would not affect the assay. During the purification of actin and S1 adenylate 
cyclase, which converts ADP and inorganic phosphate back to ATP, can be purified. P1, 
P5-Di(adenosine- ? ? )ƉĞŶƚĂƉŚŽƐƉŚĂƚĞ ?Ɖ ? )ǁĂƐĂĚĚĞĚƚŽƚŚĞĂĐƚŽ ?^ ?ƐŽůƵƚŝŽŶƐƚŽŝŶŚŝďŝƚ
any adenylate cyclase activity. 
The concentrations of reactants used in the stopped-flow given are those after mixing 
unless stated otherwise. 
2.3.2.1  Transient Kinetics 
 
First order reactions are dependent upon the concentration of only one reactant. While 
some other reactants may be present they are zero-order and therefore do not affect the 
observed rate constant. Scheme 2.1 shows the rate law of a first order reaction with 
respect to A. 
 
The rate at which A is lost can be expressed as: 
Scheme 2.1 
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 െ  ?ሾ ?ሿ౪ ? ?ൌ ሾሿ ?        Equation 2.1 
 
Where k is the first order rate constant with units of s-1. 
Integration of equation 2.1 gives the integrated 1st order rate law: 
 ሾሿ ?െ ሾሿ ?ൌ െ       Equation 2.2 
 
Where [A]t is the concentration of A at time t and [A]0 is the initial concentration of A. A 
rearrangement of this equation gives: 
 ሾሿ ?ൌ ሾሿ ? ? ? ?        Equation 2.3 
 
All single exponential transients from the stopped-flow were fit to a single exponential 
equation derived from equation 2.3 using: 
  ? ൌ  ?ሺ െ  ? ? �?ሻ ൅  ?        Equation 2.4 
 
Where: F = fluorescence, A = amplitude, t = time, k = rate constant, c = fluorescence 
offset. While all the double exponential transients were fitted to a two exponential 
equation also based off of equation 2.3: 
  ? ൌ  ? ?ሺ ? െ ? ? ?భ ?ሻ ൅  ? ?ሺ ? െ  ? ? ?మ ?ሻ ൅  ?     Equation 2.5 
 
Where: F = fluorescence, A = amplitude, t = time, k = rate constant, c = fluorescence offset 
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When dealing with the stopped-flow second-order 1 step reversible and 2 step reversible 
reactions are used. However these reactions are complex to work with due to there being 
two variables involved. Therefore pseudo-first order reactions were employed where one 
reactant is used in large excess (over 5-fold) over the concentration of the second 
reactant. This ensures that the concentration of the first reactant stays constant and the 
reaction does not become second-order. 
In a second-order 2 step reversible reaction one of the two steps needs to be faster in 




Here we make the assumption that step 1 is very fast and that the k-2 value is very small. 
Therefore: 
  ?ሾ ? ?ሿ ? ?ൌ ሾሿൈ  ? ?       Equation 2.6 
 
If we then use the equation to find the total concentration of AM we get: 
 ሾሿ ? ? ? ? ?ൌ ሾሿ ൅ ሾሿ ൅ ሾሿ      Equation 2.7 
 
Wanting all the AM functions on one side so need to put AM in terms of AMT and MT: 
  ?ൌ ሾ ? ? ?ሿሾ ? ?ሿ ?ሾ ?ሿሾሿ ൌ  ሾ ? ? ?ሿ ?భ ?ሾ ?ሿ    Equation 2.8 
 
If we insert equation 2.8 into equation 2.7 we get: 
 
Scheme 2.2 
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ሾሿ ? ? ? ? ?ൌ ሾ ? ? ?ሿ ?భ ?ሾ ?ሿ൅ ሾሿ ൅ ሾሿ      Equation 2.9 
 
Solving for AMT gives the equation: 
 ሾሿ ൌ  ሾ ? ?ሿ౪౥౪౗ౢ ?ሾ ? ?ሿ ? ?భేభ ?ሾ౐ሿ        Equation 2.10 
 
This can be inserted into equation 2.6 which results in: 
 
 ?ሾ ? ?ሿ ? ?ൌ ቆሾ ? ?ሿ౪౥౪౗ౢ ?ሾ ? ?ሿ ? ?భేభ ?ሾ౐ሿ ቇ  ? ?       Equation 2.11 
 
This can be simplified to: 
  ?ሾ ? ?ሿ ? ?ൌ ሾ ? ?ሿ౪౥౪౗ౢ ? ?భ ?శమ ?ሾ ?ሿ ?భሾ ?ሿ ? ? െ ሾሿ ቀ ?భ ?శమ ?ሾ ?ሿ ? ? ?భሾ ?ሿቁ     Equation 2.12 
 
The second part of Equation 2.12 can be simplified to: 
  ? ? ?ൌ ?భ ?శమሾ ?ሿ ? ? ?భሾ ?ሿ        Equation 2.13 
 
This hyperbola was used to fit the kobs values from the ATP induced dissociation of S1 
from pyrene-labelled actin and ATP binding to S1 when observing the increase in 
tryptophan fluorescence. 
When ADP is added to the system there are three processes that need to be taken into 
account (Scheme 2.3).  
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There are two different assumptions that need to be made depending on the behaviour 
of the S1. 
Assumption 1  W Steps 1 and D are fast this gives the same equation as equation 2.13 with 
the added ADP function: 
  ? ? ?ൌ  ?భ ?శమ ?ሾ ?ሿ ? ? ?భ ሾీሿేሾీሿ        Equation 2.14 
 
When the ATP and ADP are in rapid competition for binding and K1[ATP] < 1 then the 
equation is linear with respect to [ATP]. 
  ? ? ?ൌ  ?భ ?శమ ?ሾ ?ሿ ? ?ሾీሿేሾీሿ         Equation 2.15 
 
If in the absence of ADP kobs = k0 then normalising equation 2.15 would give: 
  ? ? ?ൌ  ?౥ౘ౩ ?బ ൌ  ? ? ?ሾీሿేሾీሿ        Equation 2.16 
 
This is the normal case for the skeletal myosin class II myosin S1 with actin when using the 
competition assay. 
Scheme 2.3 
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Assumption 2  W Step D is slow and steps 1 and 2 are fast. In this case we can focus on just 
the step D (Scheme 2.4). This will result in a fast and a slow phase in the transients. 
  
Solving for total AM concentration: 
 ሾሿ ? ? ? ? ?ൌ ሾሿ ൅ ሾሿ       Equation 2.17 
 
To get all functions we can use the rate law equation when solving for AMD: 
 ሾሿ ൌ  ሾ ? ?ሿ ?ሾ ?ሿ ?ీ         Equation 2.18 
 
By inserting equation 2.18 into equation 2.17 we get: 
 ሾሿ ൌ  ሾሿ ? ? ? ? ? ?  ?ీ ?ీ  ?ሾ ?ሿ        ሾ ? ?ሿሾ ? ?ሿ౪౥౪౗ౢ ൌ  ?ీ ?ీ ?ሾ ?ሿ        Equation 2.19 
 
When [AM] is proportional to Afast and [AM]total is proportional to Amax, Equation 2.19 
becomes: 
  ? ? ? ?ൌ  ?ౣ ౗౮  ? ?ీሾ ?ሿ ? ?ీ൅ ? ? ?       Equation 2.20 
 
Scheme 2.4 
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Here the Amin value only applies if there is a second phase at saturating ADP 
concentration.  
If instead we solve for AM with equation 2.18 rather than AMD we get: 
 ሾሿ ൌ  ?ీ  ?ሾ ? ? ?ሿሾ ?ሿ         Equation 2.21 
 
When we insert this into equation 2.17 we end up with: 
 ሾሿ ? ? ? ? ?ൌ  ?ీ  ?ሾ ? ? ?ሿሾ ?ሿ ൅ ሾሿ      Equation 2.22 
 
Solving for AMD yields: 
 ሾሿ ൌ  ሾሿ ? ? ? ? ? ? ሾ ?ሿሾ ?ሿ ? ?ీ  ሾ ? ? ?ሿሾ ? ?ሿ౪౥౪౗ౢ ൌ ሾ ?ሿሾ ?ሿ ? ?ీ        Equation 2.23 
 
When [AMD] is proportional to Aslow and [AM]total is proportional to Amax, Equation 2.23 
becomes: 
  ? ? ? ?ൌ  ?ౣ ౗౮ሾ ?ሿ ?ీ  ?ሾ ?ሿ൅  ? ? ?       Equation 2.24 
 
This is a hyperbolic equation that best describes the slow phase of the stopped-flow 
transients. This biphasic nature is generally seen in the assays for ADP binding to S1 alone 
without actin. 
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For actin affinity assays the following equation could be used (Bloemink, Deacon et al. 
2014). 
Į  ሾ0ሿ.'>$@-ටሾ0ሿ.'ሾ$ሿ- ሾ0ሿ>$@>$@         Eq. 2.25 
Where: ɲ = fraction of actin bound to S1 
  [M] = total concentration of myosin or S1  
  KD = the dissociation constant of S1 for actin in the presence or absence of ADP 
  [A]0 = concentration of actin 
2.3.2.2 Temperature effect 
 
To investigate the effects of temperature on stopped-flow experiments the assays were 
repeated in the same conditions with varied temperatures. The thermodynamic 
parameters, enthalpy and entropy, can be determined by plotting the kobs as a function of 
temperature. 
Plotting the natural log of an equilibrium constant K (lnK) as a function of 1/absolute 
ƚĞŵƉĞƌĂƚƵƌĞĂŶĚĐĂŶďĞĂŶĂůǇƐĞĚǁŝƚŚƚŚĞsĂŶ ?ƚ,ŽĨĨĞƋƵĂƚŝŽŶ P 
   ൌ െ  ? ? ? ?  ? ? ?൅  ? ? ? ? ȟ
 ? ൌ ȟ ? െ   ? ȟ ?   Equation 2.26 
 
Where: R = molar gas constant (8.314 J.K-1mol-1 ) ? d A? dĞŵƉĞƌĂƚƵƌĞ  ?< ) ? ȴ, ? A? ƌĞĂĐƚŝŽŶ
ĞŶƚŚĂůƉǇ ?ƐƚĂŶĚĂƌĚƐƚĂƚĞ ) ?ȴ^ ?A?ƌĞĂĐƚŝŽŶĞŶƚƌŽƉǇ ?ƐƚĂŶĚĂƌĚƐƚĂƚĞ ) 
The intercept of a linear ĨŝƚŽĨĂsĂŶ ?ƚ,ŽĨĨƉůŽƚŐŝǀĞƐƚŚĞȴ^ ?ǁŚŝůĞƚŚĞƐůŽƉĞŽĨƚŚĞsĂŶ ?ƚ
Hoff plot is equal to -ȴ, ? ?Z ? 
An Arrhenius equation can also be used to determine the activation energy of a reaction 
by investigating the effect of temperature on the rate of reaction.  
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  ൌ   ? ?ș ?  ? ? ?൅  ? ?ș ?൅  ቀ ?ా ? ? ?ቁ ȟ
 ? ൌ ȟ ? െ   ? ȟ ? Equation 2.27 
 
Where: R = molar gas constant (8.314 J.K-1mol-1 ) ?dA?dĞŵƉĞƌĂƚƵƌĞ ?< ) ?ȴ' ? = free energy 
of activation, ȴ, ? = activation enthalpy, ȴ^ ? = activation entropy, kB = Boltzmann constant 
(1.3806 x 10-23 J.K-1 ) ?ŚA?WůĂŶĐŬ ?ƐĐŽŶƐƚĂŶƚ ? ? ? ? ? ?ǆ ? ?-34 J.s) 
In this case lnkobs is plotted as a function of 1/absolute temperature. The slope of the 
linear fit is equal to -ȴ, ?/R. The activation energy can be easily calculated as it is equal to 
ȴ, ?.  
2.3.3 NADH-coupled ATPase assay 
 
The NADH-coupled ATPase assay was conducted by Carlos Vera (University of Colorado, 
USA).  
 
Myosin S1 was added to a mixture of 0.5 mM phosphoenolpyruvate (PEP), 0.05 mg/mL 
pyruvate kinase (PK), 0.02 mg/mL lactate dehydrogenase (LDH), 0.2 mM NADH, and 0.5 
mM ATP. As the myosin hydrolyses ATP to ADP and phosphate, PK transfers a phosphate 
from PEP to ADP. This creates a new ATP molecule and pyruvate. Therefore the ATP is 
kept at a relatively constant concentration. LDH converts the pyruvate to lactate by 
transferring an H+ from NADH to form NAD+. Since NADH absorbs at 340 nm the 
conversion of pyruvate to lactate can be measured. This therefore gives an indirect 
measurement of the ATPase cycle since ADP concentration drives the formation of 
pyruvate from PEP. Then in the absence of actin the myosin S1 basal ATPase rate can be 
measured. Actin is an activator of the ATPase cycle, forcing phosphate and ADP to be 
Scheme 2.5 
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released faster and therefore adding more actin to the mixture increases the ATPase rate. 
The data can be fit with the Michaelis-Menten equation:  ? ൌ ?೘ೌೣሾ ?ሿ ?ಾ ?ሾ ?ሿ         Equation 2.28 
Where Vmax is the maximum rate of the ATPase cycle where the myosin is saturated with 
actin and KM is the relationship between the rate of reaction and concentration of actin 
depends on the affinity of the myosin for actin 
 The ATPase assays used here were conducted at 25 °C. 
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3 New methods for measuring kinetic parameters and equilibrium 
constants 
3.1 Temperature manifold 
 
Stopped-flow spectroscopy is a very powerful tool to investigate fast kinetic reactions, 
being able to measure and record reactions on millisecond time scales. However there 
are a few draw backs to this method, which include: only being able to operate within a 
certain temperature window without damaging parts of the machine, and using large 
volumes of precious sample. 
Commercial stopped-flow spectroscopy systems have the capability to be thermostated, 
usually by an external water bath. This allows reactions to be monitored at a constant 
temperature. However measuring reactions at temperatures above or below a 
recommended level can damage the mechanical components of the system. Also 
adjusting the temperature from one to another can lead to expansion and contraction of 
drive valves which over time can lead to leaking of these valves resulting in improper 
mixing i.e. not a 1:1 ratio. Specialist equipment exists provided by manufacturers of 
stopped-flow systems that allows for very extreme temperatures to be reached, however 
this is specialised equipment and may not be cost effective. The use of temperature can 
be valuable when investigating reaction kinetics as at low temperatures it is possible to 
observe intermediates within a reaction pathway (Travers, Barman 1995, Petsko 2009). A 
temperature control that can work both above room temperature and close to 
physiological temperature can be vital in determining the kinetics of a protein and gaining 
a deeper understanding into its function. As has been shown by Millar and Geeves (Millar, 
Geeves 1983) that the ATP induced dissociation of myosin S1 from actin is not linear 
across all temperature points.  
The aim of this section is to show using an existing system that a temperature manifold 
can be used to measure kinetic parameters at temperatures above and below 20 °C. The 
first aim was to calibrate the efficiency of the thermal transfer. To do this a fluorescent 
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probe, fluorescein, was be used. From here the shot volumes could be investigated to 
determine the maximum volume that could be used. From here the manifold would be 
investigated using the well-established ATP induced dissociation of myosin S1 from actin. 
This has previously been investigated over a temperature range above and below 0 °C. 
Using the data from these investigations the design of the temperature manifold could be 
changed to make it more efficient at adjusting the temperature before mixing, which 
requires building new prototypes. 
 
The temperature manifold project was published in Analytical Biochemistry in May 2015. 
This contained just the obtained using ethylene glycol, here a more detailed explanation 
of how the manifold was tested is given. This includes assays conducted above 0 °C in the 
absence of ethylene glycol.  
Walklate, J., Geeves, M. A. Temperature manifold for a stopped-flow machine to allow 
measurements from -10 to +40 °C Anal. Biochem. 2015. 476: p. 11-16.   
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3.1.1 Temperature manifold development 
 
In collaboration with TgK Scientific we developed a simple manifold that could be 
attached to a commercial stopped-flow, in this case a HiTech TgK Scientific SF-61 DX2. 
Figure 3.1 shows a schematic of the manifold attached to the stopped-flow along with 














Sample/waste tube extender 
Observation block 
Figure 3.1  W Design of the temperature manifold and how it works in relation to the 
stopped-flow. (A) A schematic diagram of the stopped-flow with the temperature 
manifold attachment. (B) The component parts that make up the temperature manifold. 
The insulation plate, the manifold and the observation block. (C) The interface between 
the stopped-flow and the observation block. 
                 Chapter 3  W New methods for measuring kinetic parameters and equilibrium constants 
70 
 
The schematic in figure 3.1A shows that the main body of the stopped-flow and the drive 
syringes which contain the sample prior to being pushed are at the initial temperature T1. 
The manifold itself is set at the desired temperature (T2) and is isolated from the drive 
block by the insulation plate. The observation cell, where the mixing of the reactants and 
the reaction is observed is also at T2. 
The insulation plate is a 59 x 45 x 7 mm block of acetal (Figure 3.1B). This has a low-
thermoconductivity making it ideal for insulation. The face of this insulation plate has a 
return loop engraved to return the coolant back into the reservoir. It also has two O-rings 
to prevent any leaking between coolant and sample. The back of the insulation plate is a 
flat surface allowing it to join to the back of the manifold. 
The manifold itself is made of a 59 x 45 x 20 mm block of aluminium which has a higher-
thermoconductivity than acetal and so is better suited for thermal transfer between 
sample and manifold. The interface between the manifold and the observation block 
mimics the interface between the stopped-flow and the observation block (Figure 3.1C). 
Due to the extra space between the back of the stopped-flow and the observation cell an 
extension tube was required to allow the sample to enter the observation cell and waste 
to exit. This was made of PEEK (polyether ether ketone) which is inert and is a thermal 
conductor to acetal.  
3.1.2 Calibration of the manifold 
 
In order to calibrate the efficiency of the thermal transfer a fluorescent probe was used. 
The combination of fluorescein and imidazole was an ideal choice. The pH of imidazole is 
dependent upon the temperature of its environment, pKIm ?ȴdA?-0.02 °C-1 (Burton 2002). 
The fluorescence of fluorescein however is dependent on the pH of its environment 
(Chen, Cheng et al. 2008). Therefore as the temperature of the sample changes, so will 
the pH causing a change in fluorescence from the fluorescein which can be measured. To 
measure the fluorescence, the fluorescein was excited at 488 nm and detected through 
an OG530 nm cut-off filter. The buffer used was the imidazole temperature manifold 
buffer (chapter 2  W 2.1.2 buffers).  




It was required to investigate what size shot volumes were suitable and the speed at 
which the sample got to temperature once pushed. To investigate this 1 µM fluorescein 
was loaded into both drive syringes and pushed with the manifold being set at different 
temperatures. The fluorescence was allowed to reach a steady state to determine the 
fluorescence at different temperatures (Figure 3.2). This was repeated in both the 
aqueous buffer and the buffer containing 40 % ethylene glycol to measure the difference 
between the two. 
 
 
These steady state fluorescence signals were plotted against temperature (Figure 3.3A) 
which had a linear dependence. The gradient for the aqueous solution was 1.6 %/°C while 
the buffer containing ethylene glycol had a gradient of 1.2 %/°C.  




















Figure 3.2  W Steady state fluorescence of fluorescein in 5 °C increments from -10 °C to 40 °C  




Using this relationship it was then possible to work out the temperature of the sample 
based on the fluorescence detected. The next step was to determine the maximum shot 
volume that could be used to ensure that the sample was at or close to the desired 
temperature when the reaction was monitored. The shot volume was increased from 30 
µL up to 150 µL (including 40, 50, 60, 70, 80, 90, 100, and 120 µL) and the fluorescence 
was monitored for 20 seconds to allow it to reach a steady state (Figures 3.3B and 3.3C). 
Figure 3.3B shows how the fluorescence decreases as the temperature increases (from 
20-45 °C) but also shows how far away from the desired temperature some shot volumes 
are at time zero. Figure 3.3C also shows the efficiency of the system at varied shot 
volumes but this time with a decrease in temperature (from 20 °C to -10 °C). The shot 
volume assays were repeated 4 times with different temperature changes starting from 
20 °C (+10, +25, -15, and -30 °C) to investigate how quickly the temperatures can 
Figure 3.3  W Calibration curves for the temperature manifold. (A) Temperature dependence of 
fluorescence of 1 µM fluorescein in aqueous solution (open squares) and ethylene glycol (filled 
square). (B) Varied shot volumes (30 -150 µL) over a 25 °C increase from 20 to 45 °C. (C) Varied 
shot volumes (same as (B)) over a 30 °C decrease from 20 to -10 °C. (D) The observed 
fluorescence change for each shot volume at the 4 different temperature changes of +25, +10, -
15, and -30 °C to show what temperature the sample is arriving. The change in fluorescence 
has been converted into a temperature difference. 
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equilibrate and what shot volume was best to use. It is worth noting that the assays were 
carried out in the aqueous buffer, however the 20 °C to -10 °C assay had to contain 
ethylene glycol since the reaction went below 0 °C. This therefore gave a slightly different 
shape to the graph in figure 3.3D. Our usual set up when using myosin S1 is to use a shot 
volume of 60 µL, which can adequately flush out the previous shot from the observation 
cell. It was therefore encouraging to see that the 60 µL was not very far from the desired 
temperature.  
3.1.3 ATP induced dissociation data at different temperatures 
 
To investigate whether the temperature manifold could work on a real system, the ATP 
induced dissociation assay was used over a range of different temperatures. This reaction 
is made of two steps. The first step is the binding of ATP to the actomyosin complex, 
which is a rapid equilibration of ATP binding. During the second myosin-ATP becomes 
loosely bound to actin and rapidly dissociates. Previous study (Iorga, Adamek et al. 2007) 
found that the equilibrium constant of the first step (scheme 3.1, K1) is 
thermodynamically unaffected by a change in temperature. The second step (scheme 3.1, 
k+2) however is strongly affected. The primes (') after the constants indicate that actin is 
present in the assay. 
In order to investigate the efficacy of the temperature manifold below 0 °C it was 
necessary to add 40 % ethylene glycol to prevent the buffer from freezing. However the 
presence of ethylene glycol weakens the binding of ATP (Millar, Geeves 1983) but leaves 
the rate of isomerisation unaffected. The buffer used throughout was the cacodylate 
temperature manifold buffer (Chapter 2.1.2  W section 2.1.2) because cacodylate has a 
relatively stable pH over a large temperature range and was also used in the previous 
Scheme 3.1  W ATP induced dissociation of myosin from actin. K'1 
denotes the equilibrium constant for ATP binding and k'+2 is used to 
describe the irreversible dissociation of myosin-ATP from actin.  
K'1 k'+2 
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investigations (Iorga, Adamek et al. 2007, Millar, Geeves 1983). When used in assays that 
went below 0 °C, ethylene glycol was added to prevent the buffer from freezing.  
The first assay performed was to mix a constant acto.S1 concentration (0.5 µM) against a 
constant ATP concentration (10 µM) at varied temperatures. Figure 3.4 shows example 
traces from -6 to +38 °C.  
 
 
All the traces were fit by a single exponential. The observed rate constant (kobs) increased 
with the temperature as expected. 
The next step was to investigate how the temperature of the manifold affected the 
ƐĞĐŽŶĚŽƌĚĞƌƌĂƚĞĐŽŶƐƚĂŶƚŽĨdWďŝŶĚŝŶŐ ?< ?1Ŭ ?+2). This is determined by plotting the kobs 
against the concentration of ATP. At low concentrations of ATP (<100 µM) this can be 
ĚĞƐĐƌŝďĞĚďǇĂůŝŶĞĂƌĨŝƚǁŚŝĐŚĞƋƵĂƚĞƐƚŽƚŚĞ< ?1Ŭ ?+2.  
Figure 3.5A shows the transients of 10 to 50 µM ATP over a temperature range of 6.5 to 
37.8 °C in an aqueous solution ?dŚĞǀĂůƵĞŽĨ< ?1Ŭ ?+2 increased from 2.04 µM-1 s-1 to 7.66 
µM-1 s-1 indicating that the reaction has a temperature dependence. The values of kobs 
were then used in an Arrhenius plot to determine the thermodynamic parameters of the 
reaction (Figure 3.5B).  
Figure 3.4  W Example traces of ATP induced dissociation at different temperatures. 10 µM ATP 
was rapidly mixed with 0.5 µM acto.S1. The temperatures shown are -5,7 (slowest transient), -
1.4, 3, and 7.3 °C (fastest transient). 
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As was expected the linear fits of this plot (Figure 3.5B) were parallel to each other since 
the activation energy (Ea) remains the same for each concentration of ATP. However upon 
further examination it was found that the data in the Arrhenius plot did not strictly follow 
a linear dependence, and could alternatively be fit with a curve as shown here two linear 
lines with a break point between 11.7 and 13.4 °C. This is comparable to earlier data 
(Millar, Geeves 1983) and with the general explanation that there is a phase change in the 
myosin structure causing this nonlinearity of the plot (Anson 1992, Biosca, Travers et al. 
1983) ?dŚĞǀĂůƵĞĨŽƌƚŚĞȴ,0 for figure 3.5B is given in table 3.2.  
Figure 3.5  W ATP induced dissociation over varied temperatures at low ATP concentrations in 
an aqueous solution. (A) Linear dependence of kobs at low ATP concentrations from 6.5 to 
 ? ? ? ? ? ? ? ?ƌƌŚĞŶŝƵƐƉůŽƚŽĨƚŚĞƉŽŝŶƚƐĨƌŽŵƉĂŶĞůƚŽĐĂůĐƵůĂƚĞƚŚĞȴ,0 of the reaction. 
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This assay was then repeated at 5 temperatures, from 6.5 to 16 °C, over an ATP 
concentration range of 10 to 800 µM (Figure 3.6). At higher concentrations of ATP the 
plot of kobs ďĞĐŽŵĞƐŚǇƉĞƌďŽůŝĐĂůůǇĚĞƉĞŶĚĞŶƚĂŶĚĂůůŽǁƐĨŽƌƚŚĞĚĞƚĞƌŵŝŶĂƚŝŽŶŽĨ< ?1 and 
Ŭ ?+2 by fitting the data with equation 2.13 (Chapter 2.3.2.1). This experiment is only 
possible at lower temperatures (<20 °C in most cases) as the kobs becomes very fast 
(>1,000 s-1) at the higher ATP concentrations which becomes hard to measure with 
current stopped-flow devices. The valuĞƐĨŽƌ< ?1  ?ŐŝǀĞŶĂƐ ? ?< ?1 ƚŽƐŝŵƉůŝĨǇƵŶŝƚƐ )ĂŶĚŬ ?+2 
are summarised in table 3.1.  
dŚĞ ǀĂůƵĞƐ ĨŽƌ < ?1 ĂŶĚ Ŭ ?+2 ǁĞƌĞ ƚŚĞŶ ƉůŽƚƚĞĚ ŝŶ Ă sĂŶ ?ƚ ,ŽĨĨ ƉůŽƚ  ?&ŝŐƵƌĞ  ? ? ? )ĂŶĚ
ƌƌŚĞŶŝƵƐƉůŽƚ ?&ŝŐƵƌĞ ? ? ? )ƌĞƐƉĞĐƚŝǀĞůǇƚŽĚĞƚĞƌŵŝŶĞƚŚĞȴ,0 ĂŶĚȴ^0 Žƌȴ, ? ĂŶĚȴ^ ? of 
the reaction which are summarised in table 3.2.  
 
Figure 3.7  W ƌƌŚĞŶŝƵƐ ?sĂŶ ?ƚ,ŽĨĨƉůŽts of the values from figure 3.6 ? ? ?sĂŶ ?ƚ,ŽĨĨƉůŽƚŽĨƚŚĞ
1/< ?1 values from figure 3.6 ? ? ?ƌƌŚĞŶŝƵƐƉůŽƚƐŽĨƚŚĞŬ ?+2 values from figure 3.6. Two dashed 
lines have been added to show a potential break point. 












































Figure 3.6  W ATP induced dissociation up to high concentrations of ATP 
from 6.5 to 16 °C. 
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To then investigate the capabilities of the manifold at sub-zero temperatures is was 
necessary to add 40% ethylene glycol to the cacodylate temperature manifold buffer 
(Chapter 2  W section 2.1.2). This prevented the buffer from freezing at the lower 
temperatures used, however it also increased the viscosity and as stated earlier (section 
3.2.2) the presence of ethylene glycol weakens ATP binding. It was therefore necessary to 
repeat the above assays with ethylene glycol to compare to previous study (Millar, 
Geeves 1983).   
 
Figure 3.8A shows the linear dependence of ATP induced dissociation at low 
concentrations of ATP over a temperature range of -5.7 to + 37.5 °C. The values for the 
< ?1Ŭ ?+2 are given in table 3.1. Figure 3.8B shows an Arrhenius plot of the data from the ATP 
Figure 3.8  W ATP induced dissociation at low ATP concentrations over varied temperatures. (A) 
Linear dependence of kobs on ATP concentration from -5.7 to +37.8 °C. (B) An Arrhenius plot of 
ƚŚĞĚĂƚĂĨƌŽŵƉĂŶĞůƚŽĚĞƚĞƌŵŝŶĞƚŚĞȴ,0 of the reaction. 
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induced dissociation which again showed a non-linear dependence or a break point 
ďĞƚǁĞĞŶ ? ? ? ?ĂŶĚ ? ? ? ?dŚŝƐŚĂƐƚŚĞƌĞĨŽƌĞďĞĞŶĨŝƚǁŝƚŚƚ ŽůŝŶĞĂƌůŝŶĞƐ ?ĂŶĚƚŚĞȴ,0 for 
the two fits are summarised in table 3.2. 
As before the ATP induced dissociation assays were then repeated at high ATP 
concentrations however this could only be done at lower temperatures (-5.7 to 11.7 °C). 
The kobs ĂŐĂŝŶĨŽůůŽǁĞĚĂŚǇƉĞƌďŽůŝĐĐƵƌǀĞ ?&ŝŐƵƌĞ ? ? ? )ĂůůŽǁŝŶŐĨŽƌƚŚĞĐĂůĐƵůĂƚŝŽŶŽĨ< ?1 
ĂŶĚŬ ?+2 ?dŚĞǀĂůƵĞƐĨŽƌ< ?1 ĂŶĚŬ ?+2 are summarised in table 3.1.  
 
dŚĞǀĂůƵĞƐĨŽƌ< ?1 ǁĞƌĞƉůŽƚƚĞĚŝŶĂsĂŶ ?ƚ,ŽĨĨƉůŽƚ ?&ŝŐƵƌĞ ? ? ? ? )ĂŶĚƚŚĞǀĂůƵĞƐŽĨŬ ?+2 in 
ĂŶƌƌŚĞŶŝƵƐƉůŽƚ ?&ŝŐƵƌĞ ? ? ? ? ) ?&ƌŽŵƚŚĞƐĞŐƌĂƉŚƐƚŚĞȴ,0 ĂŶĚȴ^0 Žƌȴ, ? ĂŶĚȴ^ ? could 
be determined and is summarised is table 3.2.   
Figure 3.9  W ATP induced dissociation up to a saturating ATP concentration over a temperature 
range of -5.7 to 11.7 °C. 
Figure 3.10  W sĂŶ ?ƚ,ŽĨĨ ?ƌƌŚĞŶŝƵƐƉůŽƚƐŽĨƚŚĞǀĂůƵĞƐĨƌŽŵĨŝŐƵƌĞ ? ? ? ?  ? ?sĂŶ ?ƚ,ŽĨĨƉůŽƚŽĨ
ƚŚĞ ? ?< ?1 values from figure 3 ? ? ? ? ?ƌƌŚĞŶŝƵƐƉůŽƚŽĨƚŚĞŬ ?+2 values from figure 3.9. 






< ?1Ŭ ?+2 (µM-1 s-1)  ? ?< ?1 (µM) Ŭ ?+2 (s-1) 
Aqueous 
6.5 2.04 ± 0.03 160 ± 15 817 ± 36 
9.0 2.79 ± 0.04 156 ± 13 928 ± 35 
11.7 3.24 ± 0.04 157 ± 22 1061 ± 70 
13.4 3.51 ± 0.04 154 ± 16 1084 ± 53 
16.0 3.86 ± 0.04 155 ± 12 1139 ± 42 
20.0 4.60 ± 0.07 - - 
24.8 5.36 ± 0.10 - - 
29.1 6.11 ± 0.09 - - 
33.5 6.83 ± 0.15 - - 




-5.7 0.18 ± 0.01 579 ± 43 210 ± 6.5 
-1.4 0.28 ± 0.01 510 ± 17 261 ± 3.6 
3.0 0.39 ± 0.02 615 ± 29 381 ± 7.6 
7.3 0.51 ± 0.01 439 ± 25 423 ± 9.3 
11.7 0.69 ± 0.03 447 ± 63 562 ± 29 
16.0 0.92 ± 0.03 - - 
20.0 1.19 ± 0.04 - - 
24.8 1.50 ± 0.06 - - 
29.1 1.85 ± 0.05 - - 
33.5 2.20 ± 0.07 - - 
37.8 2.56 ± 0.05 - - 
 
 
Table 3.1  W sĂůƵĞƐ ĨŽƌ < ?1Ŭ ?+2 ?  ? ?< ?1 ? ĂŶĚ Ŭ ?+2 in both conditions at varied temperatures 
derived from figures 3.5, 3.6, 3.8, and 3.9. Values are those from the fits ± standard error. 





 Aqueous buffer 





(-5.7 °C to 10 °C) 
 ?< ?1Ŭ ?+2 values) 
Gradient (K)  -7.17 ± 0.2 -6.2 ± 0.3 
ȴ,0  ?Ŭ: ?ŵŽů-1)  59.6 ± 1.5 51.5 ± 2.5 
Arrhenius plot 
after break point 
(10 °C to 37.8 °C) 
 ?< ?1Ŭ ?+2 values) 
Gradient (K)  -3.0 ± 0.08 -4.6 ± 0.2 
ȴ,0  ?Ŭ: ?ŵŽů-1)  24.9 ± 0.67 38.2 ± 1.7 
sĂŶ ?ƚ,ŽĨĨƉůŽƚ 
 ?< ?1 values) 
Gradient (K) 0.26 ± 0.10 1.14  ± 0.7 
Intercept 4.14 ± 0.37 2.13 ± 2.5 
ȴ,0  ?Ŭ: ?ŵŽů-1) -2.2 ± 0.9 -9.5 ± 5.8 
ȴ^0  ?: ?< ?ŵŽů-1) 34.4 ± 3.1 17.7 ± 21.0 
Arrhenius plot 
 ?Ŭ ?+2 values) 
Gradient (K) -2.87 ± 0.4 -4.3 ± 0.3 
Intercept 17.0 ± 1.4 21.5 ± 2.25 
ȴ, ?  ?Ŭ: ?ŵŽů-1) 23.9 ± 3.4 35.8 ± 2.9 
ȴ^ ?  ?: ?< ?ŵŽů-1) 141.4 ± 11.8 178.8 ± 10.4 
Table 3.2  W Thermodynamic parameters derived from figure 3.5, 3.7, 3.8, and 3.10. Values 
are those from the fits ± standard error. 





With the exception of having to adjust the temperature slightly to get the desired 
temperature in the observation chamber the temperature manifold appears to work as 
expected where the sample temperature is rapidly increased/decreased. A correction 
ĨĂĐƚŽƌ ǁĂƐ ĚĞƚĞƌŵŝŶĞĚ ĨƌŽŵ ƚŚĞ ƚĞŵƉĞƌĂƚƵƌĞ ŝŶĚƵĐĞĚ ƐƚĞƉ  ?ȴd A? d1  W T2) versus the 
ƚĞŵƉĞƌĂƚƵƌĞŝŵŵĞĚŝĂƚĞůǇĂĨƚĞƌŵŝǆŝŶŐ ?dŚĞƌĞĨŽƌĞƚŚĞƚĞŵƉĞƌĂƚƵƌĞŽĨƚŚĞƌĞĂĐƚŝŽŶ ?ȴd ? )A?
 ? ? ? ? ǆ ȴd ? ǁŚĞƌĞ ȴd ? is the difference between T2 and the temperature of the sample 
immediately after mixing.  The results obtained from the assays above are very similar to 
the published data (Iorga, Adamek et al. 2007, Millar, Geeves 1983). For the assays in 
aqueous soůƵƚŝŽŶƚŚĞǀĂůƵĞƐŽĨȴ,0 ĂŶĚȴ^0 Žƌȴ, ? ĂŶĚȴ^ ? can be compared between this 
study and that of previous work (Iorga, Adamek et al. 2007). Iorga et al found that for 
ƌĂďďŝƚƉƐŽĂƐ^ ?ƚŚĞȴ,0 ŽĨ< ?1 = -1.9 ± 3.6 kJ.mol-1 whŝůĞŚĞƌĞƚŚĞȴ,0 = -2.2 ± 0.9 kJ.mol-1. 
dŚĞȴ^0 = 37.0 ± 12.8 J.K.mol-1 ǁŚŝůĞŚĞƌĞƚŚĞǀĂůƵĞŽĨȴ^0 = 34.4 ± 3.1 J.K.mol-1 ĨŽƌ< ?1. 
dŚĞ ǀĂůƵĞƐ ŽĨ ďŽƚŚ ȴ,0 ĂŶĚ ȴ^0 are very similar between the Iorga et al data and that 
shown here with overlapping values when considering the standard error. When 
ĐŽŵƉĂƌŝŶŐƚŚĞƚŚĞƌŵŽĚǇŶĂŵŝĐƉĂƌĂŵĞƚĞƌƐĨŽƌƚŚĞŬ ?+2 value they are again very similar. 
dŚĞ ȴ, ? = 35.7 ± 7.2 kJ.mol-1 from Iorga et al ǁŚŝůĞ ŚĞƌĞ ƚŚĞǀĂůƵĞ ŽĨȴ, ? = 23.9 ± 3.4 
kJ.mol-1 ?dŚĞ ȴ ^? = 178.7 ± 25.3 J.K.mol-1 from Iorga et al ǁŚŝůĞ ŚĞƌĞ ƚŚĞ ȴ^ ? = 141.4 ± 
 ? ? ? ? ?ŐĂŝŶƚŚĞǀĂůƵĞƐŽĨȴ, ? ĂŶĚȴ^ 退 ĂƌĞǀĞƌǇƐŝŵŝůĂƌĂŶĚǁŝƚŚŝŶĞĂĐŚŽƚŚĞƌ ?ƐƌĂŶŐĞ ?dŚŝƐ
gives us great confidence that the manifold is working as expected when using an 
aqueous solution above 0 °C.  
For a comparison between the data presented here and that presented by Millar and 
Geeves there is a clear similarity in the behaviour of the data presented in the Arrhenius 
plots. ,ŽǁĞǀĞƌ ƚŚĞ ǀĂůƵĞƐ ĨŽƌ ȴ, ? are different between the two investigations for 
reasons unknown. For each ATP concentration there are two distinct linear relationships 
between rate constant and temperature, one below 10 °C and the other above 10 °C.  
The design could be altered as needed to fit other manufactures simply. This will give 
laboratories that possess stopped-flow equipment, but are not specialising in extreme 
temperature effects on reaction, an option to explore the effects of temperature on their 
systems.  
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3.3 Micro-volume manifold 
 
A limiting factor for many when considering the use of stopped-flow spectroscopy is the 
large volume of sample needed to obtain consistent reproducible data. One assay using 
the standard set up would require the use of 300-500 µL of sample per data point. When 
ĐŽŶƐŝĚĞƌŝŶŐA? ? ? ?A?> of samples is used to fill the observation cell and clear the previous 
reaction this can become very wasteful. Use of a smaller observation cell can alleviate 
some of these limitations. By reducing the volume of the observation cell, the volume 
needed to clear the cell also become smaller, as does the volume needed per shot. This 
does have the drawback that there less fluorescent molecules to fluoresce so the 
amplitudes will be smaller. Therefore decreasing the volume that is loaded into the 
system as well as using a smaller cell volume will have a cumulative effect of saving the 
volume of sample needed.  
3.3.1 Micro-volume manifold (MVM) development 
 
The need to reduce the volume of sample needed to perform stopped-flow spectroscopy 
is very apparent when using samples that are expensive to make and/or yield low 
amounts of the protein. In collaboration with TgK Scientific we have developed a 
manifold, similar to the temperature manifold that it is positioned between the back of 
the stopped-flow and the observation block. The original design was created by Michael 
Geeves and TgK scientific. The testing of the design and method of loading the micro-
volume manifold was performed by myself. The information was then fed back to TgK 
scientific who redesigned the manifold to the prototype shown in this thesis. 
The principle of the design is to reduce the distance between where the sample is loaded 
and the observation cell. the loading volume can be reduced leading to fewer samples 
being wasted to set up the stopped-flow. By turning a valve on the MVM the sample 
could be pulled into the tubing in the stopped-flow spectrometer. Pulling on the stop 
syringe would normally pull buffer coming from the drive syringe into the stop syringe. 
However in this case the sample is pulled in instead sandwiched between buffer. When 
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the sample is loaded it can be pushed into the observation cell by buffer from the drive 
syringe.  
The standard setup requires 3 observation cell volume shots to clear the observation cell 
of previous reactant/buffer and replace it with the new sample. Since the observation cell 
is 22.5 µL the volume of sample that should be pushed through the system would have to 
be 67.5 µL.  
Figure 3.11: A schematic of how the micro-volume manifold fits into the stopped-flow. (A) The 
inlet cups for the sample on the manifold are represented by two funnel shapes. Given the 
complexity of the manifold the flow circuit is opposite within the manifold. Therefore the 
ƐĂŵƉůĞƚŚĂƚǁŽƵůĚďĞĂĚĚĞĚƚŽĚƌŝǀĞƐǇƌŝŶŐĞŚĂƐƚŽďĞĂĚĚĞĚŽŶƚŚĞŽƉƉŽƐŝƚĞƐŝĚĞ ? ? ?  ? ?
Passage of sample into the tubing in the stopped-flow spectrometer. By turning a valve on the 
manifold the sample could be pulled into the tubing, then pushed into the observation cell via 
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However it is possible to use a shot volume of 60 µL three times to clear the cell giving a 
total volume wasted of 90 µL from each syringe (30 µL from syringe A + 30 µL from 
syringe B = 60 µL x 3). Figure 3.11 shows a schematic of where the MVM is positioned in 
respect to the rest of the stopped-flow and how the sample is loaded.  
The MVM is made of a solid block of PEEK (polyether ether ketone) that has two cone 
shaped cups at the top for loading of the sample in either side (Figure 3.12A). The shape 
of the loading cups was chosen to reduce the chance of air entering the flow circuit. The 
manifold fits onto the back of the stopped-flow unit and the observation block attaches 
to the back of the manifold. Pins on the stopped-flow drive unit interlock with holes in the 
MVM and pins on the MVM lock into holes on the observation block. This is further 
secured with screws to help make the seal water tight. The sample and waste tubes are 
also surrounded by small O rings to form a water tight seal between stopped-flow and 
manifold and observation cell. On the sides of the MVM (Figure 3.12A and B) are two 
valves that allow the samples to be loaded and also prevent the sample from flowing 
straight into the observation cell. Lastly the sample and waste tubes on the MVM create a 
seal with the tubes on the stopped-flow to transfer sample through the MVM to the 
observation cell.  
Assys using the MVM were compared to the standard set up of the stopped-flow 
spectrometer. This consisted on the observation block attached to the back of the 
stopped-flow drive unit without the MVM in place. The temperature was kept constant at 
20 °C using an external water bath using a 5 µL observation cell. S1 or acto.S1 was loaded 
into one drive syringe and ATP into the other. For the MVM assays ATP was still in one of 
the drive syringes while buffer was loaded into the other drive syringe. S1 or acto.S1 was 
loaded into the drive unit via the MVM. The temperature could not be maintained by an 
external water bath and therefore was subject to the temperature of the room which 
varied between 20-23 °C.  




3.3.2 Load volume calibration  
 
Since the aim of this attachment is to reduce the volume of sample needed a 5 µL 
observation cell was used. The light path for this observation cell is the same as that of 
the 22.5 µL cell. This meant that to effectively clear the cell of the previous sample then a 
minimum of 15 µL would be needed as 3x the observation cell volume can adequately 
clear the cell of the previous shot. A 20 µL shot volume was used (10 µL from syringes A 
and B). This required setting the stop syringe to fill up to 20 µL before hitting the back 
stop and triggering the stopped-flow to start recording the data. 
It was necessary to determine what volume to load into the stopped-flow from the MVM. 
To do this a volume of S1 greater than that loaded (for example 100 µL pipetted, 80 µL 
Figure 3.12: The micro-volume manifold and how it joins on to the stopped-flow. (A) A photo 
of the top, back and side of the MVM. (B) The interaction between the stopped-flow and the 
MVM. 
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loaded) was pipetted into the cup on the MVM that was labelled S1. This extra volume 
allowed for any error associated with pipetting and prevented any air being pulled into 
the system.  
The desired volume was then loaded into the stopped-flow (this method is for filling just 
one side of the MVM). In order to do this; firstly the valve on the manifold must be in the 
load position with the drive valve in the drive or waste position, not flush. To pull the 
sample into the system the stop syringe had to be emptied by turning the stop valve to 
waste (if not already done so) then pushing the syringe up to eject the waste. Next the 
stop valve needed to be turned to drive and the stop syringe pulled down to the back 
stop thus filling this syringe. This will have pulled 20 µL of the sample from the manifold 
into the flow circuit. This process of filling and emptying the stop syringe can be repeated 
as many times as needed to load the desired volume. The stopped-flow was then used as 
normal using buffer in the drive syringe used for the S1 which pushed the S1 into the 
ŽďƐĞƌǀĂƚŝŽŶ ĐĞůů ?  ? ?  ‘ƐŚŽƚƐ ? ǁĞƌĞ ƵƐĞĚ ƚŽ ĚĞƚĞƌŵŝŶĞǁŚĞƚŚĞƌ ƚŚĞƌĞ ǁĂƐ Ă ĚĞůĂǇ ŝŶ ƚŚĞ
sample reaching the observation cell, and also how many traces containing protein could 
be obtained with the volume loaded.  
The tryptophan fluorescence assay was investigated using the MVM setup. It relies on a 
tryptophan residue at the end of the relay helix in the S1 domain moving relative to the 
rest of the molecule. The signal from the tryptophan fluorescence is much smaller than 
that seen for the pyrene-actin (Figure 3.4) and will test the limits of the MVM. Tryptophan 
fluorescence is also a more widely used fluorophore and therefore is more applicable to 
most researchers. 
80, 100, or 120 µL of rabbit myosin S1 was loaded into the system via the MVM as 
described above. The drive syringe, which would normally contain the S1, was filled with 
the micro-volume manifold stopped-flow buffer. The other drive syringe was filled with 
20 µM ATP. The stopped-flow was then triggered 20 times to monitor the fluorescence 
amplitude and determine how many similar transients could be obtained before the S1 
was completely washed out (Figure 3.13). As the protein was washed out the 
fluorescence signal was too. Therefore the fluorescence amplitude decreased as the 
protein was replaced with buffer. 




Figure 3.14 shows a comparison of the parameters from the standard stopped-flow 
method to the MVM with a load volume of 80, 100, and 120 µL. The values of kobs, 
amplitude, maximum fluorescence/end point, and relative amplitude would ideally be 
similar to the standard method. Figure 3.14A shows the observed rate constant (kobs) 
from the standard method, and the different load volumes. Here the values should all be 
similar since the concentration of ATP (which kobs is dependent on) is unchanged. 
However as the S1 is being washed out the trace becomes harder to define and so the kobs 
will become less reliable. However the values of kobs are similar to the values of the 
standard method up until shot 15. Figure 3.14B shows the fluorescence amplitudes of the 
two methods. After 6-7 shots the amplitude begins to reduce to 0 as the S1 is washed out. 
Figure 3.14C is similar to figure 3.14B but this time shows the maximum fluorescence 
signal (end point). The amplitudes and end points are larger for the MVM for an unknown 
reason. Figure 3.14D shows the relative amplitude ((amplitude/end point) x 100) for the 
two methods. This value is very useful when the end point is moving. Overall the 
amplitude, end point, and relative amplitude all show that the MVM works for the 3 
volumes loaded (80, 100, and 120 µL) up until shot 7. After this they all begin to decrease 
Figure 3.13  W 120 µL 0.5 µM rabbit myosin S1 rapidly mixed with 10 µM ATP. ATP was loaded 
into the drive syringe as per the standard stopped-flow method while buffer was loaded in the 
other drive syringe. 120 µL of 1 µM S1 was loaded into the flow circuit via the MVM before 20 
 ‘ƐŚŽƚƐ ? ǁĞƌĞ ƉƵƐŚĞĚ ?  ƐĞůĞĐƚŝŽŶ ŚĂƐ ďĞĞŶ ĚŝƐƉůĂǇĞĚƚŽ ƐŚŽǁ ƚŚĂƚ ƚŚĞ ŝŶŝƚŝĂů  ?-7 transients 
contain protein and have high amplitudes. After this the protein concentration rapidly 
decreases as it is replaced with buffer reducing the fluorescence change to zero. 
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which will make fitting the data harder and therefore makes the kobs less reliable. The 80 
µL load volume while possible showed some variability in the first few shots for the 
amplitudes, end points, and relative amplitudes suggesting that not all the sample has 
reached the observation cell from the first shot. There is therefore still buffer between 
the sample and the observation cell in the case of 80 µL of sample added. For the 100 and 
120 µL load volumes this buffer has passed through the observation cell and from the first 
shot there is sample in the observation cell. It would then be prudent to use either 100 or 
120 µL to load the stopped-flow.  
This test was repeated for its suitability with myosin S1 in complex with pyrene-labelled 
actin (Figure 3.15). The same load volumes were used as for tryptophan fluorescence 
assays (80, 100, 120 µL). The kobs values (Figure 3.16A) were higher in the MVM 
Figure 3.14: Different load volumes of myosin S1 (0.5µM S1) versus 10 µM MgATP. Filled 
squares  W standard method, open squares  W 80 µL load volume, filled triangles  W 100 µL load 
volume, open triangles  W 120 µL load volume. (A) The observed rate constant over 20 shots for 
the standard method versus MVM. (B) Fluorescence amplitude over 20 shots for the standard 
method versus MVM. (C) Maximum fluorescence (end point) for standard method and MVM. 
(D) The relative fluorescence amplitude ((Fluorescence amplitude/end point) x 100) for the 
standard method versus MVM.  
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measurements compared to the standard setup. This was largely due to the MVM not 
being thermostated with a water bath as the standard method. Given that the room 
temperature varied and in some instances  was warmer than the standard method the 
reaction had a faster rate constant. 
 
Figure 3.16B shows the amplitude per shot similar to figure 3.14B. However in this case 
the amplitude was lower than the standard method, again the reason for this in 
unknown. Figure 3.16C shows the end points similar to figure 3.14C, and similar to the 
amplitudes the MVM shots have a lower end point. In both figure 3.16B and C there is a 
decrease in the fluorescence after shot 7, which is the same observation as for the 
tryptophan fluorescence. Figure 3.16D shows the relative amplitude of the pyrene-
actin.S1 and similar to figure 3.14D the relative amplitude decreases after shot 7.  
Both of these figures suggest that it is possible to obtain 7 shots that are similar to the 
standard setup using the MVM using 80, 100, or 120 µL load volumes. However if the 
variable being measured is the amplitude as is the case for the actin affinity 
measurements (KA) then 120 µL load volume would be best since all 7 shots are very 
similar.  
Figure 3.15  W 120 µL 0.5 µM rabbit myosin S1-pyrene actin (pA.S1) rapidly mixed with 10 µM 
ATP. ATP was loaded into the drive syringe as per the standard stopped-flow method while 
buffer was loaded into the other drive syringe. 120 µL of 1 µM acto.S1 was loaded into the flow 
ĐŝƌĐƵŝƚǀŝĂƚŚĞDsDďĞĨŽƌĞ  ? ?  ‘ƐŚŽƚƐ ?ǁĞƌĞƉƵƐŚĞĚ ?ƐĞůĞĐƚŝŽŶŽĨ ƚƌĂŶƐŝĞŶƚƐĂƌĞĚŝƐƉůĂǇĞĚƚŽ
show that the protein is present at a high concentration in the first 6-7 shots. The change in 
fluorescence decreasing shows the acto.S1 washing out of the system and buffer is replacing it.  
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One potential cause for the difference in kobs for the tryptophan and pyrene fluorescence 
assays is a lack of thermoregulation in the MVM. The temperature of the assay was 
dependent upon the temperature of the room and if this increased as the investigation 
proceeded then the kobs would also increase. The air conditioning of the room was set to 
20 °C however this may not have kept the room at a constant temperature. 
 
3.3.3 Determining the actin affinity using the micro-volume manifold  
 
Having established that the micro-volume manifold worked as intended, it seemed 
prudent to test its efficacy compared to the standard set up using an established assay. 
Figure 3.16: Different load volumes of myosin S1-pyrene actin (0.5µM pA.S1) and standard 
method versus 10 µM MgATP. Filled squares  W standard method, open squares  W 80 µL load 
volume, filled triangles  W 100 µL load volume, open triangles  W 120 µL load volume. (A) The 
observed rate constant over 20 shots for the standard method versus MVM. (B) Amplitude over 
20 shots for the standard method versus MVM. (C) End point for standard method and MVM. 
(D) The relative fluorescence amplitude for the standard method versus MVM. 
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Kurzawa et al (Kurzawa, Geeves 1996) previously demonstrated that the actin affinity of 
myosin S1 could be determined by using a fixed concentration of actin (30 nM) 
preincubated with increasing concentrations of S1. This can then be rapidly mixed with 
ATP in the stopped-flow to induce dissociation. Plotting the relative amplitude against the 
concentration of S1 before mixing it is possible to determine the actin affinity using 
equation 2.25 (Chapter 2.3.2.1). 
Kurzawa et al found the affinity of actin to be 44 nM using their method and could 
measure the KA using concentrations as low as 10 nM pyrene-labelled actin. This was 
possible by using phalloidin which stabilises actin in the F-actin state allowing the ability 
to work at lower concentrations of F-actin. In the Kurzawa et al investigation they used a 
20 µL observation cell, while here a 5 µL cell volume was used to reduce the shot volume 
needed (from 60 µL to 20 µL). The drawback to using the smaller observation cell is the 
reduced fluorescence amplitude due to the smaller volume of sample and smaller volume 
of excitation, which will result in less fluorescence emission. Therefore a higher 
concentration of pyrene-labelled actin was used to acquire adequate fluorescence. 
This assay was conducted with the MVM at an actin concentration (before mixing) of 50 
nM (Figure 3.17). This was done to assess whether this assay was suitable to be used with 
the MVM. The concentration of actin was chosen since it was unknown how sensitive the 
stopped-flow would be with the MVM attached due to any possible dilution of the sample 
with buffer either side when in the flow circuit. As can be seen from figure 3.17 the first 
ĐŽŶĐĞŶƚƌĂƚŝŽŶŽĨ^ ? ? ? ?ŶD )ŚĂĚĂƌĞůĂƚŝǀĞĂŵƉůŝƚƵĚĞŽĨA? ? ?A?ǁŚŝĐŚŝŶĐƌĞĂƐĞĚƚŽA? ? ?A?
at 1 µM S1.  
Figure 3.17A shows the traces of S1 (of varied concentrations) preincubated with 50 nM 
phalloidin-stabilised pyrene-labelled actin after being rapidly mixed with 20 µM MgATP. 
As more S1 is added to the actin more of the pyrene is quenched before mixing. When 
ATP binds and induces the dissociation the pyrene is exposed and fluoresces. This leads to 
an increase in fluorescence as the initial background fluorescence decreases. This figure 
has been normalised to the same start point to make it easier to see the overall change in 
fluorescence. In reality they would have the same end points as this is the maximum 
fluorescence which is dependent on the actin concentration. The relative amplitudes 
(defined by dividing the change in fluorescence by the end point) were then fit as a 
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function of S1 concentration (figure 3.17B) which can be described by the quadratic 
equation (eq. 3.1). Three repeats have been shown here to highlight the reproducibility of 
the assay. The average value of KA = 44.8 ± 5.3 nM, very similar to the value determined in 
Kurzawa et al. 
 
Having determined that the MVM was suitable to use for this assay at 50 nM pyrene-
labelled actin it seemed necessary to attempt the assay at the actin concentration used 
for most actin affinity assays, 30 nM. This is the concentration used in the original paper 
and is the concentration of actin used in chapters 4, 5, and 6 to determine the actin 
affinities. Figure 3.18A shows the traces from an actin affinity assay similar to figure 
3.17A. The relative amplitudes were then plotted against the S1 concentration (Figure 
3.18B) similar to figure 3.17B. This gave an average KA value of 45.5 ± 2.6 nM  which is 
both similar to the value at 50 nM actin and the Kurzawa et al value.  
Figure 3.17: Actin affinity of rabbit psoas S1 preincubated with 50 nM actin rapidly mixed with 
20 µM MgATP using the MVM. The S1 concentration was varied from 0 to 1 µM. (A) Averaged 
traces from one assay of the actin affinity. Each trace can be best described by a single 
exponential which has been shown on the transients. Each transient has been normalised to the 
start point to make observing the overall change in fluorescence easier. (B) The relative 
amplitudes were then plot as a function of S1 concentration and fit with the quadratic equation 
(eq. 3.1). Three repeats have been shown to demonstrate the accuracy of the measurement 
with the MVM. The individual values of KA determined are 35.6 ±9.1 nM, 44.8 ± 11.1 nM, and 
53.9 ± 9.6 nM. This gave an average KA = 44.8 ± 5.3 nM. All concentrations given are those 
before mixing since the actomyosin complex is being measured rather than the rate of 
dissociation. 




If these assays were to be conducted using the standard method then 3.5 mL of S1 would 
be needed (500 µL x 7 S1 concentrations). Using the MVM this volume was reduced to 
just over 1 mL at 1.05 mL (150 µL x 7 S1 concentrations, where 120 µL is loaded with 30 
µL spare to prevent air getting into the system). 80 µL load volume could be used 
however the first shot did not contain the full concentration of protein. Therefore this 
method is 3 times more efficient and allowed the assay to be repeated in triplicate using 
the same volume as would be needed for one assay using the standard set up.  
  
Figure 3.18: Actin affinity of varied rabbit psoas S1 preincubated with 30 nM actin rapidly 
mixed with 20 µM MgATP using the MVM. The S1 concentration was varied from 0 to 1 µM. 
(A) Averaged traces from one actin affinity assay. Again each trace was best described by a 
single exponential which are shown with a solid line.  These traces have also been normalised 
to the start point. (B) Quadratic fit of the relative amplitude versus the S1 concentration. All 
three repeats have been shown with individual KA values of 41.7 ± 7.7 nM, 50.5 ± 16.9 nM, and 
44.2 ± 13.9 nM. This gave an average KA value of 45.5 ± 2.6 nM. All concentrations are again 
those before mixing. 




3.4.1 Micro-volume Manifold 
 
As stated above the major limiting factor of using stopped-flow spectroscopy assays is the 
large volume of sample needed. The standard setup would require 300-500 µL of sample 
to acquire several repeated traces that could be averaged and give a repeatable set of 
values. Using the micro-volume manifold with a 120 µL load volume (with 150 µL pipetted 
and 120 µL loaded) allows the operator to use half to a third the sample needed to 
produce 6-7 similar traces. This could not only save time and sample in running these 
assays, but also money in producing less of a protein, or being able to do multiple assays 
from a sample that could only be used on one. 
In a similar assay using pyrene-labelled actin at 15 nM, Kurzawa and Geeves (Kurzawa, 
Geeves 1996) found the actin affinity to be 44 nM. The assays here were conducted with 
either 50 or 30 nM pyrene actin resulting in a KA = 44.8 ± 5. nM and 45.5 ± 7.7 nM 
respectively. This method therefore gives comparable results to not using the MVM 
whilst using a third of the volume when using 500 µL for the standard setup. The possible 
limitation of this investigation is the use of the micro-volume observation cell (5 µL). 
Using a smaller volume of fluorophore will reduce the fluorescence signal which drove 
the decision to use a higher concentration of pyrene-actin. However given more time it 
would be useful to investigate whether a concentration as low as 10 nM pyrene-actin 
could result reliable data. 
There are several sources of error with this investigation that Kurzawa and Geeves 
identified. One error is an incorrect protein concentration calculation which may result 
from an unknown fraction of inactive protein. Activity test are conducted on the rabbit S1 
after it has been dialysed to get a more accurate estimation of the active S1 
concentration compared to that measured from UV/vis spectroscopy. A second error 
could occur as a result of the phalloidin used to keep the actin in the filamentous state. 
However Kurzawa and Geeves investigated the effects of phalloidin on the KA when 
investigated at high actin concentrations (2 µM) where little G-actin is expected. Here 
they found that the phalloidin had little effect on the KA (Kurzawa, Geeves 1996). 





The MVM is still an early prototype with some issues that would need to be addressed 
before it could be released as a commercial product. One of these is the lack of a 
thermostatic control on the manifold which means that the temperature the reaction is 
recorded at cannot be controlled. However the manifold functions as intended by 
reducing the volume loaded into the stopped-flow whilst providing data similar to that 
obtained using the standard setup.   
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4 Characterisation of wild type embryonic skeletal muscle myosin S1  
4.1 Introduction 
 
During mammalian foetal development, three skeletal heavy chain myosin isoforms have 
been shown to be expressed: embryonic (MyHC-emb), perinatal/neonatal (MyHC-peri), 
ĂŶĚ ɴ-slow/cardiac (MyHC-ɴ )(Schiaffino, Rossi et al. 2015). MyHC-emb was first 
identified by Whalen et al. (Whalen, Schwartz et al. 1979) in 1979 although some earlier 
studies had hinted at the existence of the developmental myosins. The genes responsible 
for the expression of MyHC-emb and MyHC-peri are MYH3 and MYH8 respectively 
(Wydro, Nguyen et al. 1983, Periasamy, Wieczorek et al. 1984) and are located on the 
same chromosome (11 for mouse, 17 for human) as the adult fast skeletal myosin 
isoforms (Leinwand, Saez et al. 1983). The sequence identity of the MyHC-peri show high 
similarities to the adult fast skeletal isoforms (MyHC-IIa, -IIb, and  WIIx, Figure 4.1) while 
the MyHC-emb has the most divergent sequence. 
 
MyHC-ɴ MyHC-ɴ
MyHC-ɲ 92.22 MyHC-ɲ Myosin head domain
MyHC-IIx 83.12 83.74 MyHC-IIx
MyHC-IIa 82.85 83.62 94.69 MyHC-IIa
MyHC-IIb 82.68 83.60 96.13 94.26 MyHC-IIb
MyHC-peri 83.96 84.29 95.24 95.68 94.24 MyHC-peri
MyHC-emb 83.21 83.55 87.59 88.62 87.45 89.32 MyHC-emb
MyHC-ɴ MyHC-ɴ Myosin tail domain
MyHC-ɲ 94.43 MyHC-ɲ
MyHC-IIx 81.77 80.57 MyHC-IIx
MyHC-IIa 82.22 81.11 95.81 MyHC-IIa
MyHC-IIb 81.22 80.11 92.98 91.70 MyHC-IIb
MyHC-peri 80.84 80.00 91.61 91.97 89.05 MyHC-peri
MyHC-emb 78.98 78.96 83.46 83.82 82.08 83.46 MyHC-emb
Figure 4.1  W Human sequence identities of the two cardiac (MyHC-ɴĂŶĚDǇ,-ɲ ? ?ƚŚƌĞĞĂĚƵůƚ
fast skeletal (MyHC-IIx, MyHC-IIa, and MyHC-IIb) and two developmental (MyHC-peri and 
MyHC-emb) myosin isoforms. The upper table shows the identities within the head (motor) 
domain, while the lower tables shows the tail of the molecule. 
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Little is known about the expression patterns of the developmental isoforms in humans 
due to the ethical considerations in obtaining samples of foetal muscle tissue. Therefore 
we have had to rely on animal models as a guide for the expression of these myosins. 
MyHC-emb has been identified in birds and fish however the majority of work has been 
carried out in rats and mice. In the mouse in situ hybridisation has detected transcripts of 
MyHC-emb from 9.5 days post-coitum (Lyons, Ontell et al. 1990). The upregulation of 
these genes is thought to be controlled by myogenic factors MyoD and Myf5 which are 
involved in muscle differentiation (Beylkin, Allen et al. 2006). The expression of MyHC-
emb appears to vary depending on the developmental stage of the fibre. For example in 
rats MyHC-emb is co-expressed with MyHC-ɴŝŶƉƌŝŵĂƌǇŐĞŶĞƌĂƚŝŽŶĨŝďƌĞƐ ?ƚŚĞĨŝƌƐƚĨŝďƌĞƐ
formed (Narusawa, Fitzsimons et al. 1987, Rubinstein, Kelly 1981)). However the 
secondary generation fibres express MyHC-emb and MyHC-peri (Condon, Silberstein et al. 
1990).  
The developmental isoforms have been shown to be down regulated after birth and 
replaced by an upregulation of the adult fast isoforms (MyHC-IIx, MyHC-IIa, and MyHC-
IIb). In the rat, this occurs a few days after birth (DeNardi, Ausoni et al. 1993), however in 
the mouse, transcripts can be detected before birth (Lu, Allen et al. 1999). However the 
levels of protein in new born mice shows the developmental isoforms are still dominant 
(30 % MyHC-emb and 70 % MyHC-peri) (Agbulut, Noirez et al. 2003).  
In humans primary generation fibres form around week 8 while secondary generation 
fibres emerge around week 10 becoming the dominant fibre at week 21 (Fidzianska 
1980). By week 9 the MyHC-emb, MyHC-peri, and MyHC-ɴ ƚƌĂŶƐĐƌŝƉƚƐ ĐĂŶ ďĞ ĚĞƚĞĐƚĞĚ
(Figure 4.2). All the primary fibres express MyHC-emb and MyHC-ɴ(Barbet, Thornell et al. 
1991, Draeger, Weeds et al. 1987) initially, with the expression of MyHC-ɴ ĚĞĐƌĞĂƐŝŶŐ
from 75 % at week 10 to 3 % at week 21 which correlates with secondary fibres becoming 
dominant at this time (Cho, Webster et al. 1993). Secondary fibres begin to express 
MyHC-emb at week 12, and MyHC-peri later (Cho, Webster et al. 1993). Similar to the rat 
and mouse models the developmental isoforms are downregulated leading up to and 
after birth and are replaced by the adult fast skeletal isoforms (Figure 4.2). 
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MyHC-emb is thought to be a slow type myosin similar to MyHC-ɴ ĚƵĞ ƚŽ ƚŚĞ actin 
activated ATPase activity being lower than the adult fast isoforms (Drachman, Johnston 
1973, Lowey, Waller et al. 1993). A study by Resnicow et al. (Resnicow, Deacon et al. 
Figure 4.2  W Transcripts of myosin heavy chains in developing human muscle. In situ 
hybridisation probes were used to detect the following MYH genes: MYH3 (MyHC-emb, a-d), 
MYH8 (MyHC-peri, e-h), MYH7 (MyHC-ɴ ?ŝ-l), MYH2 (MyHC-IIa, m-p), and MYH1 (MyHC-IIx, q-t). 
Quadriceps femoris muscles were from 9- and 19-week old foetuses while vastus lateralis 
muscles were from 1-day- and 1-month-old new born. Scale bar = 30 µm and is the same across 
all figures Figure from (Smerdu, 2002). 
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2010) using the same method as used here for producing recombinant S1 (with a GFP tag) 
showed however that the ATPase maximum rate (Vmax) and half maximum rate (KM) were 
very similar to the adult fast isoforms. 
This is the first study to examine the transient kinetic parameters of the wild type MyHC-
emb S1 using a recombinant protein (Chapters 2.2.1.3 and 2.2.1.4). This method allows 
the examination of a pure homogeneous sample since muscle samples will contain fibres 
expressing different myosin isoforms which will affect the kinetics. C2C12 cells dervived 
from a mouse myoblast cell line were grown and transfected with the human MYH3 gene 
encoding the MyHC-emb S1 domain with a His-tag at the C-terminus by Carlos Vera 
(University of Colorado, USA). No human light chains were expressed with the S1, as such 
the endogenous mouse light chains were purified with the S1 (Figure 4.3). The 
purification was performed using the method in chapter 2 (Chapter 2.2.1.4). Previously 
protein was purified at Colorado and shipped here to the UK. Purifying the protein in the 
UK prior to use in the stopped-flow ensured the sample could be used when fully active. 
An added benefit was an increase in protein yield by removing an additional 
chromatography step following the cell lysis and nickel chromatography step. Therefore 
samples of 1-2 mL 2-5 µM myosin S1 was increased to 1-2 mL 10-20 µM myosin S1. This 
S1 was used for the stopped-flow assays.  
Since starting this project collaborators at Colorado have also improved their purification 
to obtain similar concentrations of myosin S1 without an endogenous mouse myosin 
contamination. The S1 purified in Colorado was used for the ATPase assays. 
The aim of the investigation in this chapter is to characterise the kinetics of the individual 
steps of the myosin cross-bridge cycle for MyHC-emb. This will help to determine whether 
the embryonic myosin is a slow type myosin like MyHC-ɴ Žƌ ĨĂƐƚ ůŝŬĞ ƚŚĞ ŽƚŚĞƌ ĐůĂƐƐ //
skeletal myosins. Embryonic myosin (MyHC-emb) is thought to be a slow type myosin like 
the cardiac slow myosin-ɴ ?ĐŽŵƉĂƌŝƐŽŶĐĂŶďĞĚƌĂǁŶǁŝƚŚƚŚe MyHC-ɴ isoform since it 
has recently been characterised under the same experimental conditions (Nag, Sommese 
et al. 2015). A second aim is to repeat the ATPase assay with the new construct (without 
GFP) and observe any correlation between the stopped-flow kinetics and steady-state 
ATPase data. The ATPase data will also help to fill gaps in the stopped-flow data by 
allowing estimates through modelling. In understanding the MyHC-emb this will help to 
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evaluate the consequences of disease causing mutations in the myosin molecule (Chapter 
5). 
 
The kinetic data on the wild type MyHC-emb was published along with the Freeman 
Sheldon Syndrome mutations in MyHC-emb data in the Journal of Biological Chemistry in 
May 2016: 
Walklate, J., Vera, C., Bloemink, M. J., Geeves, M. A., Leinwand, L., The most prevalent 
Freeman-Sheldon syndrome mutations in the embryonic myosin motor share functional 
defects. The Journal of Biological Chemistry, 2016, 291, p.10318-10331. 
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4.2 WT Embryonic myosin stopped-flow kinetics 
4.2.1 Purification of recombinant S1 
 
The recombinant S1 was expressed by Carlos Vera (University of Colorado, USA, Chapter 
2.2.1.3) then purified from cell pellets using nickel affinity chromatography (Chapter 
2.2.1.4) which resulted in a fairly pure solution of S1 (Figure 4.3).  
 
There was however a small contamination of full length endogenous myosin and an even 
smaller band of actin present after the column. Densitometry analysis was used to work 
out the percentage of myosin present in the solution to determine if it would have an 
effect on the stopped-flow kinetics data (Figure 4.4). 
Figure 4.3  W SDS-PAGE of the wild type MyHC-emb purified from recombinant expression in 
the mouse myoblast cell line C2C12. Molecular weights are displayed on the left hand side 
from the ladder used. MLC1A = myosin light chain 1A, MLC3F = myosin light chain 3F, MLC1F = 
myosin light chain 1F, MLC2F = myosin light chain 2F. 




The percentage of myosin compared to S1 by mass could be calculated by dividing the 
area of the myosin peak by the area of the S1 and myosin peaks and multiplying by 100: 
  ? ? ? ? ? ?ൈ  ? ? ? ൌ  ?Ǥ ? ? 
 
This value could then be used to calculate the percentage of myosin by molecular weight 
by multiplying the percentage by mass by the molecular weight of the S1 divided by the 
molecular weight of the myosin (molecular weights estimated from gel, Figure 4.3): 







Figure 4.4  W Densitometry analysis of the recombinant MyHC-emb SDS-PAGE. Here the darker or 
more intense the bands on the gel the bigger the peaks. 1 = endogenous mouse full length 
myosin, 2 = recombinant MyHC-emb S1, 3 = myosin light chain 1A (MLC1A), 4 = myosin light 
chain 3F (MLC3F), 5 = myosin light chain 1F (MLC1F), and 6 = myosin light chain 2F (MLC2F). The 
area of each peak (insert) was determined using the densitometry software (Scion Image). The 
light chains were identified using analysis from Deacon et al. (Deacon, Bloemink et al. 2012) and 
assigned based on their molecular weight. This densitometry analysis was used to estimate the 
ratio of protein bands on the SDS-PAGE gel from figure 4.3. 
actin 




Therefore the amount of endogenous mouse myosin is low and unlikely to appear in the 
stopped-flow traces since it is <5 % by weight, however caution was taken to be 
observant of slow secondary transients in the stopped-flow assays that would be 
indicative of endogenous myosin in the system. The endogenous myosin may be present 
due to the presence of actin. It is possible that the S1 is still bound to the actin and so is 
the myosin, therefore they purifying together. For the ATPase assays conducted by Carlos 
Vera he utilised a second purification step using ion exchange to remove the endogenous 
myosin. This was necessary for the steady-state ATPase assays as the basal activity was 
measured and a contaminating myosin could affect the results. However for these 
stopped-flow assays, the contaminating myosin had no interference than therefore the 
extra purification step was not needed. Using an extra day to clean the sample and 
possible purify less protein would have not been an economical use of this precious 
sample. 
One issue of the construct used is that the light chains bound to the S1 are the 
endogenous mouse light chains from the C2C12 cells. Deacon et al. (Deacon, Bloemink et 
al. 2012) analysed these light chains and found they were MLC1A, MLC3F, MLC1F, and 
MLC2F. The light chains were assigned based on their molecular weights. 
A review by Bottinelli and Reggiani (Bottinelli, Reggiani 2000) stated that the myosin light 
chains (MLC) 1A, 1F, and 2F are known to bind to the embryonic myosin. MLC1A is also 
known as the MLC-1 atrial/foetal isoform expressed in embryonic skeletal tissue and the 
heart and in the atria of adults (Whalen, Butler-Browne et al. 1978, Kurabayashi, Komuro 
et al. 1988). We were therefore encouraged to find that these light chains had a greater 
density than the MLC3F. This also correlates to the level of S1 and endogenous myosin in 
the sample, suggesting these three light chains are binding to the S1 (MLC1A - essential 
light chain, and either MLC1A or MLC2F - regulatory light chains)  while MLC3F which 
does not bind to the embryonic myosin appears to be associating with the endogenous 
myosin. Deacon et al. (Deacon, Bloemink et al. 2012) used a construct with the 
recombinant MYL3 which is a specific cardiac light chain. Since there is a specific 
embryonic myosin light chain it would be interesting to see if there is a change in the 
kinetics with the human form present as there is in the cardiac ɴ-S1. 
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4.2.2 Difference ŝŶŶƵĐůĞŽƚŝĚĞďŝŶĚŝŶŐƚŽtdĞŵďƌǇŽŶŝĐ^ ?ĐŽŵƉĂƌĞĚƚŽtdɴ^ ? 
 
Upon binding of ATP to myosin S1 (in the absence of actin) there is a fluorescence change 
associated with tryptophan-509 moving on the relay loop.  
ATP of varying concentrations was rapidly mixed with 100 nM wild type embryonic 
myosin S1. The change in fluorescence was well described by a single exponential 
(Equation 2.4, Figure 4.5A). The kobs was dependent on ATP concentration such that as 
the ATP concentration increased so did the kobs. This dependence could be well described 
by the hyperbolic equation 2.13 (Chapter 2.3.2.1, Figure 4.5B). The percentage 
fluorescence increase was 10 % and unaffected by the increase in ATP concentration.  
One value obtained from the hyperbola is the second order rate constant of ATP binding 
to S1 (K1k+2). This is determined from the initial section of the fit at the low 
concentrations of ATP (<50 µM).  The K1k+2 value was nearly 2.5 fold faster for MyHC-emb 
(12.5 ± 1.9 µM-1 s-1) than for MyHC-ɴ ? ? ? ?A? ? ? ?A?D-1 s-1, Table 4.1). Values shown are the 
average of three biological repeats with the S.E.M.  
At higher concentrations of ATP (>50 µM) the ATP becomes saturating and a different 
step becomes rate limiting. The fit then gives two more values, kmax and K50%. The value of 
kmax has been linked to the maximum rate of ATP binding to S1 (k+2) and to the hydrolysis 
































Figure 4.5  W Tryptophan fluorescence of ATP binding to wild type embryonic myosin S1. (A) An 
example trace of the fluorescence change upon 10 µM ATP binding to 100 nM S1. The kobs = 5.4 
s
-1
 with fluorescence increase = 10.6 %. (B) Hyperbolic dependence of kobs from ATP binding on 
ATP concentration. 
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the kmax which is termed 1/K1. The k+2 (or k+3 + k-3) is 30 % faster for MyHC-emb (130 ± 3.4 
s-1) than the MyHC-ɴ  ? ? ? ? ?A?  ? ? ?Ɛ-1, Table 4.1). The value 1/K1 is the ATP affinity which 
appears slightly tighter for the MyHC-emb (10.9 ± 2 µM) than MyHC-ɴ  ? ? ? ? ?A?  ? ? ?A?D ) ?
however this is not as there is not a significant difference.  
 
Using a similar assay it is possible to determine the ADP affinity (K6K7) and ADP release 
rate constant (k+6, measureable whereas step 7 is too fast to measure) in the absence of 
actin.  
100 nM S1 was preincubated with varied concentrations of ADP. These mixtures were 
rapidly mixed with 50 µM ATP. The fluorescence change was well described by a double 
exponential fit (Figure 4.6). The two phases seen in these transients are descriptive of the 
S1 complexed with ADP. The fast phase arises from ATP binding to S1 that has no 
nucleotide bound and is why only this phase is seen in the absence of ADP. The slow 
phase emerges as ADP concentration increases as it is added to the S1. This is due to ADP 
occupying the nucleotide pocket preventing ATP binding. Therefore ADP must first 
dissociate before ATP binding. The slow phase then represents the ADP release rate 
constant (k+6). For the MyHC-emb the k+6 was slightly faster (0.89 ± 0.07 s




















Figure 4.6  W ADP affinity to S1 in the absence of actin. (A) Trace of 100 nM S1 vs 50 µM ATP 
results in a transient best described by a single exponential. From this fit the value of kobs = 96 s
-1
 
and a fluorescence increase of 8 %. 100 nM S1 was pre-incubated with 0.25 µM ADP before 
being rapidly mixed with 50 µM ATP. The transients were best described by a double 
exponential. This fit yielded a kobs = 63 s
-1
 and fluorescence increase = 3.2 % for the fast phase 
while kobs = 0.8 s
-1
 and fluorescence increase = 5.7 % for the slow phase. (B) The relative 
amplitudes of the fast and slow phases could be plotted against the ADP concentration, which 
shows a hyperbolic dependence. The ADP affinity (K6K7) can be determined form these two fits. 
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MyHC-ɴ ? ? ? ? ?A? ? ? ? ?Ɛ-1) which is a statistically significant difference (Table 4.1). The kobs 
of both phases was unaffected by the increase in ADP concentration. 
The ADP affinity can be determined by plotting the amplitudes of the fast and slow 
phases against the ADP concentration. The fast phase and slow phases can be best 
described by hyperbolic fits using equations 2.20 and 2.24 respectively (Chapter 2.3.2.1). 
As the ADP concentration increase so does the amplitude of the slow phase as more S1 is 
occupied by ADP that must dissociate before ATP can bind. Conversely the fast phase 
amplitude decreases as less of the S1 is free to bind ATP without an ADP molecule already 
bound. Both fits will give similar values for ADP affinity (K6K7) which can be averaged. For 
MyHC-emb the K6K7 value was over 3.5-fold tighter (0.15 ± 0.018 µM) than MyHC-ɴ ? ? ? ? ?
± 0.07 µM, Table 4.1). 
4.2.3 Differences ŝŶŶƵĐůĞŽƚŝĚĞďŝŶĚŝŶŐƚŽtdĞŵďƌǇŽŶŝĐĂĐƚŽ ?^ ?ƚŽtdɴĂĐƚŽ ?^ ?
 
The assays above were repeated this time in the presence of actin by monitoring a pyrene 
label on Cysteine-374 of actin which is quenched when S1 is bound to the actin. The 
fluorescence can be followed when ATP binds to S1 and leads to a dissociation of S1 from 
actin.  
50 nM pyrene-labelled actin in complex with 50 nM S1 was rapidly mixed with 10 µM ATP 
(Figure 4.7A) leading to an increase in fluorescence as ATP induces a dissociation of S1 
from actin. The increase in fluorescence was best described by a single exponential at all 
ATP concentrations.  
At increasing concentrations of ATP, similar to the ATP binding to S1 assay, the kobs 
dependence on ATP concentration is hyperbolic (Figure 4.7B), well described by equation 
2.13 (Chapter 2.3.2. ? ) ?dŚĞƐĞĐŽŶĚŽƌĚĞƌƌĂƚĞĐŽŶƐƚĂŶƚĨŽƌdWďŝŶĚŝŶŐƚŽĂĐƚŽ ?^ ? ?< ?1Ŭ +2), 
is more than twice as fast for the MyHC-emb (9.4 ± 1.0 µM-1 s-1) than for MyHC-ɴ (4.4 ± 
0.2 µM-1 s-1 ?dĂďůĞ ? ? ? ) ?dŚĞŵĂǆŝŵƵŵƌĂƚĞŽĨĚŝƐƐŽĐŝĂƚŝŽŶ ?Ŭ ?+2) however is 2 fold slower 
for MyHC-emb (777 ± 17 s-1) than MyHC-ɴ ? ? ? ? ?A? ? ? ?Ɛ-1).  The affinity of ATP for acto.S1 
(1/K ?1) can be determined by the K50% from the hyperbolic fit. The  ? ?< ?1 for MyHC-emb is 
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almost 4 fold tighter (84.3 ± 9.7 µM) than MyHC-ɴ  ? ? ? ? ? ? A?  ? ? ? ? A?D ) ? dŚĞpercent 
fluorescence increase was not affected by the increase in the ATP concentration. 
 
Repeating this assay in the presence of ADP can be used to ĚĞĨŝŶĞƚŚĞWĂĨĨŝŶŝƚǇ ?< ?6< ?7) 
for acto.S1. ADP affinity could also be determined by mixing ADP with acto,S1 in the 
absence of ATP, however this was not used in this thesis 
 












Figure 4.8: ADP affinity in the presence of actin. (A) Transients showing 50 nM acto.S1 rapidly 
mixed with a combination of 10 µM ATP and 0-400 µM ADP. The increase in fluorescence was 
best described by a single exponential. As the ADP concentration increased, the kobs decreased 
from 70 s
-1
 to 4.8 s
-1
 while the fluorescence amplitude stayed stable at 29 %. (B) kobs plotted as 


















































Figure 4.7  W ATP induced dissociation of MyHC-emb from pyrene-labelled actin. (A) An example 
transient of 50 nM pyrene-actin.S1 rapidly mixed with 10 µM ATP. The increase in fluorescence 
was best described by a single exponential. The kobs = 70 s
-1
 and the increase in fluorescence = 
26.6 %. (B) The hyperbolic dependence of kobs on the ATP concentration. 
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In order to determine the ADP affinity a competition assay was used. A fixed 
concentration of 10 µM ATP was mixed with varying concentrations of ADP (0-400 µM) 
outside of the stopped-flow. Using the stopped-flow 100 nM pyrene-labelled acto.S1 was 
rapidly mixed with the ATP/ADP solutions. This led to a competition in binding between 
the ATP and ADP. As more ADP is added to the assay more will be available to bind to the 
S1 preventing it from binding ATP and therefore slowing the dissociation reaction down. 
This resulted in a slower kobs at higher ADP concentrations than at 0 µM ADP (Figure 
4.8A).  
The kobs can be plotted as a function of ADP concentration which has a hyperbolic 
dependence (Figure 4.8B). When fit with equation 2.15 (Chapter 2.3.2.1) this gives the 
WĂĨĨŝŶŝƚǇ ?< ?6< ?7). For MyHC-ĞŵďƚŚĞ< ?6< ?7 is over 2 fold weaker (14.3 ± 1.9 µM) than 
the MyHC-ɴ ? ? ? ?A? ? ? ?A?D ) ?dŚĞĨůƵŽƌĞƐĐĞŶĐĞĂŵƉůŝƚƵĚĞǁĂƐŶŽƚĂĨĨĞĐƚĞĚďǇƚŚĞŝŶĐƌĞĂƐĞ
in the ADP concentration. 
dŽĚĞƚĞƌŵŝŶĞƚŚĞWƌĞůĞĂƐĞƌĂƚĞ ?Ŭ ?+6) a displacement reaction is utilised instead of the 
competition assay. 100 nM pyrene-labelled acto.S1 is incubated with a saturating 
ĐŽŶĐĞŶƚƌĂƚŝŽŶŽĨW ?ŽǀĞƌ ? ?ƚŝŵĞƐƚŚĞ< ?6< ?7 value) which for MyHC-emb was 300 µM 
ADP. The acto.S1.ADP solution was then rapidly mixed in the stopped-flow with varying 
high concentrations (1-10 mM) of ATP. The kobs should be unaffected by the change in 
dWĐŽŶĐĞŶƚƌĂƚŝŽŶƌĞƐƵůƚŝŶŐŝŶƚŚĞWƌĞůĞĂƐĞƌĂƚĞ ?Ŭ ?+6). For MyHC-ĞŵďƚŚĞŬ ?+6 is nearly 
3 times slower (22 ± 1.8 s-1) than MyHC-ɴ ? ? ? ? ?A? ? ? ?Ɛ-1, Table 4.1). 
Using these values it is also possible to calculate the second order rate constant for ADP 
ďŝŶĚŝŶŐ ?< ?7Ŭ ?-6 ) ?dŚŝƐŝƐĂĐŚŝĞǀĞĚďǇĚŝǀŝĚŝŶŐƚŚĞŬ ?+6 ǀĂůƵĞďǇƚŚĞ< ?6< ?7 value. For MyHC-
emb again this is much slower (1.5 µM-1 s-1) than MyHC-ɴ  ? ? ? ? A?D-1 s-1), over a 6-fold 
difference. 
4.2.4 Differences ŝŶĂĐƚŝŶĂĨĨŝŶŝƚǇƚŽtdĞŵďƌǇŽŶŝĐ^ ?ĐŽŵƉĂƌĞĚƚŽtdɴ^ ? 
 
The method of determining the actin affinity described by Kurzawa et al. (Kurzawa, 
Geeves 1996) using stopped-flow spectroscopy was used for the MyHC-emb. 
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30 nM pyrene-labelled actin is incubated with a varied concentration of S1 (0  W 100 nM) 
and then rapidly mixed with 20 µM ATP (concentrations before mixing). As the S1 
concentration is increased, more of it will bind to the actin quenching the pyrene signal. 
When the acto.S1 is mixed with ATP it will lead to the dissociation step. As more S1 is 
added to the actin, an increasing amount of the pyrene will be quenched at the beginning 
of the assay. Therefore when mixed with the ATP the starting fluorescence amplitude will 
decrease, but at the end of the reaction reach the same maximum fluorescence leading to 
an overall increase in fluorescence amplitude (Figure 4.9A). Since the ATP concentration is 
kept constant the kobs remains constant also. To adjust to the fluctuation that may occur 
in the maximum fluorescence the relative amplitude was calculated ((fluorescence 
amplitude / maximum fluorescence) x 100) and plotted as a function of S1 concentration 
(Figure 4.9B). This can be well described by a quadratic equation (equation 2.25, Chapter 
2.3.2.1) which gives the actin affinity (KA) of S1. For MyHC-emb the KA appears to be 
nearly 5 times tighter (2.1 ± 0.2 nM) than MyHC-ɴ ? ? ?A? ? ? ?ŶD). 
 
This assay can be repeated in the presence of ADP to give the actin affinity in the 
presence of ADP (KDA). The same concentration of actin is used and the S1 concentration 
is varied, however since ADP weakens the S1 actin affinity, higher concentrations are 







































Figure 4.9: Actin affinity of MyHC-emb in the absence and presence of ADP. (A) Transients of 30 
nM actin + varied S1 concentrations (0-100 nM) versus a fixed concentration of 10 µM ATP in 
the absence of ADP. As the concentration of S1 increased so did the fluorescence amplitude. 
These transients are normalised to the same start point so that the increase in fluorescence can 
be observed easier. The transients reach the same end point it is the start point that changes, 
however this is hard to see when plotted on the same graph (B) Fluorescence amplitude plotted 
as a function of S1 concentration can be described by a quadratic fit which results in the actin 
affinity in the absence or presence of ADP. 
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needed than for the KA measurement. The same concentration of ADP (300 µM) is used as 
ĨŽƌƚŚĞWƌĞůĞĂƐĞƌĂƚĞĨŽƌĂĐƚŽ ?^ ? ? ? ?ƚŝŵĞƐƚŚĞ< ?6< ?7), this is to ensure that the S1 has 
a saturating level of ADP. This is incubated with the acto.S1 to allow binding. The 
acto.S1.ADP complex is then rapidly mixed with 100 µM ATP. This results in a similar 
effect to the KA measurements (Figure 4.9A) where the fluorescence amplitude increases 
with S1 concentration but the kobs remains constant. A plot of the relative amplitudes as a 
function of S1 concentration again results in an actin affinity (KDA) which should be 
weaker in the presence of ADP (Figure 4.9B). The KDA value for MyHC-emb is 5-fold 
weaker (526 ± 60.3 nM) than MyHC-ɴ  ? ? ? ? ? ? A?  ? ? ? ? ŶD ) ? For an unknown reason the 
relative amplitude in the presence of ADP does not reach the same level as when ADP is 
not present which may be indicative of S1.ADP staying bound to actin. 
4.2.5 Steady state ATPase data 
 
The steady state ATPase rate was determined using a NADH-coupled assay (Chapter 
2.3.3). The S1 binds and hydrolyses ATP to ADP. This is then converted back to ATP by 
pyruvate kinase as it converts phosphoenolpyruvate (PEP) to pyruvate. The pyruvate can 
then be converted by lactate dehydrogenase to lactate. In the process NADH is oxidised 
to NAD+, which can be monitored via optical spectroscopy. NADH absorbs light at 340 nm 
and so measuring at this wavelength the absorbance will decrease as the NADH is 
converted to NAD+. The gradient of this line can be used to determine the rate of the 
ATPase cycle. S1 has a very low basal ATPase rate in the absence of actin; however this 
rate is stimulated by actin and becomes much quicker as more actin is added.  
ATPase measurements were carried out by Carlos Vera (University of Colorado, USA). 
As the actin concentration increases the ATPase rate also increases, however this 
relationship is only linear at the lower concentrations of actin and has a hyperbolic 
dependence over larger actin concentrations (Figure 4.10). This hyperbolic dependence 
follows a classic Michaelis-Menten equation (equation 2.28, chapter 2.3.3). This results in 
the maximum ATPase rate (Vmax) and the half maximum rate concentration (KM). There 
was no significant difference in Vmax between the MyHC-emb (7.0 ± 0.15 s
-1) and MyHC-ɴ
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(6.0 ± 0.5 s-1). The same was true for the KM value where the MyHC-emb (38.5 ± 2.4 µM) 
was very similar to the MyHC-ɴ ? ? ?A? ?A?D ) ? 
 
 
To determine the MyHC-emb activity at low actin concentrations (below half Vmax) it is 
possible to use the Vmax/KM. For both the MyHC-emb (0.18 s
-1 µM-1) and MyHC-ɴ ? ? ? ? ?Ɛ-1 






















Figure 4.10  W ATPase rate for MyHC-emb. Myosin is an actin activated ATPase so as the actin 
concentration increases so does the ATPase rate. 
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Table 4.1  W Rate and equilibrium constants of the wild type MyHC-emb.S1 compared to the wild 
type MyHC-ɴ ^ ? ? ^ƚĂtistically significant differences (determined by a two-tailed ^ƚƵĚĞŶƚ ?Ɛt 
test) have been shaded grey. Values are averages of 3 biological repeats (from three different 
cell preparations) ± SEM. All assays conducted in 25 mM KCl, 20 mM MOPS, 5 mM MgCl2, 1 mM 
NaN3, pH 7.0 unless otherwise stated. 
 
a (Nag, Sommese et al. 2015) 
b p AM ? ? ? ?ĚĞƚĞƌŵŝŶĞĚďǇ^ƚƵĚĞŶƚ ?Ɛt test as compared to wild type MyHC-ɴ^ ? ?
c p AM ? ? ? ?ĚĞƚĞƌŵŝŶĞĚďǇ^ƚƵĚĞŶƚ ?Ɛt test as compared to wild type MyHC-ɴ^ ? ?
d p AM ? ? ? ? ?ĚĞƚĞƌŵŝŶĞĚďǇ^ƚƵĚĞŶƚ ?Ɛt test as compared to wild type MyHC-ɴ^ ? ?
* 0 mM KCl, 20 mM MOPS, 5 mM MgCl2, 1 mM NaN3, pH 7.0. 
Rate/Equilibrium 
Constant





) 5.8 ± 0.4 12.5 ± 1.9 b
1/K1 (µM) 15.9 ± 1.4 10.9 ± 2.0
kmax or k+3 + k-3 (s
-1
) 91.2 ± 1.8 130 ± 3.4 d









) 4.4 ± 0.2 9.4 ± 1.0 c




) 1543 ± 100 777 ± 17 d
Kɲ ? 4.1 ± 1.4 -
kA?ɲ ? (s-1) 153.4 ± 10.6 -











KA (nM) 10 ± 1.8 2.1 ± 0.2 
b





) 6.0 ± 0.5 7.0 ± 0.15







ATP binding to S1
ADP binding to S1
ATP binding to actin.S1
ADP binding to actin.S1
S1 affinity for actin





4.3.1 Comparison of wild type MyHC-emb to wild type MyHC-ɴ 
 
Much of the previous work carried out on embryonic myosin led to the idea that the 
isoform was a slow type myosin like the cardiac-ɴ ŵǇŽƐŝŶ ? /ƚ ĂƉƉĞĂƌƐ ĨƌŽŵ ƚŚŝƐ
investigation that there are similar characteristics between MyHC-emb and MyHC-ɴ ?
However there are some key differences between the two isoforms that shall be 
discussed here. A comparison of the percentage changes between MyHC-emb and MyHC-
ɴŝƐƐƵŵŵĂƌŝƐĞĚŝŶĨŝŐƵƌĞ ? ? ? ? ?  
 
The hallmark of a slow myosin is a relatively tight ADP affinity (tighter than the fast 
skeletal myosin isoforms IIa, IIb, and IIx) and a slow ADP release rate in the presence of 
actin. The study from Nag et al. (Nag, Sommese et al. 2015) showed that at the same ionic 
strength as this study the ADP affinity was very tight at 6.1 ± 0.3 µM for MyHC-ɴ ?dŚĞ
embryonic myosin has a 2-fold tighter ADP affinity though this is still very tight at 14 ± 1.9 
µM. When the fast skeletal isoforms are compared to MyHC-ɴĂƚĂŚŝŐŚĞƌƐĂůƚ ? ? ? ?ŵD
KCl) this affinity (21 ± 5 µM) is 2.5- to 6-fold weaker than IIa (80 ± 15 µM), IIb (54 ± 11), 
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and IIx (118 ± 33 µM) isoforms (Deacon et al., 2012; Bloemink et al., 2013). It would seem 
therefore that the MyHC-emb sits in-between the slow MyHC-ɴĂŶĚĨĂƐƚƐŬĞůĞƚĂůŝƐŽĨŽƌŵƐ
in terms of ADP affinity.  
The second characteristic of a slow type myosin, the ADP release rate from acto.S1  ?Ŭ ?+6), 
is also very slow for the MyHC-emb and MyHC-ɴ ?ůŽĞŵŝŶŬet al. (Bloemink et al., 2013) 
found the fast isoforms to have a very fast ADP release rate constant (> 1,000 s-1) 
compared to MyHC-ɴǁŚŝĐŚŚĂĚĂŬ ?+6 of 93 ± 5 s-1 in similar conditions (100 mM KCl). Nag 
et al. (Nag et al. ? ? ? ? ? )ĨŽƵŶĚƚŚĞŬ ?+6 to be slightly slower in the lower salt (25 mM KCl) at 
58.7 ± 1.7 s-1, which compared to MyHC-emb, at 22 ± 1.8 s-1, is almost 3 fold faster. 
One interesting difference between the MyHC-ɴĂŶĚDǇ,-emb is the lack of a second 
slow phase with pyrene fluorescence during the ATP induced dissociation assay. This slow 
phase in the transients is thought to be caused by a conformational change of the 
nucleotide binding pocket between an open and closed state. This has become indicative 
of the slow MyHC-ɴ ĂƐ ŝƚ ŝƐ ĂůƐŽ ŶŽƚ ƐĞĞŶ ĨŽƌ ƚŚĞ  ‘ĨĂƐƚ ĂĚƵůƚ ? ƐŬĞůĞƚĂů ŵǇŽƐŝŶ ĐůĂƐƐ //
isoforms. The lack of this second phase would suggest that the conformation change does 
not occur in the MyHC-emb, however there may be two other reasons why this may not 
be the case. Firstly the rate constant for the opening on the nucleotide binding pocket is 
153 s-1 for the MyHC-ɴ ?'ŝǀĞŶƚŚĂƚƚŚĞŵĂǆŝŵƵŵƌĂƚĞŽf dissociation is fairly slow for the 
MyHC-emb (777 s-1) compared to the MyHC-ɴ ? ? ? ? ?Ɛ-1) it is likely that there is insufficient 
distinction between the fast and slow phase for the MyHC-emb. The second reason could 
be the salt concentration. Deacon et al. found that the kA?ɲ ?(isomerisation between an 
open and closed state of the nucleotide pocket on myosin) = 49 s-1 at 100 mM KCl 
(Deacon, Bloemink et al. 2012) while at 25 mM KCl the kA?ɲ ? = 153 s-1 (Nag, Sommese et al. 
2015). This 3-fold reduction in the rate of conformation change could potentially allow 
the two phases to be separated if it is there. 
However the embryonic myosin does appear to have some characteristics of a faster 
myosin. This includes a 30% faster ATP hydrolysis rate constant (k+3 + k-3) and a 2-fold 
ĨĂƐƚĞƌƐĞĐŽŶĚŽƌĚĞƌƌĂƚĞĐŽŶƐƚĂŶƚĨŽƌdW ŝŶĚƵĐĞĚĚŝƐƐŽĐŝĂƚŝŽŶ ?< ?1Ŭ ?+2). Due to the slow 
ADP release rate constant, tight ADP affinity and slow ATPase rate, this has led us to 
conclude that thĞ ĞŵďƌǇŽŶŝĐ ŵǇŽƐŝŶ ǁŚŝůĞ Ă ƐůŽǁ ŝƐŽĨŽƌŵ ŝƐ ĨĂƐƚĞƌ ƚŚĂŶ ƚŚĞ ĐĂƌĚŝĂĐ ɴ-
myosin. 
                                    Chapter 4  W Characterisation of wild type embryonic skeletal muscle myosin S1 
115 
 
4.3.2 Limitations of assays 
 
One limitation of this investigation is that using a low salt buffer, the actin affinity (KA) 
becomes much tighter than if carried out at 100 mM KCl. The salt concentration chosen 
was 25 mM KCl with our collaborators to allow for easier comparison between stopped-
flow data, ATPase data, and in vitro motility assays, the latter, require low salt. Stopped-
flow spectroscopy instruments have become much more sensitive and the ability to use 
30 nM pyrene-actin is a huge achievement. However to have confidence in the value of KA 
the measurement would ideally be conducted with an actin ĐŽŶĐĞŶƚƌĂƚŝŽŶA?<A. Therefore 
the concentration of actin would have to be lower to get a more accurate measurement. 
One thing we can be sure of is that the KA for MyHC-emb is very tight similar to MyHC-ɴ ?
Given more time and protein it would have been useful to repeat this assay at a higher 
salt such as 100 mM KCl. This would have weakened the KA possibly to above 30 nM. 
A second problem with this assay is that the concentration of active myosin must be 
correct. To ascertain the concentration of active S1 we do an activity test (Chapter 
2.2.1.4). However the KA measurement was usually the second to last assay carried out. In 
the time from the activity test to this actin affinity assay the active concentration of S1 
may have decreased. Repeating the activity test would have been an option however due 
to limited amounts of sample this was not viable. 
One measure of how accurate the KA and KDA assays are, is to compare the KDA/KA to the 
< ?6< ?7/K6K7 (Table 4.1). These values should be very similar and a deviation may indicate 
an error in one of the measurements. Since the measurements of ADP affinity are only 
ĚĞƉĞŶĚĞŶƚŽŶŬŶŽǁŝŶŐƚŚĞWĐŽŶĐĞŶƚƌĂƚŝŽŶƚŚĞƐĞĂƌĞǀĞƌǇƌĞůŝĂďůĞƐŽƚŚĞ< ?6< ?7/K6K7 of 
95 is very reasonable. Since the KDA value of 526 nM, and is much higher than the actin 
concentration of 30 nM, this measurement will not be susceptible to the same error as 
the KA. Therefore the value of 250 for KDA/KA is most likely due to the KA measurement 
being slightly out due to the affinity being tighter than the actin concentration and some 
error occurring consequentially. If we assume the value should be 95, then a calculated 
value of the KA (KDA/95 = 526/95 = 5.5 nM) shows that there is some error but very small, 
and again shows the affinity is very tight and closer to the value of MyHC-ɴ ? 
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5 Characterisation of Freeman-Sheldon Syndrome causing mutations 
R672H, R672C, and T178I 
5.1 Introduction 
 
Investigations into mutations in genes that may cause FSS found out of 28 FSS cases 
tested 26 were caused by missense mutations in the MYH3 gene (T178I, E498G, Y582S, 
R672C, R672H, and V825D, Figure 5.1) which codes for MyHC-emb (Toydemir, Rutherford 
et al. 2006). The three most common mutations were: Arginine-672 to a histidine (R672H, 
12/28), Arginine-672 to a cysteine (R672C, 8/28), and Threonine-178 to an isoleucine 
(T178I, 3/28). T178I was also linked to the most common DA syndrome Sheldon-Hall 
Syndrome (SHS) (Toydemir, Rutherford et al. 2006), however this was later found to be a 
misdiagnosis and both cases of SHS where the T178I mutation was found have been 
diagnosed as FSS (Beck, McMillin et al. 2014). Beck et al. extended the study revealing 
more mutations and showed R672H (20/46), R672C (11/46), and T178I (8/46) were the 
three most common MYH3 mutations causing FSS (Beck, McMillin et al. 2014).  
The three mutations R672H, R672C, and T178I accounted for > 90% of all the MYH3 
mutations and T178I had the most severe phenotype. R672H was less severe than T178I 
and R672C the least severe of the three (Figure 5.2).  
Using recombinant myosin S1 produced by the same method as Chapter 4 it should be 
possible to determine the kinetic parameters defining the ATPase cycle to observe any 
defects caused by the mutations R672H, R672C, and T178I in MyHC-emb. The aim 
therefore is to characterise the kinetics of the mutated myosin S1 compared to the wild 
type and to investigate how the mutations may manifest the differing phenotypes 
observed. It will also be of interest to investigate the location of the R672 and T178 
residues in closer detail to predict which intermolecular interactions are affected when 
mutated using homology models of the MyHC-emb. 




Figure 5.1  W Freeman-Sheldon Syndrome (FSS) and Sheldon-Hall Syndrome (SHS) mutations in 
the MYH3 gene. (A) Locations of FSS mutations (top) and SHS mutation (bottom). (B) Location 
of mutations in the myosin motor domain. Residues in red are FSS and yellow are SHS. 5 actin 
subunits are also shown in grey. Image from (Toydemir et al., 2006). 




The kinetic data on the FSS MyHC-emb mutations was published along with the wild type 
data in the Journal of Biological Chemistry in May 2016: 
Walklate, J., Vera, C., Bloemink, M. J., Geeves, M. A., Leinwand, L., The most prevalent 
Freeman-Sheldon syndrome mutations in the embryonic myosin motor share functional 
defects. The Journal of Biological Chemistry, 2016, 291, p.10318-10331. 
 
  
Figure 5.2  W A comparison of individuals with FSS causing mutations T178I, R672H, and R672C in 
the MYH3 gene. Individuals with the T178I mutation had the most severe facial contractures, 
R672C had relatively mild, while R672H was somewhere in between. Figure from (Beck et al., 
2014) 
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5.2 FSS mutation stopped-flow kinetics 
5.2.1 Differences in nucleotide binding to R672H, R672C, and T178I embryonic S1 
compared to WT embryonic S1 
 
The preparations of the FSS mutations had similar yields to the wild type MyHC-emb of 1-
2 mL 10-20 µM active S1. 
The method for determining nucleotide binding rate and equilibrium constants was the 
same as for the wild type embryonic myosin (Chapter 4.2.1). The results of the ATP 
binding to S1 assays are shown in figure 5.3. 
 
The use of tryptophan fluorescence was more problematic for the three mutants than for 
the wild type due to the reduced fluorescence amplitude (Figure 5.3A). For wild type the 
amplitude was around 10 % (Chapter 4.2.1) however for the R672C this was 3-4 % which 
was harder to measure but still possible. For the R672H and T178I the amplitude was low, 
around 1-2 % which could be measured due to the sensitivity of the newer stopped-flow 
spectroscopy instruments and that the kobs were slower. At an ATP concentration of 50 
µM the transients were best described by a single exponential however the kobs was 






































Figure 5.3: Tryptophan fluorescence for the three FSS mutation R672H, R672C, and T178I. (A) 
Representative transients of 100 nM MyHC-emb R672H (green), R672C (red), and T178I (blue) 
S1 rapidly mixed with 50 µM ATP. The increase in fluorescence could be best described by a 
single exponential in all three cases. The kobs and fluorescence amplitudes for the three mutants 
were: 7.3 s
-1
 and 1.6 % respectively for the R672H, 12 s
-1
 and 3.5 % respectively for R672C, and 
18 s
-1
 and 1.4 % for T178I respectively. (B) The hyperbolic dependence of kobs on ATP 
concentration showing the different ATP affinities and maximum rate constants of ATP binding. 
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reduced for all three compared to the wild type MyHC-emb. The kobs for the mutants was: 
7.3 s-1 for R672H, 12 s-1 for R672C, and 18 s-1 for T178I, while the wild type had a kobs of 
102 s-1 at the same ATP concentration. 
When plotted as a function of ATP the kobs followed a hyperbolic dependence (Equation 
2.13) from which the second order rate constant of ATP binding (K1k+2), ATP affinity (1/K1) 
and maximum rate of ATP binding/ATP hydrolysis (kmax or k+3 + k-3) were determined 
(Chapter 4.2.1, Figure 5.3B). 
For R672H, the K1k+2 rate constant was over 30 times slower (0.4 ± 0.04 µM
-1 s-1) than the 
wild type MyHC-emb (12.5 ± 1.9 µM-1 s-1). The value of 1/K1 was again affected this time 
by a 3-fold weakening in the affinity (34.4 ± 5 µM) compared to the wild type (10.9 ± 2 
µM). The k+3 + k-3 was 9 times slower (14.3 ± 0.5 s
-1) for the mutant than the wild type 
(130 ± 3.4 s-1). All of these changes were statistically significant (Table 5.1). 
For R672C, the K1k+2 similar to the R672H was slower (1.1 ± 0.07 µM
-1 s-1), but not as 
marked as the R672H as there was only an 11-fold change. Again ATP affinity (1/K1), was 
2-fold weaker (23.6 ± 2.6 µM) so not as weak as the R672H. The apparent ATP hydrolysis 
rate (k+3 + k-3) however was 5 times slower than the wild type but 2-fold faster than the 
R672H. Again all these changes were significantly different than the wild type (Table 5.1). 
Finally for the T178I, the K1k+2 is the least affected (2.3 ± 0.1 µM
-1 s-1) of the three 
mutations compared to the wild type but is still 5-fold slower. The 1/K1 value was 40 % 
tighter (7.7 ± 0.6 µM) than wild type rather than the weaker affinity seen for the other 
two mutants. The k+3 + k-3 was however similar to the other two mutant by having a 
hydrolysis rate constant 7-fold slower than wild type (17.7 ± 0.6 s-1). The only change not 
significantly different was the 1/K1. 
Similar to the wild type MyHC-emb the ADP affinity measurements for the mutant MyHC-
emb S1s were attempted. However due to the very low fluorescence amplitude seen for 
the R672H and T178I this assay proved not possible. The use of fluorescent nucleotides 
both Mant-ATP and  WADP or Coumarin-ATP and  WADP failed to even yield a fluorescence 
signal change, let alone one which could be used in this assay. The small fluorescence 
signal also proved difficult for the R672C mutation. While it was possible to observe the 
reduction in the fast phase amplitude, a slow second component failed to appear. 
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However the amplitudes of the fast phase was plotted against the ADP concentration 
which followed a hyperbolic dependence and could be fit with the same equation 
(Equation 2.20) as the fast phase of the wild type MyHC-emb (Chapter 4.2.1, Figure 5.4). 
Similar to the assay for the wild type MyHC-emb the kobs was unaffected by the increase 
in ADP concentration. 
 
The ADP affinity in the absence of actin (K6K7) appeared to be slightly weaker (0.2 ± 0.04 
µM) than the wild type (0.15 ± 0.018 µM) however this difference was not significantly 
different. 
5.2.2 Differences in nucleotide binding to R672H, R672C, and T178I embryonic acto.S1 
compared to WT embryonic acto.S1 
 
The nucleotide binding rate and equilibrium constants were determined the same way as 
for the wild type MyHC-emb (Chapter 4.2.2). The results of the ATP induced dissociation 
assay are shown in figure 5.5. 
Upon ATP binding the dissociation reaction occurs (Figure 5.5A) which followed a single 
exponential for the R672C at all ATP concentrations and T178I at low concentrations. 
R672H displayed a double exponential at all ATP concentrations and T178I at high 
concentrations (above 50 µM). The dependence of fast kobs on ATP concentration 

















Figure 5.4 - R672C ADP affinity for S1. 100 nM MyHC-emb R672C S1 was preincubated with varied 
concentrations of ADP (0-0.5 µM) before being rapidly mixed with 50 µM ATP. Only the fast phase 
of the assay could be measured however the relative amplitude decreased with a hyperbolic 
dependence. 
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followed a hyperbolic dependence as with the wild type MyHC-emb (Chapter 4.2.2). From 
this the second order ƌĂƚĞ ĐŽŶƐƚĂŶƚ ŽĨ dW ďŝŶĚŝŶŐ  ?< ?1Ŭ ?+2 ) ? dW ĂĨĨŝŶŝƚǇ  ? ? ?< ?1), and 
ŵĂǆŝŵƵŵƌĂƚĞŽĨĚŝƐƐŽĐŝĂƚŝŽŶ ?Ŭ ?+2) could all be determined (Figure 5.5B). 
 
For R672H, the kobs from the two phases were plotted against ATP concentration. The fast 
phase followed the hyperbolic dependence while the slow phase was unaffected by 
increased ATP. To ensure that there was no contaminating ADP present apyrase was 
added to convert the ADP to AMP however this had no effect on the presence of the slow 
compoŶĞŶƚ ? &ƌŽŵ ƚŚĞ ĨĂƐƚ ƉŚĂƐĞ ƚŚĞ ƉĂƌĂŵĞƚĞƌƐ ĐŽƵůĚ ďĞ ĚĞƚĞƌŵŝŶĞĚ ? dŚĞ < ?1Ŭ ?+2 was 
more than 2-fold slower (4.5 ± 0.3 µM-1 s-1) than the wild type (9.4 ± 1 µM-1 s-1 ) ?dŚĞ ? ?< ?1 
was 10 % weaker (92.3 ± 9 µM) than the wild type (84.3 ± 9.7 µM) however this 
difference was ŶŽƚ ƐŝŐŶŝĨŝĐĂŶƚůǇ ĚŝĨĨĞƌĞŶƚ ?dŚĞ Ŭ ?+2 is almost 2-fold slower (413 ± 32 s-1) 
than the wild type (777 ± 17 s-1). The slow phase of ATP induced dissociation has 
previously been described (Deacon, Bloemink et al. 2012) for the MyHC-ɴ ?ĂŶĚŝƐƚŚŽƵŐŚƚ
to be the conformational change between an open and closed state of the nucleotide 
pocket. The equilibrium constant for this process (Kɲ) is calculated as the ratio of the fast 
and slow phase fluorescence amplitude percentage. The rate constant for this pocket 

























Figure 5.5  W ATP induced dissociation of the three FSS mutants from pyrene labelled actin. (A) 
Transients of the ATP induced dissociation of the mutant MyHC-emb S1 from pyrene-labelled 
actin. 10 µM ATP was rapidly mixed with 50 nM pyrene-actin.S1. R672C was described by a 
single exponential yielding a kobs = 14 s
-1
 and a fluorescence amplitude = 41 %. T178I was also 
best described by a single exponential at this concentration yielding a kobs = 24.8 s
-1
 and a 
fluorescence amplitude = 45 %. The transient of the R672H was best described by a double 
exponential yielding a kobs = 30 s
-1
 and 1.9 s
-1
 for the fast and slow phase respectively, while the 
fluorescence amplitude = 26.6 % and 3.4 % for the fast and slow phases respectively. (B) The kobs 
of the R672C, and fast phase kobs of R672H and T178I when plotted against ATP concentration 
follows a hyperbolic dependence. Neither slow phase was affected by ATP concentration. 
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present for wild type the value of Kɲ (4.4 ± 0.8) and kA㴂? (31.5 ± 2.5 s-1) is a significant 
difference. 
For R672C, there ǁĂƐŶŽƐůŽǁĞůĞŵĞŶƚƚŽƚŚĞƚƌĂŶƐŝĞŶƚƐ ?dŚĞ< ?1Ŭ ?+2 was however 4-fold 
slower (2.2 ± 0.5 µM-1 s-1 )ƚŚĂŶƚŚĞǁŝůĚƚǇƉĞĂŶĚĞǀĞŶƐůŽǁĞƌƚŚĂŶZ ? ? ?, ?dŚĞ ? ?< 1 value 
was 40 % weaker than the wild type however this is not a significant difference. The 
Ŭ ?+2value was nearly 3-fold slower (261 ± 8.4 s-1) than the wild type, and is slower than the 
R672H as well. 
&ŽƌƚŚĞd ? ? ?/ ƚŚĞ< ?1Ŭ ?+2 value sits between the two other mutants with a 3-fold slower 
rate constant (3.3 ± 0.2 µM-1 s-1) than wild type. This was the only mutant to have a 
significantly weaker ATP affinity (317.7 ± 41.1 µM) than the wild type by nearly 4-fold. 
dŚŝƐǁĂƐĂůƐŽ ƚŚĞ ŽŶůǇŵƵƚĂŶƚ ƚŚĂƚ ƐŚŽǁĞĚĂŶ ŝŶĐƌĞĂƐĞ ŝŶ ƚŚĞ Ŭ ?+2 value (1033 ± 60 s-1) 
compared to the wild type. Like the R672H there was a slower second phase that 
occurred, however unlike the R672H this only appeared at ATP concentrations above 50 
µM. The Kɲ (6.9 ± 1) was slightly higher than the R672H, and the kA㴂? was 2 times faster 
(66.1 ± 9.1 s-1) than the R672H. The Kɲ difference between T178I and R672H was not 
significantly different while the k+ɲ values were. 
The ADP affinity was determined the same way as the wild type MyHC-emb (Chapter 4.2). 
Here acto.S1 was rapidly mixed with a mixture of ATP and ADP. The T178I behaved in the 
same manner as the wild type, where there is only one phase that gets slower as the ADP 
concentration increases (Figure 5.6). 
For the T178I the kobs decreased as the ADP concentration increased (Figure 5.6). When 
kobs was plotted as a function of ADP concentration it followed a similar hyperbola as the 
wild type S1 and resulted in a similar ADP affinity (12.4 ± 2.2 µM) as the wild type (14.3 ± 
1.9 µM) with no significant difference between the two.  
For the two R672 mutations there was a constant second slow phase at all ADP 
concentrations. The kobs was not affected by the ADP concentration, but the relative 
amplitude was. Figure 5.7A shows the transients for R672H as an example of how the fast 
and slow phases were affected by the increase in ADP concentration.  As the ADP 
concentration increased the amplitude of the fast phase decreased, while the amplitude 
of the slow phase increased.   




 Plotting the relative amplitudes as a function of ADP concentration resulted in two 
hyperbolic functions (Figure 5.7B) which were best described by equations 2.20 (fast 
phase) and 2.24 (slow phase, Chapter 2.3.2.1). R672H has been shown as an example of 
what happened for both the R672 mutants. 





















Figure 5.7 - R672H ADP affinity in the presence of ADP. (A) Transients of 50 nM R672H acto.S1 
rapidly mixed with 30 µM ATP and 0-10 µM ADP. In all cases the increase in fluorescence was 
best described by a double exponential. The amplitude of the fast phase decreased while the 
amplitude of the slow phase increased, the kobs was not affected with the increase in ADP 
concentration. (B) When the relative amplitude (fluorescence amplitude/end point 
fluorescence x 100) of the two phases are plotted against the ADP concentration then it follows 





































Figure 5.6 - T178I ADP affinity in the presence of actin. (A) Transients of 50 nM acto.S1 versus 
0-160 µM ADP and 5 µM ATP. As the ADP concentration increases the kobs decreases. The 
increase in fluorescence was best described by a single exponential in all cases. (B) Plotting the 
kobs as a function of ADP concentration follows a hyperbolic dependence which resulted in a 
ǀĂůƵĞŽĨ< ?6< ?7. 
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The ADP affinity for the R672H mutation was found to be nearly 3-fold tighter (4.8 ± 0.5 
µM) than the wild type (14.3 ± 1.9 µM). For the R672C however there was no significant 
change however the affinity did become weaker (18.1 ± 1.7 µM) than the wild type. 
The ADP release rate constant (Ŭ ?+6) was determined using the same method as wild type 
MyHC-emb. Acto.S1 was incubated with a saturating concentration of ADP (20 times the 
< ?6< ?7, therefore 100, 360 or 250 µM ADP for R672H, R672C, and T178I respectively) and 
rapidly mixed with mM concentrations of ATP. Since the acto.S1 is saturated with ADP it 
will all be in the A.M.D state and the kobs will be unaffected by ATP concentration. 
Therefore the kobs ŽďƐĞƌǀĞĚǁŝůůďĞƚŚĞƌĂƚĞŽĨWƌĞůĞĂƐĞ ?&ŽƌZ ? ? ?,ƚŚĞŬ ?+6 was almost 
3-fold slower (7.4 ± 0.2 s-1) than the wild type (22 ± 1.8 s-1). However for the other two 
mutants there was a slight change but this was not found to be significantly different. 
R672C was 18.6 ± 1.1 s-1, while T178I was 25.7 ± 0.5 s-1. 
5.2.3 Differences in actin affinity to R672H, R672C, and T178I embryonic S1 compared 
to WT embryonic S1 
 
Determining the actin affinity in the absence and presence of ADP was carried out the 
same way as for the wild type MyHC-emb where a constant actin concentration was pre-
incubated with increasing S1 concentrations and rapidly mixed with a constant ATP 
concentration (Chapter 4.2.3). Similarly to the wild type this assay carries the most error 
as the exact concentration of active S1 is needed. The method of determining this is the 
same as for the wild type (Chapter 4.2.3). 
For R672H as the S1 concentration was increased the fluorescence amplitude also 
increases (Figure 5.8A). The relative amplitudes were plotted as a function of S1 
concentration and fit using quadratic equation 3.1 (Chapter 3.2.3, Figure 5.8B and C). The 
actin affinity (KA) was nearly 20-fold weaker (40.2 ± 2.1 nM) than the wild type (2.1 ± 0.2 
nM). While the actin affinity in the presence of ADP (KDA) was 40 % tighter (366.7 ± 31 
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nM) than the wild type (526 ± 60.3 nM), this was not a statistically significant difference. 
 
For R672C there was also a statistically significant weakening (7.2 ± 1.2 nM) in the KA 
compared to the wild type (Figure 5.8B) however given the limitations to this 
measurement (Chapter 4.3.2) this may not be an actual difference. The KDA similarly to 
the R672H was found to be tighter (331.3 ± 68.6 nM) than the wild type however this was 
not statistically significant either (Figure 5.8C). 
The T178I had a 2-fold weaker KA (4.8 ± 0.2 nM) which was found to be a statistically 
significant change (Figure 5.8B) however like the R672C may not be an actual change. The 
KDA on the other hand was found to be 4 times tighter (123.5 ± 15.1 nM) than the wild 
type, which is also a significant change (Figure 5.8C). 
The relative fluorescence amplitudes only reached the same maximum level for the T178I 
in the presence of ADP. This may be indicative of the S1.ADP being less able to quench 
the signal. 
Figure 5.8  W Actin affinity with and without ADP. 
(A) Transients of pyrene-labelled acto.R672H S1 
in the absence of ADP. As the S1 concentration 
increases so does the amplitude. (B) A plot of 
the relative amplitudes, in the absence of ADP, 
of all three mutations as a function of S1 
concentration. This was best described by a 
quadratic fit. (C) Same as for (B) however this 
time in the presence of saturating ADP (100, 360 
or 250 µM ADP for R672H, R672C, and T178I 
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5.2.4 Steady state ATPase data 
 
The steady state ATPase assay was carried out using the same method as for the wild type 
MyHC-emb (Chapter 4.2.4) by Carlos Vera (University of Colorado, USA). The maximum 
rate of the cycle (Vmax) and concentration of actin needed for half the maximum rate (KM) 
was determined the same way (Figure 5.9). 
For the R672H, the Vmax was 5-fold slower (1.3 ± 0.05 s
-1) compared to the wild type (7.0 ± 
0.15 s-1). The KM was also affected; this was 10 times tighter (3.7 ± 0.7 µM) than the wild 
type (Figure 5.7A). The Vmax/KM was therefore affected, this calculated value was larger 
(0.35 s-1 µM-1) than the wild type (0.18 s-1 µM-1, Table 5.1). 
The R672C also had a much slower Vmax (0.35 ± 0.05 s
-1) than the wild type and even the 
R672H; this was 20-fold slower. The KM was also tighter (4.6 ± 0.3 µM) than the wild type 
though not as tight as the R672H (Figure 5.9A). The Vmax/KM was over 4 time faster (0.76 s
-
1 µM-1) than the wild type and R672H (Table 5.1). 
 
Finally, for the T178I the Vmax was significantly slower (0.2 ± 0.008 s
-1) than the wild type. 
This value is 35 times slower, and is considerably slower than the other two mutants as 
well. The KM value is also orders of magnitude tighter (0.67 ± 0.16 µM) than the wild type 
and both R672 mutants (Figure 5.9A). The ATPase activity is so small that on a linear plot 
of ATPase rate against actin concentration the data looked like a flat line and therefore 




































Figure 5.9  W ATPase data for the three FSS mutations. (A) Comparison of all three ATPase 
curves. (B) ATPase data for the T178I plotted on a logarithmic scale to highlight that the data 
was not linear. 
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that there was no activation upon actin binding. To highlight that there is some activity 
the data was plot using a logarithmic scale of actin concentration instead (Figure 5.7B). 
The Vmax/KM was very similar to the R672H (0.30 s
-1 µM-1) and nearly 2-fold faster than the 
wild type. 
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Table 5.1  W Rate and equilibrium constants of the wild type MyHC-emb compared to the 3 FSS 
mutations: R672H, R672C, and T178I. Statistically significant differences compared to wild type 
MyHC-emb (determined by StudeŶƚ ?Ɛt test) have been shaded grey. Buffer conditions were: 25 
mM KCl, 20 mM MOPS, 5 mM MgCl2, 1 mM DTT, pH 7.0 unless stated otherwise. 
 
a Chapter 4 
b p AM ? ? ? ?ĚĞƚĞƌŵŝŶĞĚďǇ^ƚƵĚĞŶƚ ?Ɛt test as compared to wild type MyHC-emb S1. 
c p < 0.01 determined by ^ƚƵĚĞŶƚ ?Ɛt test as compared to wild type MyHC-emb S1. 
d p AM ? ? ? ? ?ĚĞƚĞƌŵŝŶĞĚďǇ^ƚƵĚĞŶƚ ?Ɛt test as compared to wild type MyHC-emb S1. 





Wild Type Emb 





) 12.5 ± 1.9 0.4 ± 0.04 d 1.1 ± 0.07 d 2.3 ± 0.1 c
1/K1 (µM) 10.9 ± 2.0 34.4 ± 5.0 
b 23.6 ± 2.6 b 7.7 ± 0.6
kmax or k+3 + k-3 (s
-1
) 130 ± 3.4 14.3 ± 0.5 d 25.4 ± 1.3 d 17.7 ± 0.6 d
K6K7 (µM) 0.15 ± 0.018 - 0.2 ± 0.04 -
k+6 (s
-1





) 9.4 ± 1.0 4.5 ± 0.3 c 2.2 ± 0.5 d 3.3 ± 0.2 d




) 777 ± 17 413 ± 32 d 261 ± 8.4 d 1033 ± 60 b
Kɲ ? - 4.4 ± 0.8 - 6.9 ± 1
kA?ɲ ? (s-1) - 31.5 ± 2.5 - 66.1 ± 9.1 
K'6K'7 (µM) 14.3 ± 1.9 4.8 ± 0.5 
c 18.1 ± 1.7 12.4 ± 2.2
k'+6 (s
-1





) 1.5 1.5 1 2.1
K'6K'7/K6K7 95 - 90.5 -
KA (nM) 2.1 ± 0.2 40.2 ± 2.1 
d 7.2 ± 1.2 b 4.8 ± 0.2 d
KDA (nM) 526 ± 60.3 366.7 ± 31 331.3 ± 68.6 123.5 ± 15.1 
d
KDA/KA 250 9 46 25.7
Vmax (s
-1
) 7.0 ± 0.15 1.3 ± 0.05 d 3.5 ± 0.05 d 0.2 ± 0.008 d
KM (µM) 38.5 ± 2.4 3.7 ± 0.7 





) 0.18 0.35 0.76 0.30
ATPase *
ATP binding to S1
ADP binding to S1
ATP binding to actin.S1
ADP binding to actin.S1
S1 affinity for actin
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5.2.5 Modelling the ATPase cycle 
 
The stopped-flow data reveals the majority of the steps in the cross-bridge cycle while the 
ATPase data shows how quickly the cycle proceeds. However, the actin rebinding step 
following the ATP hydrolysis and the phosphate release step are not well defined using 
either method. Using a more detailed cross-bridge cycle (Scheme 5.1) and modelling 
software (Berkeley Madonna), it is possible to use the data from the stopped-flow and 
ATPase assays to estimate these two steps. 
 
As scheme 5.1 shows four of the rate constants were known from the stopped-flow 
assays (green circles). Three of the steps are assumed to be fast and therefore given a 
Scheme 5.1  W Scheme used for the modelling on Berkley Madonna. Equilibria circled in green are 
values that were determined from the stopped-flow measurements. Those circled in orange are 
either diffusion limited or generally very fast and such were given values to make them fast. 
Those circled in red were not measured in the stopped-flow assays, however can be estimated 
by fitting the whole cycle to the Vmax and KM values from the ATPase assays. If step 9 were not 
there then at very high actin concentrations the cycle would be inhibited as step 3 is reversible 
and the cycle would be stuck in the A-M.T state (Stein et al, 1981)  The step numbers shown are 




Step 2 Step 3 
Step 4 
Step 5 
Step 6 Step 7 
Step 9 
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forward rate constant of 1,000 (orange circles). These variables have little impact upon 
the cycling rate and therefore the only two variables that will need to be adjusted are the 
actin rebinding and phosphate release. Using the ATPase data as a guide it was possible 
through trial and error to estimate these values to result in modelled ATPase data that 
matched the measured data.  
 
Step Equilibrium Constant Forward rate constant Reverse rate 
constant 
  value units value units value units 
1  W  
ATP binding 
0.0119 µM-1 10.0000 s -1 µM-1 843.0000 s -1 
2  W 
conformational 
change in AMT 
10.0000 - 777.0000 s -1 77.7000 s -1 
3  W 
dissociation  
100.0000 µM 1000.0000 s -1 10.0000 
s -1 
µM-1 
4  W  
hydrolysis 
10.0000 - 130.0000 s -1 13.0000 s -1 
5  W  
actin rebinding 
0.0154 µM-1 10.0000 s -1 µM-1 650.0000 s -1 
6  W  
phosphate 
release 
135.0000 µM 13.5000 s -1 0.1000 
s -1 
µM-1 
7  W 
conformational 
change in AMD 
7.3333 - 22.0000 s -1 3.0000 s -1 
10  W  
ADP release 
100.0000 µM 1000.0000 s -1 10.0000 
s -1 
µM-1 




100.0000 - 20.0000 s -1 0.2000 s -1 
Vmax 7           
KM 38.5           
Table 5.4A  W WT embryonic myosin - Values used to model the cross bridge cycle. Green text 
indicate values determined from either stopped-flow or ATPase assays, orange indicates values 
assumed to be very fast or diffusion limited, red text shows values that were estimated to fit 
the Vmax and KM, grey text indicates values from detailed balance (Ki = k+i/k-i). The forward and 
reverse rate constants were used in the Berkley Madonna software. 
 





Step Equilibrium Constant Forward rate constant Reverse rate 
constant 
  value units value units value units 
1  W  
ATP binding 
0.0109 µM-1 10.0000 s -1 µM-1 920.0000 s -1 
2  W 
conformational 
change in AMT 
100.0000 
 
400.0000 s -1 4.0000 s -1 
3  W 
dissociation  
100.0000 µM 1000.0000 s -1 10.0000 
s -1 
µM-1 




14.3000 s -1 1.4000 s -1 
5  W  
actin rebinding 
0.2500 µM-1 10.0000 s -1 µM-1 40.0000 s -1 
6  W  
phosphate 
release 
17.0000 µM 1.7000 s -1 0.1000 
s -1 
µM-1 
7  W 
conformational 
change in AMD 
18.5000 
 
7.4000 s -1 0.4000 s -1 
10  W  
ADP release 
100.0000 µM 1000.0000 s -1 10.0000 
s -1 
µM-1 






20.0000 s -1 0.2000 s -1 
Vmax 1.3           
KM 3.7           
Table 5.4B  W R672H embryonic myosin - Values used to model the cross bridge cycle. Green text 
indicate values determined from either stopped-flow or ATPase assays, orange indicates values 
assumed to be very fast or diffusion limited, red text shows values that were estimated to fit 
the Vmax and KM, grey text indicates values from detailed balance (Ki = k+i/k-i). The forward and 










Step Equilibrium Constant Forward rate constant Reverse rate 
constant 
  value units value units value units 
1  W  
ATP binding 
0.0083 µM-1 10.0000 s -1 µM-1 1200.0000 s -1 
2  W 
conformational 
change in AMT 
100.0000 
 
261.0000 s -1 2.6100 s -1 
3  W 
dissociation  
100.0000 µM 1000.0000 s -1 10.0000 
s -1 
µM-1 




25.4000 s -1 2.5400 s -1 
5  W  
actin rebinding 
0.1667 µM-1 10.0000 s -1 µM-1 60.0000 s -1 
6  W  
phosphate 
release 
60.0000 µM 6.0000 s -1 0.1000 
s -1 
µM-1 
7  W 
conformational 
change in AMD 
5.4706 
 
18.6000 s -1 3.4000 s -1 
10  W  
ADP release 
100.0000 µM 1000.0000 s -1 10.0000 
s -1 
µM-1 






20.0000 s -1 0.2000 s -1 
Vmax 3.5           
KM 4.6           
Table 5.4C  W R672C embryonic myosin - Values used to model the cross bridge cycle. Green text 
indicate values determined from either stopped-flow or ATPase assays, orange indicates values 
assumed to be very fast or diffusion limited, red text shows values that were estimated to fit 
the Vmax and KM, grey text indicates values from detailed balance (Ki = k+i/k-i). The forward and 










Step Equilibrium Constant Forward rate constant Reverse rate 
constant 
  value units value units value units 
1  W  
ATP binding 




2  W 
conformationa




1033.2000 s -1 10.3320 s -1 
3  W 
dissociation  
100.0000 µM 1000.0000 s -1 10.0000 s -1 µM-1 




17.7000 s -1 1.7700 s -1 
5  W  
actin rebinding 
1.6667 µM-1 10.0000 s -1 µM-1 6.0000 s -1 
6  W  
phosphate 
release 
2.0000 µM 0.2000 s -1 0.1000 s -1 µM-1 
7  W 
conformationa




25.7000 s -1 3.2000 s -1 
10  W  
ADP release 
100.0000 µM 1000.0000 s -1 10.0000 s -1 µM-1 






20.0000 s -1 0.2000 s -1 
Vmax 0.2           
KM 0.67           
T178I embryonic myosin 
Table 5.4D  W Values used to model the cross bridge cycle. Green text indicate values determined 
from either stopped-flow or ATPase assays, orange indicates values assumed to be very fast or 
diffusion limited, red text shows values that were estimated to fit the Vmax and KM, grey text 
indicates values from detailed balance (Ki = k+i/k-i). The forward and reverse rate constants were 
used in the Berkley Madonna software. 
To conduct the modelling a concentration of 0.1 µM S1 was set, along with 5 mM ATP. 
The program has an option to perform a batch run where the parameter changing (actin 
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concentration) could be set, the number of runs that would be performed (11 actin 
concentrations), and the initial (0 µM) and final (100 µM) actin concentrations.  
Myosin has a very low basal ATPase rate, hydrolysing ATP very slowly while actin works to 
enhance the ATPase activity by rebinding to S1 and forcing phosphate and ultimately ADP 
off the S1. Therefore to determine the ATPase rate at each actin concentration the free 
ADP concentration was monitored (Figure 5.10). The gradients from the increases in ADP 
concentration were then used to determine the ATPase rate (Equation 5.1). 
  ? ? ? ? ? ? ? ? ? ? ൌ ? ? ? ? ? ? ? ?ሾ ? ?ሿ       Equation 5.1 
These ATPase rates were then plotted as a function of actin concentration (Figure 5.11) 
and fit with the classic Michaelis-Menten equation (Equation 5.2) to determine the Vmax 
and the KM.  ? ൌ ?೘ೌೣሾ ?ሿ ?ಾ ?ሾ ?ሿ         Equation 5.2 
Figure 5.10  W An example batch run for WT MyHC-emb. The initial actin concentration was set 
at 0 µM increasing by 10 µM to a maximum concentration of 100 µM. The initial concentration 
of ATP was set at 5 mM and the concentration of ADP monitored. The units for the y-axis is µM  
and the x-axis is seconds. 




It was found that the actin rebinding step strongly influenced the KM value while the 
phosphate release step influenced the Vmax. As figure 5.10 shows the modelled data 
matches the measured ATPase data very well with KM and Vmax values very similar. This 
increased the confidence in our models since the model and measured data matched. 
Using the measured and estimated values it was then possible to run the assay until it 
reached a steady state and determine what proportion of the cycle is occupied by each 
step. The cycle at Vmax was simulated by setting the actin concentration to 3 times the KM 
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Figure 5.11  W Modelled ATPase data compared to ATPase measurements from figures 4.10 and 
5.9. (A) Modelled ATPase data versus the measured ATPase data of the wild type MyHC-emb. 
The Vmax of the measured and modelled are 7.06 s
-1
 and 7.04 s
-1
 respectively, while the KM for 
the measured and modelled are 38.5 µM and 37.1 µM respectively. (B) Modelled ATPase data 
versus the measured ATPase data of the R672H MyHC-emb. The Vmax of the measured and 
modelled are 1.26 s
-1
 and 1.25 s
-1 
respectively, while the KM for the measured and modelled are 
3.7 µM and 3.5 µM respectively. (C) Modelled ATPase data versus measured ATPase data of the 
R672C MyHC-emb. The Vmax of the measured and modelled are 3.5 s
-1
 and 3.47 s
-1
 respectively, 
while the KM for the measured and modelled are 4.6 µM and 4.62 µM respectively. (D) 
Modelled ATPase data versus the measured ATPase data of the T178I MyHC-emb. The Vmax of 
the measured and modelled are both 0.19 s
-1
, while the KM for the measured and modelled are 
0.67 µM and 0.68 µM respectively. 






 Emb R672C measured
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value for the wild type and three mutants individually (Figure 5.12). Since the actin 
concentration can vary significantly in a functioning muscle due to the proximity of a 
myosin to actin. Therefore a high concentration of actin was simulated. An actin 
concentration equal to 3 x KM was used which should give a Vmax of 75%. These models 
were under unloaded conditions. To model loaded conditions the phosphate release step 
and ADP release step are thought to be reduced. However when modelling a loaded 
system the occupancy of the cycle was relatively unchanged due to already slow 










Figure 5.12  W Myosin head domain occupancy of unloaded S1 at 75% Vmax with an actin 
concentration 3 x KM. After 1 second the reaction was at steady state for all four myosins 
when modelled. The occupancy of the cross bridge is displayed as a pie chart and colour 
coded based on the strength of binding. Blue indicates strong binding between myosin and 
actin, purple is weak binding between actin and myosin, and pink is detachment of myosin 
from actin. 
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As figure 5.12 shows approximately 75 % of the time the WT MyHC-emb is in the weakly 
bound (AMT2 and AMDP) or detached state (MT and MDP). AMDP is the largest section 
indicating that the phosphate release step is limiting the cycle somewhat as it is slow 
enough to accumulate more of the S1. The AMD state is also large due to the slow ADP 
ƌĞůĞĂƐĞƌĂƚĞĐŽŶƐƚĂŶƚ ?Ŭ ?+6). The AMDP state increases dramatically for the three mutants 
most notably for the T178I. Therefore once activated the mutants will spend a longer 
time in the AMDP state due to a slower phopshate release step. 
 
Figure 5.13  W Comparison of the weakly and unbound myosin from actin. (A) Approximately 75 
% of the WT MyHC-emb is in the weak binding or detached state. (B) The overlay of WT MyHC-
emb (red) shows that there is an increase in the detached and weakly bound states for R672H 
MyHC-emb (black). (C) The overlay of WT MyHC-emb (red) shows that there is an increase in 
the detached and weakly bound states for R672C (black), however this is smaller than the 
R672H. (D) The overlay of WT MyHC-emb (red) shows there is a huge increase in the detached 
and weakly bound states for T178I (black). This is the largest increase seen with almost all of 
the myosin either detached or weakly bound. 
A B 
C D 
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Figure 5.13 shows a comparison of the weakly bound and detached states of the WT 
MyHC-emb and the three mutants by overlaying the WT MyHC-emb (red) on top of the 
mutants (black). The R672C (Figure 5.13C) has the smallest increase in this weak 
attachment, R672H has a bigger increase (Figure 5.13B) and T178I is almost entirely 
weakly attached (Figure 5.13D).  
5.2.6 Interaction changes between surrounding residues in mutants and WT MyHC-
emb 
 
R672 and T178 are both found within the centre of the myosin motor domain (Figure 
5.10A). They are also very far apart in the myosin sequence but are very close to each 
other in the structure which will have some significance in their importance to each 
other. 
R672 is located on the third strand of the central 7-ƐƚƌĂŶĚĞĚɴ-sheet that runs through 
the motor domain. The T178 is found at the C-terminal end of the fouƌƚŚɴƐƚƌĂŶĚŽĨƚŚĞ
ĐĞŶƚƌĂů ɴ-sheet at the start of the P-loop of the nucleotide binding pocket. Preliminary 
observations have highlighted potential residues for interaction (Figure 5.10B).  
Due to no MyHC-emb X-ray crystallography structure yet being available, homology 
models were built using 6 structures of the scallop myosin S1. These represent the motor 
domain during various steps of the cross-bridge cycle and will help provide information 
into how these interactions change throughout the ATPase cycle. To build the homology 
models the sequence of the scallop structures were pairwise aligned with the sequence of 
the MyHC-emb. This was then uploaded to SWISS-MODEL (Biasini, Bienert et al. 2014, 
Arnold, Bordoli et al. 2006, Guex, Peitsch et al. 2009, Kiefer, Arnold et al. 2009) which was 
used to build the models.  
The interactions present in the wild type and two R672 mutants are summarised in Table 
5.2. 
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The two key interactions found to be partially or completely lost in the two mutants are a 
ŚǇĚƌŽŐĞŶďŽŶĚďĞƚǁĞĞŶZ ? ? ?ĂŶĚd ? ? ? ?ĂŶĚĂʋ-cation bond between R672 and F490. A 
hydrogen bond is a fairly weak intermolecular bond between a hydrogen and either an 
ŽǆǇŐĞŶ ? ŶŝƚƌŽŐĞŶ Žƌ ĨůƵŽƌŝŶĞ ?  ʋ-cation bond however is much stronger, similar to an 
ionic bond (Dougherty 1996). These occur between positive ions (in this case the R group 
of the R672) and the negative delocalised electrons of a benzene ring structure (the R 
group of the F490). A loss of such a bond could have serious and significant implications 
for the molecule. 
For the R672H, there is a partial loss of the hydrogen bond between T178 which is 
ƉƌĞƐĞŶƚŝŶĂůůƐƚƌƵĐƚƵƌĞƐŽĨƚŚĞdWĂƐĞĐǇĐůĞ ?,ŽǁĞǀĞƌƚŚĞʋ-cation to F490 is completely 
lost in all cases. The R672C on the other hand has a complete loss of the hydrogen bond 
ƚŽd ? ? ?ŝŶĂůůƚŚĞƐƚƌƵĐƚƵƌĞƐĂƐǁĞůůĂƐĐŽŵƉůĞƚĞůŽƐƐŽĨƚŚĞʋ-cation bond to F490. 
Figure 5.10  W Ribbon diagram of the homology MyHC-emb structure in the pre-power stroke state 
 ? ?Ys/ ? ? ? ?^ŚŽǁƐƚŚĞǁŚŽůĞŵŽůĞĐƵůĞǁŝƚŚƚŚĞƌĞůĂǇŚ ůŝǆ ?ǇĞůůŽǁ ? ?ĐĞŶƚƌĂůɴƐŚĞĞƚ ?ƌĞĚ ? ?ĂŶĚ^, ?-
SH2 domain (orange). R672 (green) and T178 (blue) are shown as space filling. (B) An enhanced 
image of the R672 and T178 and the residues in possible contact with the two residues. 
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The interactions for T178 are summarised in Table 5.3. There are fewer potential 
interactions compared to the R672 and only the hydrogen bond between T178 and R672 
appears to be affected by the mutation to isoleucine. This is completely lost in all 6 
models. Figure 5.11 show the conservation of T178 and R672 across different myosins in 
humans. T178 is highly conserved among the skeletal myosins and is replaced by a serine 
in the other myosin molecules. The R672 however is highly conserved across all myosins 
apart from myosin 9 which has a lysine instead. In both cases the residues may have 














Figure 5.11 - Sequence alignment of multiple human myosin heavy chains. (A) The conservation of threonine 178 
from MyHC-emb across different myosins. The threonine is either conserved or replaced by a serine. (B) The 
conservation of arginine 672 from MyHC-emb across different myosins. The arginine is highly conserved apart from a 
lysine in myosin 9. 
  
A B 













5.3.1 Kinetic differences between FSS mutants and wild type MyHC-emb 
 
It is apparent from Table 5.1 that the kinetic changes between wild type MyHC-emb and 
the other three mutants are very significant. These differences have been summarised in 
figure 5.12 which clearly shows where there is an increase or decrease in affinity (Figure 
5.12A) or rate constant (Figure 5.12B). 
 
One of the common significant changes that was seen between the wild type MyHC-emb 
and the three mutants is the reduction in ATP hydrolysis rate constant (k+3 + k-3). The 
slowing of this rate constant may even become the rate limiting step of the ATPase cycle. 
This could therefore be the cause of the reduction in maximum ATPase rate (Vmax). 
However as the Berkeley Madonna modelling shows the rate limiting step is the 
phosphate release. 
The slowing of the cycle also appears to be a common significant change for all three 
mutants. The slowing of the ATPase cycle will lead to a non-functioning motor which will 
inhibit the muscle. The reduction in the Vmax may also contribute to the phenotype seen 
Figure 5.12  W Percentage changes between FSS mutants and WT MyHC-emb. (A) Percentage 
changes in the equilibrium constants of the three FSS mutants compared to wild type MyHC-
emb. An increase or decrease in equilibrium constant indicates a weakening or tightening of 
the affinities compared to wild type respectively. (B) Percentage changes in rate constants of 
the three FSS mutants compared to wild type MyHC-emb. An increase or decrease in rate 
constant indicates the step is faster or slower than wild type respectively. * p < 0.05, ** p < 
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for the T178I. Beck et al. (Beck, McMillin et al. 2014) showed that the phenotype of T178I 
was the most severe of the three mutations, followed by R672H, and R672C as the least 
severe. Taking into account the ATPase assay the kinetics begin to mirror the phenotypes 
somewhat. R672H has more differences compared to the wild type, T178I has some of 
the most significant differences and R672C while still having big changes may not be as 
severe as the other two. 
5.3.2 Berkeley Madonna modelling 
 
The modelling data gives a clear impression of how the ATPase cycle is behaving in the 
WT MyHC-emb and the three mutants. It also shows how the duty ratio will be affected in 
each case. For the WT MyHC-ĞŵďA? ? ?A?ŽĨƚŚĞ^ ?ǁĂƐin the weakly bound and detached 
state. For the two R672 mutations the detached state increases to around 80  W 85 % of 
the cycle, while for the T178I almost all of the S1 is in either the detached or weakly bond 
state (Figure 5.13). This decreased attachment will reduce the force producing capabilities 
of the mutants, potentially causing them to be redundant motors. This would result in a 
net loss of energy as the ATP can still be hydrolysed but at a slower rate. The modelling 
data also estimates that the phosphate release step becomes the rate limiting step in the 
cycle, particularly in the T178I where the Vmax is significantly limited by the phosphate 
release. Given that T178 is located in the P-ůŽŽƉǁŚŝĐŚŝƐƌĞƐƉŽŶƐŝďůĞĨŽƌďŝŶĚŝŶŐƚŽƚŚĞɶ-
ƉŚŽƐƉŚĂƚĞ ŽĨ dW ŝƚ ŝƐ ƵŶƐƵƌƉƌŝƐŝŶŐ ƚŚĂƚ ƚŚĞ ƌĞůĞĂƐĞ ŽĨ ƚŚŝƐ ɶ-phosphate is affected. 
However a prediction of how the mutation could affect the phosphate release step could 
not be made based on the structure.  
5.3.3 Significance of interaction losses in the mutated myosin motor 
 
Some clues as to the stopped-flow kinetic changes can be found in the homology models 
that were built. Both residues are located near to or adjacent to the nucleotide binding 
pocket. The loss of the hydrogen bond between the R672 and T178 may explain why the 
dW ďŝŶĚŝŶŐ  ?< ?1Ŭ ?+2) is reduced for all three mutations. This may also explain why the 
R672H mutation is the least effected since the hydrogen bond is maintained in some of 
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the structures. This would indicate that the bond is stabilising the nucleotide pocket, and 
losing it significantly affects the ability for ATP to bind. The effect of the two R672 
mutĂƚŝŽŶƐ ŽŶ ƚŚĞ ɶ-phosphate release could be caused by one of two things or both: 
Firstly the loss of the H-bond between R672 and T178 disrupts the P-loop. Secondly the 
loss of the interaction with the relay helix limits the power stroke which is linked to the 
phosphate release. 
Another observation from the structures is the cause for the reduced tryptophan 
ĨůƵŽƌĞƐĐĞŶĐĞŝŶĂůůŵƵƚĂŶƚƐŵŽƐƚŶŽƚĂďůǇŝŶƚŚĞZ ? ? ?,ĂŶĚd ? ? ?/ ?dŚĞůŽƐƐŽĨƚŚĞʋ-cation 
bond between R672 and F490 on the relay helix may be a cause for this observation. 
Upon investigation in two structures: one in the rigor conformation (PDB 2OS8) where the 
relay helix is straight, and the other in the pre-power stroke (1QVI) where the relay helix 
is bent (Figure 5.13A). When the relay helix bends during ATP binding, the loop at the N-
terminus of the helix moves in relation to the rest of the molecule. This results in the 
fluorescence signal seen. The F490 is located on the relay helix just before the helix bend 
and may contribute to holding the relay helix in place. Considering that the two R672 
mutations lose tryptophan fluorescence and F490 interaction, this is a possible cause. 
F490 has also been identified as one of three phenylalanines (Fischer et al., 2005) (Figure 
5.13B) that lock together to form a fulcrum for the relay helix to bend around and 
generate the force of the power stroke.  
The reduction in tryptophan fluorescence for the T178I however is less obvious. It may be 
a disruption in the nucleotide pocket or the hydrogen bond to R672, which may in turn 
relay the signal. F490 also has been identified as one of three phenyalanines that may 
play a part in creating a hinge around which the relay helix bends. Therefore the loss of 
ƚŚĞʋ-cation bond may reduce the stability of this region. 







Figure 5.13  W Interaction between R672 and F490 in the rigor and pre-power stroke. (A) The 
relay helix in the rigor structure (blue) and in the pre-power stroke (red) are superimposed to 
display that the helix bends just after the F490. (B) Two other phenylalanines (F489 and F670) 
have been postulates to be involved in a hinge point around which the relay helix bends (Fischer 
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Hypertrophic cardiomyopathy (HCM) is an autosomal dominant disease with a variable 
clinical expression (Spirito, Seidman et al. 1997). The clinical symptom of HCM is enlarged 
hypertrophic ventricle walls and a reduced intra-ventricular volume (Colan, Lipshultz et al. 
2007). While adult cardiomyopathy is a fairly common disease (rate of incidence is 1 in 
500 in the US, (Maron, Gardin et al. 1995, Harvey, Leinwand 2011, Semsarian, Ingles et al. 
2015)) the juvenile form of the disease is rarer (estimated 1.13 in 100,000 children for all 
juvenile cardiomyopathies, (Bublik, Alvarez et al. 2008)).  
There is however debate as to the underlying cause of HCM in both adults and children 
with sarcomeric mutations only accounting for between 40-60 % of cases (Richard, 
Charron et al. 2003, Van Driest, Vasile et al. 2004, Van Driest, Ommen et al. 2005). Non-
sarcomeric disorders have also being linked to causes of HCM, such as: Glycogen storage 
disease (Arad, Maron et al. 2005) ? ? ?ĂĚĞŶŽƐŝŶĞŵŽŶŽƉŚŽƐƉŚĂƚĞ-activated protein kinase 
(Murphy, Mogensen et al. 2005), and lysosomal storage disease (Sachdev, Takenaka et al. 
2002). However recent studies claim that these conditions may account for less than 10 % 
of HCM cases (Colan, Lipshultz et al. 2007, Nugent, Daubeney et al. 2005) and therefore 
mutations in sarcomeric proteins may account for more HCM cases that currently 
believed. 
A study from 2009 (Kaski, Syrris et al. 2009) investigated causes of HCM in 140 patients 
diagnosed before or at the age of 13. Of these 25 had a syndrome or metabolic disorder 
and 36 other patients refused to take part in the study. In the end 79 patients took part of 
which 42 were found to be mutation positive. Many of these mutations were known 
mutations in actin, myosin binding protein-C (MyBP- ) ? ɴ ĐĂƌĚŝĂĐ ŵǇŽƐŝŶ  ?DǇ,-ɴ ) ?
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myosin light chain, troponin I and troponin T. However several novel mutations were also 
identified, among these was H251N in the MyHC-ɴ ?dŚŝƐǁĂƐĂŶŽǀĞůŵƵƚĂƚŝŽŶĨŽƵŶĚ ŝŶ
one of the 42 preadolescents investigated in that study. Little is known about the causes 
of HCM in children due to observational studies reporting a lower frequency of the 
disease in children (Colan, Lipshultz et al. 2007, Nugent, Daubeney et al. 2005) and that 
left ventricle hypertrophy usually develops during the adolescent growth spurt (Maron, 
Spirito et al. 1986). This has meant the cases are overlooked and we are only just starting 
to investigate the diseases in children. A recent study reported that in patients diagnosed 
with HCM under the age of 15, 55% had a mutation in a sarcomeric protein (Morita, 
Rehm et al. 2008). These studies have helped to highlight the growing evidence that 
sarcomeric gene mutations causing HCM are as common in children as in adults. 
6.1.2 Aim 
  
In order to investigate the effects of this mutation on the function of MyHC-ɴ ?ǁĞƵƐĞĚ
the same recombinant expression system (Chapter 2.2) as the WT embryonic myosin 
(Chapter 4), and the 3 Freeman-Sheldon Syndrome mutations (Chapter 5). The purified 
H251N was then used in a number of kinetic stopped-flow spectroscopy assays to assess 
how the ATPase cycle is affected in the mutation. 
The aim of this investigation then is to assess whether or not there is a significant change 
in one or all of the kinetic parameters of the ATPase ĐǇĐůĞ ?dǁŽ ‘ĂĚƵůƚ ?ŵƵƚĂƚŝŽŶƐZ ? ? ?Y
(Nag, Sommese et al. 2015) and R453C (Bloemink, Deacon et al. 2014) have already been 
characterised; however the unloaded kinetic parameters changed very little suggesting 
these severe mutations alter the myosin only very slightly. It is thought that this novel 
 ‘ũƵǀĞŶŝůĞ,D ?ŵƵƚĂƚŝŽŶŵĂǇŚĂǀĞĂŵŽƌĞƐŝŐŶŝĨŝĐĂŶƚĞĨĨĐƚŽŶƚŚĞŵǇŽƐŝŶůĞĂĚŝŶŐƚŽƚŚĞ
phenotypic HCM heart to present itself in infants and children. 
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6.2 MyHC-ɴ, ? ? ?EŬŝŶĞƚŝĐƐ 
 
6.2.1 ŚĂŶŐĞƐŝŶŶƵĐůĞŽƚŝĚĞďŝŶĚŝŶŐƚŽ, ? ? ?Eɴ-S1 compared to WT MyHC-ɴ-S1 
 
The H251N MyHC-ɴǁĂƐĞǆƉƌĞƐƐĞĚƵƐŝŶŐƚŚĞƐĂŵĞŵĞƚŚŽĚ (Chapter 2.2.1.3) as the wild 
type (Chapter 4) and FSS mutants (Chapter 5).Here however the his- tag was located on 
the human essential light chain (MYL3). This meant that only the S1 was purified along 
with one light chain. The yields were similar as well at 1-2 mL 10-20 µM active S1 which is 
similar to the yields obtained for the wild type MyHC-ɴ S1 (Nag, Sommese et al. 2015). 
The data presented here for the H251N mutation was compared to wild type MyHC-ɴ S1 
obtained by Nag et al. The buffer conditions used here are the same as those used in the 
wild type S1 stopped-flow assays. 
It is possible to follow the ATP binding to myosin S1 through the exploitation of the 
tryptophan at the end of the relay helix (Trp508). Upon binding the conformational 
change associated with the recovery stroke causes the tryptophan to move relative to the 
rest of the motor domain. Mixing S1 (100 nM after mixing) with MgATP (10 µM after 
mixing) leads to a change in fluorescence that can be measured (Figure 6.1A). By 
increasing the MgATP concentration the kobs increases in a hyperbolic manner (Figure 
6.1B) which can be described by equation 2.3 (Chapter 2.3.2.1). 
The second order rate constant for ATP binding (K1k+2 )ƚŽ, ? ? ?Eɴ-S1 is 6.4 ± 0.6 µM-1 s-1 
which is slightly faster than wild type (5.8 ± 0.4 µM-1 s-1) but this was not significant 
different. The ATP binding affinity for S1 (1/K1) for the mutant is 20.3 ± 3.4 µM. This is 
weaker than the wild type (15.9 ± 1.4 µM) but again not significantly different. The most 
drastic change determined from this assay is the kmax which is associated with the 
hydrolysis rate constant (k+3 + k-3). For the mutant, this hydrolysis rate constant value 
(125.7 ± 9.3 s-1) was significantly 38 % faster (91.2 ± 1.8 s-1) than the wild type.   
Tryptophan fluorescence can also be used to measure the ADP affinity for S1 (K6K7) as 
well as the ADP release rate constant (k+6, Figure 6.2). S1 was incubated with varying 
concentrations of ADP and rapidly mixed with a fixed concentration of ATP.  





, ? ? ?E ɴ-S1 (100 nM after mixing) was preincubated with increasing concentrations of 
ADP to allow ADP to bind to the nucleotide pocket of the motor. It was then rapidly mixed 
with a fixed concentration of MgATP (20 µM after mixing) which displaced the ADP and 
Figure 6.2  W , ? ? ?Eɴ-S1 ADP affinity.  ? ?dŚĞďůĂĐŬƚƌĂĐĞƐŚŽǁƐ ? ? ?ŶD, ? ? ?Eɴ-S1 rapidly 
mixed with 20 µM MgATP. This was best described by a single exponential (red fit line). This 
resulted in a kobs = 58 s
-1
 and an increase in fluorescence amplitude = 4.5 %. The red trace 
shows 100 nM H251N ɴ-S1 preincubated with 2 µM ADP rapidly mixed with 20 µM MgATP. 
This was best described by a double exponential (black fit line). This yielded a kobs = 90 s
-1
 for 
the fast phase and 0.8 s
-1
 for the slow phase. The increase in fluorescence amplitude = 0.5 % 
for the fast phase and 3.1 % for the slow phase. (B) The hyperbolic dependence of the 
amplitude of the fast (black) and slow (red) phases on ADP concentration.  































 0 µM ADP
 2 µM ADP
A
Figure 6.1  W dƌǇƉƚŽƉŚĂŶĨůƵŽƌĞƐĐĞŶĐĞŽĨDŐdWďŝŶĚŝŶŐƚŽ, ? ? ?Eɴ-S1. (A) A trace of 100 nM 
, ? ? ?E ɴ-S1 rapidly mixed with 10 µM MgATP. As MgATP bound to the S1 it caused a 
conformational change in the relay helix of the S1, which led to a change in fluorescence. This 
could be well described by a single exponential fit (black line). This yielded a kobs = 55.2 s
-1
 and 
an increase in fluorescence amplitude = 4.8 %. (B) As the MgATP concentration increased so 
did the kobs. This was plotted against MgATP concentration and follows a hyperbolic 
dependence.  
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bound to the S1. The fast phase in figure 6.2A represents the MgATP binding to S1 with 
no ADP already bound. The slow phase is indicative of ADP being released from the 
nucleotide binding pocket and ATP binding resulting in the fluorescence change. 
Given that the fluorescence amplitude is associated with the tryptophan fluorescence 
upon ATP binding, as the ADP concentration increases the amplitude of the fast phase 
ĚĞĐƌĞĂƐĞƐ ?dŚŝƐŝƐĚƵĞƚŽƚŚĞƉŽŽůŽĨ ‘ĨƌĞĞ ?^ ?ďĞŝŶŐƌĞĚƵĐĞĚĂƐŝƚŝƐĂůƌĞĂĚǇŽĐĐƵƉŝĞĚǁŝƚŚ
ADP. Therefore the amount of S1 that ATP can bind to will decrease, leading to the 
reduced amplitude observed. Similarly for the slow phase more S1 has an ADP bound 
which has to be released before ATP can bind and so the amplitude increases. The kobs 
should be unaffected by the ADP concentration. However at the higher ADP 
concentration the kobs increased from 58 s
-1 to 90 s-1. This was most likely caused by the 
amplitude of the fast phase becoming too small and measuring the kobs accurately 
became harder. 
The kobs of the slow phase is also very important since this represents the ADP being 
displaced from the S1 before ATP binding. The average of the slow phase kobs therefore 
yields the ADP release rate constant (k+6 ) ?&ŽƌƚŚĞŵƵƚĂŶƚ, ? ? ?Eɴ-S1 the k+6 (1.0 ± 0.2 
s-1) is not significantly faster than the wild type (0.63 ± 0.03 s-1, Table 6.1). 
Finally the amplitudes of the fast and slow phases can be plotted against the ADP 
concentrations. This yields two hyperbolic curves, with the fast phase decreasing and the 
slow phase increasing. The plot of the fast phase is well described by equation 2.20 
(Chapter 2.3.2.1) and the slow phase by equation 2.24 (Chapter 2.3.2.1). Both fits result in 
a K50% value equal to the ADP affinity (K6K7 ) ?dŚĞǀĂůƵĞĨŽƌƚŚĞŵƵƚĂŶƚ, ? ? ?Eɴ-S1 (0.19 ± 
0.01 µM) is significantly tighter than the wild type (0.53 ± 0.07 µM). 
6.2.2 Changes in nucleotide bindŝŶŐƚŽ, ? ? ?EɴĂĐƚŽ ?^ ?ĐŽŵƉĂƌĞĚƚŽtdDǇ,-ɴ
acto.S1 
 
Myosin S1 when bound to pyrene-actin (pA) quenches the fluorescence signal. When ATP 
is mixed with the pyrene-actin.S1 (pA.S1) it rapidly dissociates the S1 from actin. This 
leads to an increase in fluorescence (Figure 6.3A). 
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50 nM pA.S1 (concentration after mixing) was rapidly mixed with increasing 
concentrations of MgATP. At MgATP concentrations lower than 40 µM the transient was 
best described by a single exponential (Figure 6.3A). At 40 µM MgATP and above a slow 
phase emerged (Figures 6.3A and B) which is thought to be associated with an opening of 
the nucleotide pocket (Deacon, Bloemink et al. 2012).  The equilibrium constant for the 
opening of the pocket (Kɲ ?) is determined by the ratio of fast phase amplitude to slow 
phase amplitude (Figure 6.3B). The ratio was calculated for each trace best described by a 
double exponential then averaged per biological replicate. The rate of the fast phase 
becomes so fast at the higher ATP concentrations that the amplitude becomes lost in the 
dead time of the instrument. Therefore the value calculated for figure 6.3B is lower than 
the average value of Kɲ ?. The Kɲ ? for the mutant is 6.7 ± 1.1 compared to the wild type 4.1 
± 1.4; however this is not a statistically significant difference. 
The rate constant for the pocket opening (kA?ɲ ?) can also be determined from the traces in 
figure 6.3A. ATP cannot bind to the S1 while it is in the closed state. Since the 
fluorescence change can only occur once ATP binds to S1 causing it to dissociate and stop 
quenching the pyrene, the slow phase must be the rate of the conformation change from 
closed to open. Also the kobs did not increase with ATP concentration consistent with it 
ŶŽƚďĞŝŶŐdWĚĞƉĞŶĚĞŶƚ ?dŚĞĂǀĞƌĂŐĞŽĨƚŚĞƐůŽǁƉŚĂƐĞĨŽƌƚŚĞŵƵƚĂŶƚ, ? ? ?Eɴ-S1 gave 
a kA?ɲ ? (39.7 ± 5.9 s-1) significantly slower than the wild type (153.4 ± 10.6 s-1, Table 6.1).  
Plotting the fast phase kobs as a function of MgATP concentration (Figure 6.3B) the kobs can 
be best described by a hyperbolic dependence using equation 2.3 (Chapter 2.3.2.1). At 
low MgATP concentration the dependence is linear resulting in the second order rate 
ĐŽŶƐƚĂŶƚ ?< ?1Ŭ ?+2 ) ?dŚĞ< ?1Ŭ ?+2 ǀĂůƵĞĨŽƌ, ? ? ?Eɴ-S1 is 5.1 ± 0.4 µM-1 s-1 compared to the 
wild type value of 4.4 ± 0.2 µM-1 s-1; however this is not a significant difference. The S1 
dWĂĨĨŝŶŝƚǇ ? ? ?< ?1), as determined by the K50% of the hyperbola, is almost 3 fold tighter for 
ƚŚĞ , ? ? ?Eɴ-S1 (131 ± 19 µM) compared to the wild type (327.9 ± 53.3 µM). The final 
rate constant that can be determined from this assay is the maximum rate of ATP induced 
ĚŝƐƐŽĐŝĂƚŝŽŶ ?Ŭ ?+2). This is over 2 fold slower for the H251N (666 ± 58 s-1) when compared 
to the wild type (1543 ± 100 s-1).  




/ŶŽƌĚĞƌ ƚŽĚĞƚĞƌŵŝŶĞ ƚŚĞ , ? ? ?Eɴ-S1 ADP affinity in the pA.S1 complex a competition 
assay is used where pA.S1 is pushed against a mixture of a constant ATP concentration 

























Figure 6.3  W dWŝŶĚƵĐĞĚĚŝƐƐŽĐŝĂƚŝŽŶŽĨ, ? ? ?Eɴ-S1 from pyrene labelled actin. (A) The black 
trace shows 50 nM pyrene-actin.S1 (pA.S1) vs 10 µM MgATP (concentrations after mixing). 
This is best described by a single exponential (red fit line). This resulted in a kobs = 36.8 s
-1
 and 
an increase in fluorescence amplitude = 17.6 %. At the highest MgATP concentration (800 µM 
after mixing, red trace) the transient was described by a double exponential (black fit line), 
which can be seen more clearly in (B). Graph has been normalised between 0 and 1. (B) 50 
nM pyrene-ĂĐƚŝŶ, ? ? ?Eɴ-S1 rapidly mixed with 800 µM MgATP resulted in a kobs = 369 s-1 
and 33.1 s
-1
 for the fast and slow phase respectively, while the increase in fluorescence 
amplitude = 8.6 % and 3.1 % for the fast and slow phase respectively. The Kɲ ? can be 
calculated from the ratio of these amplitudes, for the H251N mutation Kɲ ? = 2.8.  (C) The kobs 
of the fast phase when plotted against MgATP concentration had a hyperbolic dependence 
on MgATP concentration whereas the slow phase did not. 
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for binding, occupying the nucleotide binding pocket, and therefore slowing the rate of 
ATP binding and dissociation.  
 
Figure 6.4A shows the transients of the ADP competition assay. 50 nM pA.S1 
(concentration after mixing) was rapidly mixed with 50 µM MgATP and 0 to 200 µM ADP 
(concentrations after mixing). The trace obtained at 0 µM ADP was best described by a 
single exponential while the traces at all other ADP concentrations were double 
exponentials. This can be caused by the ADP binding to the acto.S1 preventing an ATP 
from binding. The slow phase emerges as ADP dissociates at a slow rate before either a 
new ADP or an ATP can bind. A second cause of the slow phase observed is thought to be 
associated to the open and closed state of the nucleotide pocket as seen with the ATP 
induced dissociation (Deacon, Bloemink et al. 2012). ADP can bind to pA.S1 in the open 
state and the pocket closes.  Therefore the conformational change from closed to open 
Figure 6.4  W Acto- ? ? ?Eɴ-S1 affinity for ADP using the ATP competition assay. (A) Transients of 
50 nM pA.S1 rapidly mixed with a constant 50 µM MgATP and increasing ADP concentrations (0 
 W 200 µM). Either ADP or ATP binds to the acto.S1 with the dissociation event occurring after 
ATP binding. If ADP binds then this needs to dissociate before an ATP can bind. For a fast type 
myosin the ADP dissociation is very fast and no slow phase would be seen. However for slow 
type myosins such as MyHC-ɴ the dissociation is slow and a slow phase appears in the 
transients. All were fit with a double exponential with the fast phase kobs slowing as ADP 
concentration increased, except for the 0 µM ADP trace which was a single exponential. The 
slow phase kobs is indicative of the nucleotide pocket opening/closing and averaged to 39.7 s
-1
. 
(B) The fast phase kobs plotted against ADP concentration. The kobs has a hyperbolic dependence 
upon ADP concentration. 
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must occur before ADP can be released and before ATP can bind and lead to the 
dissociation step. The equilibrium constant for the close to open step (Kɲ) is 5.5 ± 1.1 for 
ƚŚĞ, ? ? ?Eɴ-S1 (Table 6.1). This step was not observed for the wild type under the same 
conditions (25 mM KCl) however it was seen at higher salt (100 mM KCl, (Deacon, 
Bloemink et al. 2012)) suggesting some salt dependence. The rate constant for the 
conformational change from closed to open (k+ɲ) was determined from the kobs of the 
slow phase. Again this was not observed for the wild type under the same conditions but 
was at the higher salt (Deacon, Bloemink et al. 2012) ?dŚĞǀĂůƵĞĨŽƌ, ? ? ?Eɴ-S1 is 5.4 ± 
2.7 s-1 (Table 6.1). This value is an average of the slow phases observed. The kobs and 
fluorescence amplitude were unaffected by the increase in ADP. 
dŚĞWĂĨĨŝŶŝƚǇ ĨŽƌĂĐƚŽ ?^ ?  ?< ?6 7) could be determined by plotting the kobs of the fast 
phase against the ADP concentration (Figure 6.4B). As the concentration of ADP increases 
more will be available to bind to the acto.S1 complex therefore outcompeting the MgATP 
slowing the dissociation reaction. This leads to the curve seen in figure 6.4B which has a 
hyperbolic dependence best described by equation 2.16 (Chapter 2.3.2.1) which gives the 
< ?6< ?7 ǀĂůƵĞ ?dŚĞŵƵƚĂŶƚ, ? ? ?Eɴ-S1 was found to have a significantly weaker ADP affinity 
(20.8 ± 3.6 µM) compared to wild type (6.1 ± 0.3 µM) in the presence of actin.  
/Ŷ Ă ƐĞƉĂƌĂƚĞ ĂƐƐĂǇ ƚŽ ŵĞĂƐƵƌĞ ƚŚĞ W ƌĞůĞĂƐĞ ƌĂƚĞ ĐŽŶƐƚĂŶƚ  ?Ŭ ?+6), 50 nM pA.S1 was 
preincubated with a saturating ADP concentration (0.5 mM) and rapidly mixed with high 
concentrations of MgATP (0.5-4 mM). The ADP was pre-treated with hexokinase and 
glucose to ensure any ATP contamination was converted to ADP and would not affect the 
assay. P1, P5-Di(adenosine- ? ? ) ƉĞŶƚĂƉŚŽƐƉŚĂƚĞ  ?Ɖ ? ) ǁĂƐ ĂůƐŽ ĂĚĚĞĚ ƚŽ ŝŶŚŝďŝƚ ĂŶǇ
adenylate cyclase activity, which would phosphorylate ADP back to ATP. An average of 
the kobs was calculated and summarised in table 6.1. The ADP release rate constant is not 
significantly different for the mutant (56.7 ± 2.9 s-1) and the wild type (58.7 ± 1.7 s-1). 
hƐŝŶŐƚŚĞWĂĨĨŝŶŝƚǇ ?< ?6< ?7) and the ADP release rate constants it is possible to calculate 
ƚŚĞ ƐĞĐŽŶĚ ŽƌĚĞƌ W ďŝŶĚŝŶŐ ƌĂƚĞ ĐŽŶƐƚĂŶƚ  ?< ?7Ŭ ?-6 ) ďǇ ĚŝǀŝĚŝŶŐ ƚŚĞ Ŭ ?+6 value by the 
< ?6< ?7. This rate of ADP binding is over three fold slower for the mutant (27 µM-1 s-1) 
compared to the wild type (9.6 µM-1 s-1). 
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6.2.3 Changes in actin affinity to H251N MyHC-ɴ^ ?ĐŽŵƉĂƌĞĚƚŽtdDǇ,-ɴ^ ? 
 
The affinity of S1 for actin was determined by the method previously described in Chapter 
3. A fixed concentration of pyrene-actin is incubate with varied S1 concentrations and 
rapidly mixed with a constant concentration of MgATP. As the S1 concentration increases 
the start point of the dissociation trace decreases, resulting in increasing fluorescence 
amplitudes. This can be carried out in the absence (KA) or presence (KDA) of ADP. 
For the actin affinity in the absence of ADP (KA) assay, 30 nM pA was incubated with 
varying S1 concentrations (0-240 nM) which was rapidly mixed with 20 µM MgATP (Figure 
6.5A, concentrations before mixing). As the S1 concentration increased so did the relative 
amplitude ((fluorescence amplitude/end point fluorescence) x 100) which was plotted as 
a function of S1 concentration (figure 6.5B). The data was then fit with the quadratic 
equation 3.1 (Chapter 3.2.3). The actin affinity in the absence of ADP was slightly tighter 
for the mutant (8.7 ± 1.5 nM) but not significantly different to the wild type (10 ± 1.8 nM). 
Figure 6.5  W Actin affinity of H25 ?Eɴ-S1 in the absence and presence of ADP. (A) Transients of 
increasing concentrations of S1 (0  W 200 nM) incubated with a fixed concentration of 30 nM pA 
rapidly mixed with a fixed MgATP concentration (20 µM). Since the ATP concentration was 
fixed the kobs remained constant throughout. The transients have been normalised to the 
same start point to highlight that the fluorescence increases, in reality they would all have the 
same end point. (B) The relative amplitudes plotted as a function of the S1 concentration. The 
black squares indicate the assay without ADP present, while the red triangles represent the 
assay with (500 µM) ADP present.  
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The assay could be repeated this time in the presence of ADP to determine the actin 
affinity with ADP (KDA). 30 nM pA was incubated with varied S1 concentrations and 500 
µM ADP (treated with hexokinase and glucose, see above) and Ap5A and was rapidly 
mixed with 500 µM MgATP (concentrations before mixing). ADP weakens S1 affinity for 
actin so a higher concentration was required to determine the KDA. The relative amplitude 
increased with S1 concentration as in the absence of ADP and again is best described by a 
ƋƵĂĚƌĂƚŝĐ ĞƋƵĂƚŝŽŶ  ?&ŝŐƵƌĞ  ? ? ? ) ?dŚĞ ŵƵƚĂŶƚ , ? ? ?E ɴ-S1 has an almost 2 fold tighter 
affinity for actin in the presence of ADP (56.3 ± 9.3 nM) compared to the wild type (109.3 
± 24.1 nM). The number of repeats for the mutant was only 2 for this measurement. 
  




Table 6.1  W ZĂƚĞĂŶĚĞƋƵŝůŝďƌŝƵŵĐŽŶƐƚĂŶƚƐŽĨƚŚĞ, ? ? ?Eɴ-^ ?ĐŽŵƉĂƌĞĚƚŽƚŚĞǁŝůĚƚǇƉĞɴ-S1. 
Statistically significant differences (determined ďǇ^ƚƵĚĞŶƚ ?ƐƚƚĞƐƚ ?ŚĂǀĞďĞĞŶƐŚĂĚĞĚŐƌĞǇ ? 
Rate/Equilibrium 
Constant 
tŝůĚdǇƉĞɴa ɴ, ? ? ?E 





) 5.8 ± 0.4 6.4 ± 0.6 
1/K1 (µM) 15.9 ± 1.4 20.3 ± 3.4 
kmax or k+3 + k-3 (s
-1
) 91.2 ± 1.8 125.7 ± 9.3 b 
ADP binding to S1 




) 0.63 ± 0.03 1.0 ± 0.2 





) 4.4 ± 0.2 5.1 ± 0.4 




) 1543 ± 100 666 ± 58 d 
Kɲ ? 4.1 ± 1.4 6.7 ± 1.1 
kA?ɲ ? (s-1) 153.4 ± 10.6 39.7 ± 5.9 d 
ADP binding to actin.S1 









) 9.6 2.7 
Kɲ No second phase 5.5 ± 1.1 
kA?ɲ (s-1) No second phase 5.4 ± 2.7 
K'6K'7/K6K7 11.5 109.5 
S1 affinity for actin 
KA (nM) 10 ± 1.8 8.7 ± 1.5 
KDA (nM) 109.3 ± 24.1 56.3 ± 9.3 
KDA/KA 10.9 6.5 
a (Nag, Sommese et al. 2015) 
b p AM ? ? ? ?ĚĞƚĞƌŵŝŶĞĚďǇ^ƚƵĚĞŶƚ ?Ɛt ƚĞƐƚĂƐĐŽŵƉĂƌĞĚƚŽǁŝůĚƚǇƉĞɴ-S1. 
c p AM ? ? ? ?ĚĞƚĞƌŵŝŶĞĚďǇ^ƚƵĚĞŶƚ ?Ɛt test as coŵƉĂƌĞĚƚŽǁŝůĚƚǇƉĞɴ-S1. 
d p AM ? ? ? ? ?ĚĞƚĞƌŵŝŶĞĚďǇ^ƚƵĚĞŶƚ ?Ɛt ƚĞƐƚĂƐĐŽŵƉĂƌĞĚƚŽǁŝůĚƚǇƉĞɴ-S1. 
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6.2.4 Structure analysis 
 
/Ŷ ĂŶ ĂƚƚĞŵƉƚ ƚŽ ƵŶĚĞƌƐƚĂŶĚ ƚŚĞ ĐĂƵƐĞ ŽĨ ƚŚĞ ĐŚĂŶŐĞƐ ŝŶ ƚŚĞ , ? ? ?E ɴ-S1, structural 
analysis was carried out. H251 is located on the 6th ɴ-ƐƚƌĂŶĚŽŶƚŚĞĐĞŶƚƌĂů ?ƐƚƌĂŶĚĞĚɴ-
sheet than runs through the middle of the myosin motor domain separating the upper 
and lower 50 K domains (Figure 6.6). 
The location of H251 is very close to the HO-linker previously described for the Arginine 
453 Cysteine (R453C) mutation in MyHC-ɴĂůƐŽĂƐƐŽĐŝĂƚĞĚǁŝƚŚ,D (Bloemink, Deacon 
et al. 2014). In fact Bloemink et al. identified H251 as a residue that interacts with the 
R453 residue throughout the myosin cross-bridge cycle. 
To investigate this further, 6 homology models were made using SWISS-MODEL (Biasini, 
Bienert et al. 2014, Arnold, Bordoli et al. 2006, Guex, Peitsch et al. 2009, Kiefer, Arnold et 
al. 2009). The 6 scallop structures (PDB: 2OTG, 2OS8, 1SR6, 1QVI, 1KK8, and 1S5G) were 
used as a template to which the MyHC-ɴƐĞƋƵĞŶĐĞǁĂƐŵĂƉƉĞĚ ?dŽĚŽƚŚŝƐƚŚĞƐĞƋƵĞŶĐĞ
for MyHC-ɴǁĂƐƉĂŝƌǁŝƐĞĂůŝŐŶĞĚƚŽƚŚĞƐĞƋƵĞŶĐĞŽĨƚŚĞWƐƚƌƵĐƚƵƌĞƐ ?ĂŶĚƚŚĞŶ^t/^-^
MODEL was used to create the homology models. These scallop structures represent 
nearly all the states of the cross-bridge cycle so give us an indication of how the molecule 
structure changes as well as the intramolecular bonds. The structures were visualised 
using Visual Molecular Dynamics (VMD) software (Humphrey, Dalke et al. 1996). The 
interactions of H251 are summarised in table 6.2 along with the interactions lost in the 
ŵƵƚĂŶƚ , ? ? ?E ? dŚĞ ƐƚƌƵĐƚƵƌĞ ŽĨ ƚŚĞ ƌĞĐŽŵďŝŶĂŶƚ ŚƵŵĂŶɴ-cardiac GFP chimera (PDB 
4P7H) was also visualised to verify the interactions seen in the homology models were 
consistent and accurate. 




H251 interacts with 3 residues (Figure 6.7); Alanine 259 (A259), Serine 260 (S260), and 
ƌŐŝŶŝŶĞ  ? ? ?  ?Z ? ? ? ) ? ? ? ?ĂŶĚ^ ? ? ?ĂƌĞĨŽƵŶĚŽŶɴ-strand 6 opposite H251 and form a 
hydrogen bond (H bond) to the histidine backbone rather than the R group. This 
interaction was found to persist in all but one of the homology models (PDB 2OS8). The 
interaction was also unaffected by the mutation of the histidine to asparagine so is 
ƵŶůŝŬĞůǇ ƚŽĂĨĨĞĐƚ ƚŚĞ ƐƚƌƵĐƚƵƌĞ ŽĨ ƚŚĞ ɴ-sheet. The third interaction between H251 and 
R453 as mentioned has already been identified in Bloemink et al. (Bloemink, Deacon et al. 
2014) ? dŚŝƐ ŝƐ Ă ʋ-cation bond which forms between the positive charge of certain 
residues (arginine, lysine, or histidine) and the delocalised electrons of benzene like ring 
Figure 6.6  W A homology model of the MyHC-ɴƐŚŽǁŝŶŐƚŚĞůŽĐĂƚŝŽŶŽĨ, ? ? ?ďƵŝůƚƵƐŝŶg PDB 
1QVI. (A) The overall structure of the motor domain showing the relay helix (yellow), SH1-SH2 
(orange), O-helix (pale green), HO-ůŝŶŬĞƌ  ?ƉĂůĞ ďůƵĞ ? ĂŶĚ ĐĞŶƚƌĂů ɴ-sheet (red). (B) A 180 ° 
rotation of (A) showing the location of H251 (blue). H251 is on the 6
th
 ƐƚƌĂŶĚŽĨƚŚĞĐĞŶƚƌĂůɴ-
sheet facing towards the HO-linker. 
180 ° rotation about the y-axis 
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structures (phenylalanine, tryptophan, tyrosine, and histidine). These interactions can be 
as strong, or stronger, than salt bridges (Dougherty 1996). In this case R453 is the positive 
residue binding to the ring of histidine. This interaction persists through all the structures; 
however it is lost when the histidine is mutated to asparagine, which is unsurprising since 
asparagine is a non-charged polar residue.  
 
Two other interactions identified are an H bond to R249 (PDB 2OS8 and 1S5G) and an H 




Figure 6.7  W Interactions between H251 and surrounding residues. H251 (dark blue) can form 
multiple intermolecular bonds with its neighbours: R249 (yellow), A259 (orange), S260 
(purple), R453 (pink), and Y455 (green). Dark green dashed lines indicate hydrogen bonds 
ǁŚŝůĞ ƐŽůŝĚ ŽƌĂŶŐĞ ůŝŶĞƐʋ-cation bonds. Colours of the structures are the same as in figure 
6.6. 
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6.3 Discussion  
6.3.1 Kinetics 
 
It is clear from the stopped-flow spectroscopy kinetics that there are few but significant 
ĚŝĨĨĞƌĞŶĐĞƐ ďĞƚǁĞĞŶ ƚŚĞ ŵƵƚĂŶƚ , ? ? ?E ɴ-S1 and the wild type. These have been 
summarised in figure 6.8 which clearly shows where there is an increase or decrease in 
affinity (Figure 6.8A) or rate constant (Figure 6.8B).  
 
There was no significant difference in the second order rate constant of ATP binding 
(< ?1Ŭ ?+2) but the ATP affinity for acto.S1 (1/K ?1) 3 fold tighter. This is offset by the 
ŵĂǆŝŵƵŵƌĂƚĞĐŽŶƐƚĂŶƚŽĨĚŝƐƐŽĐŝĂƚŝŽŶ ?Ŭ ?+2) slowing by just over 2 times. To add to this, 
the rate constant for the pocket conformational change is nearly 4 times slower. The 
cumulative effect of these changes in the dissociation step of the cross-bridge cycle would 
lead to the myosin being bound to actin longer and detaching slower. This step depends 
upon the ATP concentration but it would not be wrong to assume that the concentration 
of ATP in the heart will be relatively constant and high. 
Figure 6.8  W Percentage changes between MyHC-ɴ , ? ? ?E ĂŶĚ td DǇ,-ɴ ?  ? ? WĞƌcentage 
changes in the equilibrium constants of MyHC-ɴ, ? ? ?EĐŽŵƉĂƌĞĚƚŽǁŝůĚƚǇƉĞ ?dŚĞŝŶĐƌĞĂƐĞƐ
and decreases in equilibrium constant indicate a weakening or tightening of the affinities 
respectively compared to wild type. (B) Percentage changes in the rate constants of MyHC-ɴ
H251N compared to wild type. The increases and decreases in rate constant indicate a faster or 
slower rate constant respectively compared to wild type. * p < 0.05, ** p < 0.01, *** p < 0.005, 
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Once the myosin has detached from actin however the rate constant for ATP hydrolysis 
(k+3 + k-3) is around 30 % faster for H251N. Once S1 hydrolyses ATP to ADP it forms an 
S1.ADP.Pi complex which has a low affinity for actin. Once bound to the actin phosphate 
is released and the power stroke occurs. This newly formed actin.S1.ADP complex will be 
stronger for the H251N mutation given that the actin affinity in the presence of ADP 
equilibrium constant (KDA) is almost 2 fold tighter than wild type. The lack of a significant 
difference for the KDA value could simply be due to the lack of technical repeats for the 
mutant (n=2 rather than n=3). This would potentially make the detached state shorter as 
the affinity for actin increases after hydrolysis. It is unlikely but possible that the myosin 
will not detach from the actin and actually just hydrolyse the ATP while still bound to 
actin and therefore not go through the recovery stroke. 
The ADP has to be released from the myosin before ATP can bind and repeat the cycle. 
dŚĞWĂĨĨŝŶŝƚǇĨŽƌĂĐƚŽ ?^ ? ?< ?6 7) is over 3 times weaker than the wild type suggesting 
once ADP is displaced from the myosin it is unlikely to rebind over ATP. However the ADP 
ƌĞůĞĂƐĞƌĂƚĞ ?Ŭ ?+6) is very similar to the wild type.  
With the reduced maximum rate of detachment and stronger actin affinity in the 
presence of ADP it could be possible that the H251N mutant has a higher duty ratio. This 
ƉƌŽůŽŶŐĞĚ ĂƚƚĂĐŚŵĞŶƚ ŵĂǇ ŚĂǀĞ Ă ŶĞŐĂƚŝǀĞ ĐŽŶƐĞƋƵĞŶĐĞ ŽĨ ƉƌŽǀŝĚŝŶŐ Ă  ‘ĚƌĂŐ ? ŽŶ ƚŚĞ
system. Therefore the fibres will not be able to shorten as quickly as if the fibre just 
contained wild type protein. A second effect of this prolonged attachment could be an 




The major change in the structure for this mutation was ƚŚĞʋ-cation bond between H251 
and R453 being completely lost when the histidine is mutated to an asparagine. R453 is 
also the location of a mutation (R453C) that leads to HCM. The mutation R453C has been 
associated with a severe form of HCM in adults but has also been identified in children 
(Kaski, Syrris et al. 2009). It seems wise then to compare the two mutations given their 
proximity and phenotype. 
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R453 is located on a surface loop of the upper 50-kDa domain in a linker region. At the C-
terminal end is Switch-2 which is part of the nucleotide binding pocket, which binds ATP 
ǀŝĂ ɴ ? ŽĨ ƚŚĞ ĐĞŶƚƌĂů ɴ-sheet. The N terminal end connects to the actin binding site 
 ?ĐĂƌĚŝŽŵǇŽƉĂƚŚǇůŽŽƉ )ǀŝĂĂůŽŶŐɲ-helix (helix O). This HO-linker is in an ideal location to 
sense changes in both the actin binding site and nucleotide binding pocket. Meanwhile 
, ? ? ?ŝƐůŽĐĂƚĞĚŽŶɴ ?ŽĨƚŚĞĐĞŶƚƌĂůɴsheet. The N terminal end of this strand is directly 
linked to Switch-1 of the nucleotide pocket (Geeves, Fedorov et al. 2005). This bond 
between H251 and R453 could give the linker even more sensitivity to nucleotide binding 
through both Switch-1 and Switch-2. 
For both mutants the rate constant for ATP hydrolysis is significantly affected (Figure 6.8, 
(Bloemink, Deacon et al. 2014)) which may be due to the proximity of the residues to the 
nucleotide binding pocket. However there is an increase in the hydrolysis step for H251N 
(125.7 ± 9.3 s-1) compared to the wild type (91.2 ± 1.8 s-1) in the 25 mM KCl buffer, while 
for the R453C, the hydrolysis step (102 ± 14 s-1) is slower than the wild type (160 ± 23 s-1) 
in a 100 mM KCl buffer. It seems that destabilisation of this HO-linker can have a 
downstream effect on the nucleotide pocket and its ability to hydrolyse ATP. This is also 
appĂƌĞŶƚŝŶƚŚĞǀĂůƵĞƐĨŽƌŬ ?+2 which is decreased in both the H251N and R453C. This rate 
ĐŽŶƐƚĂŶƚ ĞƐƚŝŵĂƚĞƐ ƚŚĞ ŵĂǆŝŵƵŵ ƌĂƚĞ ŽĨ dW ŝŶĚƵĐĞĚ ĚŝƐƐŽĐŝĂƚŝŽŶ ? dŚĞ Ŭ ?+2 value then 
links the rate of ATP binding and actin dissociation, and a reduction in this value for both 
mutants adds to the theory that the HO-linker is relaying changes in both domains 
(Bloemink, Deacon et al. 2014). 
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7 General Discussion and Conclusions 
7.1 General discussion 
7.1.1 Stopped-flow modifications  
 
Stopped-flow is a powerful tool for studying the rapid kinetics biological systems that 
would not be measurable otherwise. However, as discussed in chapter 1.4.3 there are a 
few limitations to using this method.  
7.1.1.1 Temperature manifold 
 
The temperature manifold was designed to be a simple solution for laboratories that do 
not have access to the more specialised equipment for using temperature to affect rapid 
kinetics. This method differs from temperature jump or joule heating assays where a 
temperature change is used to perturb the system. Instead the sample, which may be 
labile at high temperatures such as delicate proteins can be kept at a tolerable 
temperature then rapidly heated or cooled just prior to mixing. Therefore the mixture 
would be at the desired temperature upon measurement without risking damaging the 
proteins by holding them at a high temperature for a prolonged amount of time.  
The design of the manifold is very simple with a machined block that allows water or 
other coolant from a water bath to heat up or cool down the aluminium block. It was 
then a simple case of insulating the block from the rest of the stopped-flow to minimize 
any thermal diffusion. By placing insulation and the manifold between the drive syringes 
and observation cell the distance the samples have to move also increases. This was a 
problem since the tubes that carry the samples rely on the stopped-flow being attached 
directly to the observation cell. We therefore filled this gap with an extender which 
contained two tubes for sample to flow into the cell and a waste tube for samples to exit 
the cell. This had to be a smooth surface to prevent perturbation of the sample which 
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would result in undesirable mixing artefacts in the transients. They also had to be the 
same diameter as the tubes from the stopped-flow and the cell again to prevent any 
turbulence of the samples. The material also had to be inert to prevent any unexpected 
reactions before mixing and measurement. Also the material had to be a thermal 
conductor in order for the sample to reach the desired temperature before mixing. 
To determine the temperature of the samples when they reached the observation cell 
fluorescein in a temperature sensitive buffer was used. As the temperature changed so 
did the pH, which in turn changed the fluorescence of the fluorescein. The initial 
amplitude for differing shot volumes gave information on how far from the desired 
temperature the sample was. The minimum shot volume that would be used for a 22.5 µL 
observation cell, 60 µL, was at most 3 °C away for the biggest temperature differences 
from the desired temperature in an aqueous solution. When ethylene glycol was added to 
allow temperatures below 0 °C it was > 5 °C away this is most likely a result of the large 
temperature differencĞ ?ȴdA? ? ? ? ) ?KŶĐĞŝŶƚŚĞŽďƐĞƌǀĂƚŝŽŶĐĞůůƚŚĞƚĞŵƉĞƌĂƚƵƌĞŽĨƚŚĞ
sample continued to adjust to the desired slowly over 20 seconds and may have had 
some undesired effects on the transients. However this should not be a problem on 
reactions that are complete within 1 second. Therefore we investigated a well-established 
system, ATP-induced dissociation of myosin S1 from actin. Acto.S1 was rapidly mixed with 
a fixed ATP concentration in in the stopped-flow using the temperature manifold, which 
was set at different temperatures to the stopped-flow. The transients were all best 
described by a single exponential fit which is expected and seen using the conventional 
set up. If there was an artefact caused by the gradual temperature change seen with the 
fluorescein then it would have presented as a second phase. 
Previous work (Iorga, Adamek et al. 2007) had shown that as temperature increase the 
ƐĞĐŽŶĚ ŽƌĚĞƌ ƌĂƚĞ ĐŽŶƐƚĂŶƚ ĨŽƌ dW ŝŶĚƵĐĞĚ ĚŝƐƐŽĐŝĂƚŝŽŶ  ?< ?1Ŭ ?+2) also increases. Upon 
ƐĞƉĂƌĂƚŝŶŐƚŚĞƚǁŽĐŽŶƐƚĂŶƚƐ ? ? ?< ?1  W ƚŚĞƌĞĐŝƉƌŽĐĂůŽĨƚŚĞ< ?1 ƚĞƌŵ ?ĂŶĚŬ ?+2) it was shown 
ƚŚĂƚ ? ?< ?1 ŝƐŶŽƚĞĨĨĞĐƚĞĚďǇƚĞŵƉĞƌĂƚƵƌĞ ?ǁŚŝůĞŬ ?+2 is and therefore it is the change in the 
Ŭ ?+2 ǀĂůƵĞƚŚĂƚĞĨĨĞĐƚƐƚŚĞǀĂůƵĞŽĨ< ?1Ŭ ?+2. In this investigation the whole system was set to 
the same temperature. This therefore gave a control with which to test the efficiency of 
the temperature manifold. An earlier investigation (Millar, Geeves 1983) also looked at 
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the ATP induced dissociation at sub-zero temperatures which also acted as a control for 
those assays. 
&ŽƌƚŚĞĂƋƵĞŽƵƐƐŽůƵƚŝŽŶƐƚŚĞsĂŶ ?ƚ,ŽĨĨƉůŽƚŽĨ ? ?< ?1 ŐĂǀĞĂƐŝŵŝůĂƌȴ,0 ĂŶĚȴ^0 as that 
ĂůƌĞĂĚǇ ƉƵďůŝƐŚĞĚ ? dŚĞ ȴ,0 is the most significant here in that it is very close to 0 and 
ƚŚĞƌĞĨŽƌĞƵŶĂĨĨĞĐƚĞĚďǇƚŚĞĐŚĂŶŐĞŝŶƚĞŵƉĞƌĂƚƵƌĞ ?dŚĞƌƌŚĞŶŝƵƐƉůŽƚŽĨƚŚĞŬ ?+2 showed 
the same trend as Iorga et al., where the ȴ, ? is positive (23.9-35.7 kJ.mol-1 )ĂŶĚƚŚĞȴ  ^? is 
larger (140-180 J.K.mol-1) however the values found here were slightly lower than that 
seen previously (Iorga, Adamek et al. 2007). One cause of this is most likely due to a more 
ƉƌŽŶŽƵŶĐĞĚ ‘ďƌĞĂŬƉŽŝŶƚ ?ƚŚĂƚǁĂƐŝŶŝƚŝĂůůǇƐĞĞŶŝŶ(Millar, Geeves 1983) where there are 
two linear lines for the Arrhenius plot. One linear relationship exists below 12 °C and the 
other above this point. Therefore to fit a linear line is strictly not true but given the small 
temperature window explored they only affected the results slightly. Regardless the trend 
was the more important result and helped to show that the temperature manifold 
worked over this temperature range.  
The temperature manifold therefore is a simple addition to the stopped-flow that could 
facilitate non-specialist labs to conduct assays at temperatures that would otherwise 
damage the machinery. It will also allow these laboratories to study chemical and 
biochemical intermediates. 
One limitation of the temperature manifold is the lack of insulation around the aluminium 
block and the pipes supplying the manifold from the water bath. These are both areas in 
which the coolant loses or gains thermal energy. As such the water bath would have to be 
set higher or lower so that the manifold was at the correct temperature. To monitor the 
temperature of the manifold a digital thermometer was inserted into a screw hole of the 
observation block close to the back of the cell close to where the reaction is measured. 
This gave some indication of the temperature within the cell and could adjust the water 
bath accordingly. Foam tubes and tissue paper were used as a makeshift insulator for the 
purposes of this investigation, however a more appropriate solution to this should be 
found if turned into a commercial product. One solution would be to cover the aluminium 
block in acetate which was used for the insulation plate. 
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7.1.1.2 Micro-volume manifold 
 
One of the major limitations when considering stopped-flow is the need for large volumes 
and high concentrations when working ǁŝƚŚ Ă  ‘ǁĞĂŬ ? ĨůƵŽƌŽƉŚŽƌĞ ? /Ĩworking with an 
expression system that does not yield a large amount of protein, or unstable protein this 
can become a real issue and prevent experiments from being conducted. Reducing the 
volumes needed therefore seemed like an issue that could be tackled. To do this a new 
manifold was designed that is positioned between the stopped-flow and observation cell 
like the temperature manifold. Moving the sample loading closer to the observation cell 
would reduce the volume of sample needed since 90-120 µL of each sample are wasted in 
order to clear the system of buffer/previous sample. 
The manifold was designed to have two inputs at the top for reagents, one for each drive 
syringe. These were cone shaped in order to reduce the chance of developing an air 
bubble which could ruin a measurement. Each had a valve that could be independently 
opened and closed to allow sample into the loading loop. The volume in the loops contain 
approximately 150 µL. To investigate whether this volume was adequate to be loaded 
into the system, different load volumes were used and the kobs, amplitude, end point, and 
relative amplitude were monitored with different shot volumes. A 5 µL cell was used since 
the shot volume could be reduced while clearing the cell of the previous sample. 
Therefore a shot volume of 20 µL (10 µL from each side) could be used. ATP was loaded 
using the normal method, while S1 or acto.S1 were added through one of the inputs and 
then pushed using buffer in the drive syringe. Using a load volume of 80, 100, and 120 µL 
it was apparent that a load volume of 120 µL gave the most stable amplitude and 
endpoint which are both important measures of the fluorescence and therefore protein 
concentration in the observation cell.  
Actin affinity of myosin S1 in the absence and presence of ADP can be very demanding on 
protein since high concentrations of S1 are needed. As such this method could lend itself 
to reducing the overall protein needed to determining these variables. Using a method of 
determining the actin affinity on the stopped-flow (Kurzawa, Geeves 1996) where the 
acto.S1 complex is made then rapidly mixed with ATP. The fluorescence amplitude of the 
dissociation event increases as the S1 concentration is increased. When fitted with a 
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quadratic function (equation 3.1) results in the actin affinity. The values obtained were 
compared to the value observed originally (Kurzawa, Geeves 1996) at both 50 and 30 nM 
pyrene actin with both giving similar results to the Kurzawa and Geeves findings.  
It therefore seems that the micro-volume manifold is a useful addition to the stopped-
flow set-up for reducing volumes of proteins needed. A user could conduct a stopped-
flow assay with 300 µL of their protein so even halving this volume needed would be 
beneficial for those with low yields of samples.     
There are three design issues that need to be addressed before this could become a 
commercial product.  
1. There was no thermostat since there are no coolant channels within the manifold. 
This meant that the manifold is at room temperature. This is a major issue that will 
need to be addressed due to temperature playing such a large role in kinetics.  
2. When the valve on the manifold is in the position to load the sample, if the waste 
valve is in the flush position the sample will leak straight through the system into the 
waste. It is unlikely that there is a solution to this other than making the user aware 
that when loading the sample the waste valve must be on either drive or waste.  
3. Due to the complex plumbing within the manifold the lines for syringe A and B swap 
over (Figure 7.1). This is very important to know if the user is using just one reagent in 
the manifold since both reagents could be mixed before they should be. However this 
is an early prototype and the design can be addressed in later iterations of the 
manifold.  




7.1.1.3 Wild type MyHC-emb 
 
Previous work has shown that the embryonic myosin is a slow type myosin similar to the 
ɴ-myosin. One of the characteristic features of a slow type myosin is a tight ADP affinity 
and a slow ADP release rate as well as a slower ATPase rate which is indicative of the 
overall cross-bridge cycle.  
The ADP affinity of the MyHC-emb was over two fold weaker than the MyHC-ɴ ?ŚŽǁĞǀĞƌ
this was still tighter than comparisons with the other adult isoforms expressed in humans. 
The issue of comparing the rates between the MyHC-emb in this study and the adult 
isoforms (Bloemink, Deacon et al. 2013) is that the studies are at different salt 
concentrations. However the MyHC-ɴ ŚĂƐ ďĞĞŶ ĐŚĂƌĂĐƚĞƌŝƐĞĚ Ăƚ ďŽƚŚ  ? ? ? ŵD <ů
(Deacon, Bloemink et al. 2012) and 25 mM KCl (Nag, Sommese et al. 2015), which allowed 
the direct comparison of MyHC-emb to MyHC-ɴ ?ƚŚĞŶĐŽŵƉĂƌŝƐŽŶŽĨDǇ,-ɴƚŽƚŚĞĂĚƵůƚ
muscle isoforms. The differences between the two salt concentrations for the wild type 
MyHC-ɴ are mainly increases in the affinities for nucleotide and actin at the lower salt 
concentration. Some of the rate constants are also increased, likely due to the reduced 
ionic concentration which may reduce the rates of association. At the higher salt, the ADP 
affinity of the MyHC-ɴ ǁĂƐ ĂƌŽƵŶĚ  ? ? ?-fold weaker than at the lower salt. If the trend 
Figure 7.1  W Schematic to show how the inputs on the manifold match up to the drive syringes. 
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holds true for the MyHC-emb then the ADP affinity at higher salt would be around 50 µM. 
This is similar to the MyHC-IIb value (which is not expressed in humans), but much weaker 
than the MyHC-IIa, MyHC-IIx, MyHC-extraocular, and MyHC-ɲ ? 
The ADP release rate for MyHC-emb is over two-fold slower than the MyHC-ɴ ?ŽŵƉĂƌŝŶŐ
the salt differences both MyHC-emb and MyHC-ɴĂƌĞƐŝŐŶŝĨŝĐĂŶƚůǇƐůŽǁĞƌƚŚĂŶƚŚĞĂĚƵůƚ
isoforms as these rate constants are >1,000 s-1. This step is also thought to be the rate 
limiting step for slow myosin velocity and is the main characteristic of a slow type myosin. 
The maximum cycling time (Vmax) however showed that there is only a slight difference 
between the MyHC-emb and MyHC-ɴ ?ǁŝƚŚƚŚĞĞŵďƌǇŽŶŝĐŝƐŽĨŽƌŵŚĂǀŝŶŐĂĨĂƐƚĞƌsmax.  
The data presented supports the hypothesis that the MyHC-emb is a slow type myosin 
due to the slow ADP release rate constant. One observation is a second slow phase during 
the ATP induced dissociation of acto.S1 was not seen for the wild type MyHC-emb. This 
step has been suggested to be caused by a conformational change from a closed to open 
state in the nucleotide binding pocket. This is only seen in the MyHC-ɴĂŶĚĐŽƵůĚ ďĞ Ă
characteristic of slow type myosins (myosin I, V, VI etc.) or just the beta isoform. One 
explanation why this was not seen in the MyHC-emb is that the maximum rate of 
ĚŝƐƐŽĐŝĂƚŝŽŶ  ?Ŭ ?+2) is relatively slow, over half the rate as seen for MyHC-ɴ ? dŚŝƐ ǁŽƵůĚ
make it difficult to isolate the two phases in the transients and may result in it being 
missed. It is also unlikely that an increase in ionic strength would increase the dissociation 
rate as it has no effect for MyHC-ɴ ? dŚĞ dWĂƐĞ smax was also slightly faster than the 
MyHC-ɴ  ? ?Ɛ-1 rather than 6 s-1) which are both slower than the adult isoforms (Vmax for 
MyHC-IIa is >16 s-1, (Swenson, Trivedi et al. 2014)).  
One limitation of this investigation is that using a low salt buffer, the actin affinity (KA) 
becomes much tighter than if carried out at 100 mM KCl. Stopped-flow spectroscopy 
instruments have become much more sensitive and the ability to use 30 nM pyrene-actin 
is a huge achievement. However to have confidence in the value of KA the measurement 
ǁŽƵůĚŝĚĞĂůůǇďĞĐŽŶĚƵĐƚĞĚǁŝƚŚĂŶĂĐƚŝŶĐŽŶĐĞŶƚƌĂƚŝŽŶA?<A. So when we get an affinity 
of 2.1 nM for the MyHC-emb some doubt occurs to the accuracy of the measurement. 
One thing we can be sure of it that the KA for MyHC-emb is very tight similar to MyHC-ɴ ?
Given more time and protein it would have been useful to repeat this assay at a higher 
salt such as 100 mM KCl where the KA for MyHC-ɴŝƐ ? ?ŶD. 
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A second problem with this KA assay is that the concentration of active myosin must be 
correct. To ascertain the concentration of active S1 we do an activity test. This is a similar 
and simpler assay to the KA measurement where equimolar acto.S1 is rapidly mixed with 
ATP. The S1 concentration is then doubled to observe if the relative amplitude also 
doubles or increases. This is repeated until the relative amplitude remains the same. The 
active S1 concentration can then be estimated more accurately than using UV 
spectroscopy. However the KA measurement was usually the second to last assay carried 
out and as such the active concentration of S1 may have decreased. Ideally this activity 
test would have been repeated before the actin affinity measurements; however these 
assays use large quantities of protein which could not be used on a second activity test. 
The length of time between purification and the KA assay was also within 3-4 days which 
will have limited the deterioration of S1. 
One issue of the construct used is that the light chains bound to the S1 are the 
endogenous mouse light chains from the C2C12 cells. Deacon et al. (Deacon, Bloemink et 
al. 2012) analysed these light chains and found they were MLC1A, MLC3F, MLC1F, and 
MLC2F.  
A review by Bottinelli and Reggiani (Bottinelli, Reggiani 2000) stated the myosin light 
chains (MLC) 1A, 1F, and 2F are known to bind to the embryonic myosin. MLC1A is also 
known as the MLC-1 atrial/foetal isoform expressed in embryonic tissue and heart and in 
the atria of adults (Whalen, Butler-Browne et al. 1978, Kurabayashi, Komuro et al. 1988). 
We were therefore encouraged to find that these light chains had a greater density than 
the MLC3F. This also correlates to the level of S1 and endogenous myosin in the sample, 
suggesting these three light chains are binding correctly to the S1 while MLC3F which 
does not bind to the embryonic myosin appears to be associating with the endogenous 
myosin. Deacon et al. (Deacon, Bloemink et al. 2012) used a construct with the 
recombinant MYL3 which is known to be associated with a specific cardiac light chain. 
Since there is a specific embryonic myosin light chain it would be interesting to see if 
there ŝƐĂĐŚĂŶŐĞŝŶƚŚĞŬŝŶĞƚŝĐƐǁŝƚŚƚŚĞŚƵŵĂŶĨŽƌŵƉƌĞƐĞŶƚĂƐƚŚĞƌĞŝƐŝŶƚŚĞĐĂƌĚŝĂĐɴ-
S1. 
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7.1.2 FSS mutations 
 
T178I, R672H, and R672C are the three most common mutations in embryonic myosin 
that cause Freeman-Sheldon syndrome. Given the location of the residues it is 
unsurprising that they have such dramatic effects on the patients. It is also unsurprising 
ƚŚĂƚ ƐŝŶĐĞ ƚŚĞ ƌĞƐŝĚƵĞƐ ĂƌĞ ĐůŽƐĞ ƚŽ ƚŚĞ ŶƵĐůĞŽƚŝĚĞ ďŝŶĚŝŶŐ ƉŽĐŬĞƚ  ?Ăƚ ƚŚĞ ɶ-phosphate 
binding site) that ATP hydrolysis is so significantly affected. The slowing of the ATP 
hydrolysis may be one cause of the decrease in the Vmax of the ATPase assay. The changes 
in the ATPase assays compared to the wild type correlate with the severity of the 
phenotypes observed with these mutations. T178I has the most severe phenotype, 
slowest Vmax, and tightest KM. On the other hand the R672C has the least severe 
phenotype, fastest Vmax, and weakest KM, which is closest to the wild type.  
Using Berkley Madonna, the ATPase cycle was modelled using the values from the 
stopped-flow kinetics and the ATPase assays. The rate constants for actin rebinding after 
the ATP hydrolysis step and the phosphate release step were then estimated. As can be 
seen in chapter 5 the A.M.D.P state is the highest occupied state in the wild type MyHC-
emb, caused by a slow phosphate release step. This state becomes greater still for the 
mutations with T178I having the largest portion of the cycle in this stage. Therefore 
although not measured directly, the data from the modelling indicates that the 
phosphate release is affected in the three mutations and again correlates with the clinical 
findings of phenotype severity. It could therefore be possible the myopathy is caused by a 
reduced hydrolysis step and phosphate release step leading to the myosin occupying a 
non/weakly bound state for longer. It is possible to estimate the velocity of each motor 
and whether the S1 could produce force (Table 7.1).  
 
Isoform Vmax (s
-1) strongly attached ʏtotal (s) ʏstrong att. (s) V0 (nm/s)
WT MyHC-emb 7.0000 0.2500 0.1429 0.0357 140-280
MyHC- emb R672H 1.3000 0.1300 0.7692 0.1000 50-100
MyHC- emb R672C 3.5000 0.1600 0.2857 0.0457 109-218
MyHC-emb T178I 0.2000 0.0060 5.0000 0.0300 166-333
Table 7.1 - ƐƚŝŵĂƚĞƐŽĨǀĞůŽĐŝƚǇĚĞƚĞƌŵŝŶĞĚĨƌŽŵƚŚĞĞƌŬůĞǇDĂĚŽŶŶĂŵŽĚĞůůŝŶŐ ?ʏtotal = total 
cycling time, ʏstorng att. = strongly attached time, V0 = velocity 
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The proportion of strongly attached states was determined from the occupancy of the 
ƐƚƌŽŶŐůǇ ďŽƵŶĚ ƐƚĂƚĞƐ  ?D ? Dd ? D ? ĂŶĚ D ? ) ? dŚĞ ƚŽƚĂů ĐǇĐůŝŶŐ ƚŝŵĞ  ?ʏtotal) was 
calculated from 1/Vmax ? Ǉ ŵƵůƚŝƉůǇŝŶŐ ƚŚĞ ʏtotal by the proportion of strongly attached 
states, how long this event lasted could be calculated. Finally a step size of 5-10 nm was 
used to estimate the velocity of each S1. From this the velocity of wild type MyHC-emb is 
estimated to be 140-280 nm/s, and is reduced for the two R672 mutations. However this 
method is less suited to the T178I mutation. Due to the low Vmax the total cycling time 
would be around 5 seconds. Combined with the very low proportion of strongly attached 
states this resulted in a strongly attached time similar to the wild type. This is therefore 
not a very good method for modelling the T178I velocity. The proportion of strongly 
attached states is also useful in determining how much force each motor could produce. 
Force will be proportional to the strongly attached state as this is where the power stoke 
occurs and tension can be held. Therefore the larger the occupancy of these strongly 
attached states the more force they can produce. The wild type MyHC-emb could 
produce the most force, with the two R672 producing less (R672H slightly less than 
R672C), and T178I not being attached for long enough to produce significant force. 
Observations of the structure found there appears to be two key interactions involving 
T178 and R672. The first of these interactions is a hydrogen bond between the two 
residues which is lost entirely for the T178I and R672C and partially for the R672H. The 
ůŽƐƐ ŽĨ ƚŚŝƐ ďŽŶĚ ŵĂǇ ĞǆƉůĂŝŶ ƚŚĞ A? ?-fold weakening of ATP affinity in the presence of 
actin for T178I, and slight weakening in the two R672 mutants. The bond may help to 
stabilise the nucleotide binding pocket since T178 is located adjacent to the P-loop which 
plays a major role in ATP binding through the gamma phosphate. If the ATP is not binding 
as tightly or properly this may explain why the tryptophan fluorescence signal was so 
ǁĞĂŬ ŝŶ ƚŚĞ ŵƵƚĂŶƚƐ ?dŚĞ ƐĞĐŽŶĚ ŝŶƚĞƌĂĐƚŝŽŶ ŝƐ Ă ʋ-cation bond between the R672 and 
F490 on the relay helix. This is lost entirely for the two mutants. F490 is located prior to 
ǁŚĞƌĞƚŚĞƌĞůĂǇŚĞůŝǆ ‘ŬŝŶŬƐ ?ĚƵƌŝŶŐƚŚĞdWĂƐĞĐǇĐůĞ ?dŚŝƐŬŝŶŬĨŽƌĐĞƐƚŚĞƌĞůĂǇůŽŽƉĂƚƚŚĞ
C-terminus to move relative to the rest of the molecule. This loop, as well as containing 
the tryptophan that leads to the fluorescence change observed upon ATP binding, also 
interacts with the converter domain. The converter domain leads into the lever arm and it 
is thought this area is the fulcrum point in myosin where force is generated. It is 
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interesting then to observe that F490 is located just before the kink and appears to be 
ĂŶĐŚŽƌŝŶŐƚŚĞŚĞůŝǆŝŶƉůĂĐĞƚŽĂůůŽǁƚŚĞŬŝŶŬƚŽŚĂƉƉĞŶ ?tŝƚŚƚŚĞʋ-cation bond broken in 
the two mutations it is possible that the helix is more flexible at the N-terminal end. This 
may prevent the kink occurring or reduce it and therefore reduce the force produced by 
the mutant myosin. This correlates to the reduction in specific force observed in 
myofibrils obtained from FSS patients (Racca, Beck et al. 2015), however it is unclear if 
this was due to the mutant protein or the hypertrophied nature of the muscle. It is also 
unclear if compensation from upregulating other myosin isoforms could be a cause for 
the myopathy. Perinatal myosin has been found to be expressed in a FSS patient longer 
into postnatal development than in normal muscle tissue (Tajsharghi, Kimber et al. 2007).  
It would be interesting to see if the force produced by wild type MyHC-emb and MyHC-
peri are comparable, and then to compare them to the FSS causing mutants. If the force is 
reduced in the mutants then it would add to the R672-T178 interaction playing a role in 
force production and give a molecular reason why the myopathy manifests in these 
mutations. The causes for the T178I seem clear that it is the nucleotide pocket that is 
being disrupted causing the motor to hold on to phosphate for longer. However any 
downstream effects caused by the loss of the T178-R672 H-bond should not be ruled out. 
7.1.3 MyHC-ɴ, ? ? ?EŵƵƚĂƚŝŽŶƐ 
 
Given that this H251N mutation has only been discovered in children suffering from the 
juvenile form of HCM (Kaski, Syrris et al. 2009) it would seem logical that the mutation is 
more severe than mutations in the adult form. However the paper which first identified 
the H251N mutation also showed two adult HCM mutations, R403Q and R453C, in 
children (Kaski, Syrris et al. 2009). This would suggest that the two  ‘ĂĚƵůƚ ?ŵƵƚĂƚŝŽŶƐĂƌĞ
as severe as the H251N mutation.  
This then raises the question, why were the R403Q and R453C mutations identified in 
children with HCM when these mutations usually take 20-30 years to manifest which can 
lead to death, starting at 20 years.  
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The paper states that 29 of their 79 patients were diagnosed as a result of clinical 
screening for a family history of HCM. They do not state whether these were the patients 
where the R403Q and R453C mutations were identified but it is probable. A study into 
familial and sporadic disease in Austrian children (Greber-Platzer, Marx et al. 2001) found 
those with the R453C mutation had little to no clinical symptoms of HCM. However the 
non-familial mutations had left ventricle hypertrophy and other clinical symptoms. 
Secondary causes may also contribute to these mutations increasing in severity. These 
include inborn errors of metabolism, mitochondrial dysfunction and neuromuscular 
conditions. 
Compared with tŚĞ Z ? ? ?Y ĂŶĚ Z ? ? ? ŵƵƚĂƚŝŽŶ ?Ɛ ĚŝĨĨĞƌĞŶĐĞƐ ƚŽ ǁŝůĚ ƚǇƉĞƚŚ , ? ? ?E
mutation has more significant differences in stopped-flow kinetics. The only significant 
change in the R403Q was a weakening in the actin affinity (Nag, Sommese et al. 2015). 
The R453C again only showed small changes most notably weakening of the KDA value, 
ĂŶĚƐůŽǁŝŶŐŽĨƚŚĞ< ?1Ŭ ?+2 ĂŶĚŬ ?+2 values (Bloemink, Deacon et al. 2014). By contrast the 
changes seen in the H251N mutant are far more significant and numerous. These 
dramatic changes are a likely explanation to why the disease progresses much faster with 
this mutation than the other two stated. 
One interesting finding is the comparison between the FSS mutations and the H251N 
mutation. Simply comparing the percentage changes of the equilibrium and rate 
constants (Figures 5.11 and 6.8) it is clear to see that the FSS have more significant 
differences than the wild types. Of the HCM mutations so far investigated there appears 
to be limited differences between the wild type MyHC-ɴĂŶĚŵƵƚĂŶƚƐ ?^ŝŶĐĞ DǇ,-ɴ ŝƐ
essential for correct function of the heart this maybe the why the HCM mutations do not 
show such severe changes as this would lead to non-viable embryos. Therefore these 
mutations may exist in the MyHC-ɴďƵƚŵĂǇŶŽƚŚĂǀĞďĞĞŶŝĚĞŶƚŝĨŝĞĚ ?  
  





KŶĞ ůŝŵŝƚĂƚŝŽŶ ŽĨ ƚŚĞ ĂƐƐĂǇƐ ĐŽŶĚƵĐƚĞĚ ǁŝƚŚ ƚŚĞ ƌĞĐŽŵďŝŶĂŶƚ ^ ? ?Ɛ ǁĂƐ ƚŚĞ ƵƐĞ ŽĨ Ă  ? ?
mM KCl buffer. The standard salt concentration used by our lab for stopped-flow assays is 
100 mM KCl, while physiological salt concentrations are around 150 mM (Lodish, Berk et 
al. 2000). While magnesium, chloride, and other ions were present the salt 
concentrations used here were much lower than physiological. The reasoning behind the 
choice of salt concentration was to achieve comparable environments between the 
stopped-flow and ATPase assays, which are usually done at low to zero salt. As part of the 
wider collaboration there is also the scope to perform in vitro motility assays on these 
ƌĞĐŽŵďŝŶĂŶƚ^ ? ?ƐǁŚŝĐŚĂŐĂŝŶƌĞƋƵŝƌĞƐĂůŽǁŝŽŶŝĐƐƚƌĞŶŐƚŚ ? 
The rate constants of myosin kinetics are incredibly fast which is why stopped-flow lends 
itself well to the study of these parameters. However when measured at human body 
temperature (37.5 °C) the rate constants can become too fast for current machines to 
measure reliably. As such the assays were carried out at 20 °C which gave measureable 
data as close to physiological temperatures as possible.  
The use of the temperature manifold would have been ideal to determine some of the 
ŬŝŶĞƚŝĐ ƉĂƌĂŵĞƚĞƌƐ  ?Ğ ?Ő ?  ? ?< ?1 ĂŶĚ < ?1Ŭ ?+2) which would have allowed the calculation of 
ŽƚŚĞƌ ǀĂůƵĞƐ  ?Ŭ ?+2) at 37 °C. However due to the low yields of protein, using the 
temperature manifold for this was not possible while also completing the other kinetic 
parameters shown in Chapters 4, 5, and 6. 
This leads to another limitation of the study, being the cost and low yields of protein 
produced using this method. From a 3L cell culture only 1-2 mg of protein could be 
purified which was just enough in some cases to do a full series of assays. The cost of this 
process was probably one of the most significant limitations as cell culturing involved not 
just the C2C12 cells, but also HEK293 cells were used to amplify the viruses. However 
careful use of protein or the micro-volume manifold allowed the full analysis of 
recombinant S1s. 
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7.3 Future work 
Myopathies are very complex diseases and a better understanding of the progression is 
needed.  
The role that embryonic myosin plays during muscle development is also very poorly 
understood. Since it is expressed during embryo development and muscle regeneration it 
is not unreasonable to assume it is helping to build new sarcomeres within fibres.  
One potential therapeutic proposed is dATP (Racca, Beck et al. 2013). They showed that 
the use of dATP can increase the Vmax of the ATPase rate, which would be beneficial for 
the three FSS mutations investigated here (Chapter 5) since the Vmax is reduced in all 
cases. Given more time and available samples, the stopped-flow kinetics could be 
examined again this time with dATP present in place of MgATP. Although it is unlikely that 
a treatment that encourages dATP production in the developing embryo would ever be 
accepted, it would be interesting to observe whether dATP could rectify the changes seen 
in the mutants. Using stopped-flow it would then be possible to determine which parts of 
the cross-bridge cycle are restored.  
The emergence of juvenile HCM makes the disease more complex in that some mutations 
in the sarcomeric proteins can be tolerated into adulthood before symptoms present, 
while others lead to a disease state in infancy. More information therefore needs to be 
collected on potential causes on juvenile HCM and any potential risk factors that may 
contribute to the disease progressing earlier. Collecting data on more HCM mutations 
may provide a common effect between them all that could explain the phenotype seen. It 
would then be interesting to see if the juvenile HCM mutations share the same common 
dysfunction.  
Ionic interactions play a big role in the cross-bridge cycle. As such existing data on other 
myosin isoforms have been conducted at 100 mM KCl, close to physiological 
concentrations. In these studies to compare the stopped-flow data to the ATPase and in 
vitro measurements the KCl concentration was 25 mM. To help make the comparison 
between the embryonic myosin and the other characterised myosins easier it would be 
beneficial to repeat the assays in higher salt buffers. 
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Given that the temperature manifold works nicely at allowing measurements at human 
physiological body temperature, it would be good to investigate which constants within 
the cross-bridge cycle are affected by temperature. It may be the case that the larger 
differences seen between wild type and mutant are not so significant at 37 °C, or the 
opposite maybe true that the mutations are in fact much worse.  
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